JP2009533315A - Antibacterial agent - Google Patents

Abstract

Provided herein are aromatic compound substitutes that are tRNA synthetase inhibitors and thus can be used as antibacterial agents. The compounds described herein are gram positive, gram negative, anaerobic or fungal microorganisms, more particularly bacteria such as Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae, and fungal organisms, e.g. Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Tricos Can be used for the treatment or prevention of pathologies caused by or promoted by. Also provided are methods for preparing these compounds, pharmaceutical compositions thereof, and treating microbial infections.
[Selection figure] None

Description

  Provided herein are aromatic substituted compounds that are tRNA synthetase inhibitors and thus can be used as antibacterial agents. The compounds described herein are gram positive, gram negative, anaerobic or fungal microorganisms, more particularly bacteria such as Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae, and fungal organisms, e.g. Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Tricos It can be used for the treatment or prevention of pathologies caused by or promoted by. Also provided are methods of preparing these compounds, their pharmaceutical compositions, and treating microbial infections.

  Antibiotics have immense value in the fight against infectious diseases. In recent decades, antibiotic efficacy has been threatened by the relentless increase in the incidence of microbial drug resistance. Some important pathogens have serious resistance problems. Of these pathogens, Staphylococcus aureus is probably the most serious. This causes community and hospital infections and is associated with high morbidity and mortality. Vancomycin has been used as a last resort antibiotic in the treatment of mesicillin-resistant Staphylococcus aureus infection (MRSA) with multiple resistances. A strain with some level of resistance to vancomycin (vancomycin moderately resistant S. aureus, VISA) has been known since 1996, but the emergence of a newly identified highly resistant strain (VRSA) It is a harbinger to announce that the battle has entered a new stage. Other important treatment issues include multidrug resistance in tuberculosis, resistance to vancomycin-resistant enterococci (VRE), Enterobacteriaceae and Pseudomonas aeruginosa, and resistance to extended spectrum β-lactamases (ESBL), and resistance to penicillin in Streptococcus pneumoniae Is mentioned.

  A wide national epidemic of multidrug-resistant Salmonell typhi occurred in 1990, but has not yet completely ended. Antimicrobial resistance found among respiratory pathogens has become a common clinical problem. Recently, more than 90% of Morexella catarrhalis and 25% of Haemophilus influenzae produce β-lactamase. This requires treatment with β-lactamase stable cephalosporins, or concomitant drugs. In recent years, the number of strains resistant to penicillin, cephalosporin, macrolides, and fluoroquinolones has increased rapidly.

  These situations have prompted efforts to develop new antibiotics that will break down emerging antibiotic-resistant bacteria. Aminoacyl-tRNA synthetase is an essential enzyme found in all living organisms. This enzyme has emerged as a new target for the development of new antibiotics. An aminoacyl tRNA synthetase charges tRNA with its corresponding amino acid. This is an essential step in protein synthesis. There are 20 tRNA synthetases, most of which are fortunately consistent with broad spectrum targets. Pseudomonas acid, also called mupirocin, is an effective target class in view of the fact that it suppresses isoleucyl tRNA synthase and is marketed as a topical antibiotic Bactropan. Other known natural products to which aminoacyl-tRNA synthetases are directed include borrelidin, furanomycin, granaticin, indolmycin, ocartoxin A, and cispentacin, none of which have been developed as antibiotic compounds .

  US patent applications 2004/0224981 and 2003/0013724 disclose tRNA synthetase inhibitors. WO00 / 18772 discloses imidazolidinone condensates as tRNA synthetase inhibitors. US Pat. Nos. 5,191,093 and 4,916,155 disclose crystalline pseudomonas acid, a method for its production, and its use in human medicine and veterinary medicine. US Pat. No. 4,916,155 discloses crystalline calcium pseudomonate, or a hydrate thereof, and its use in human medicine and veterinary medicine.

  Novel synthetic compounds that target tRNA synthetases offer clear advantages as useful therapeutic agents to circumvent the threat of drug resistance.

  Accordingly, the present invention provides aromatic substituent compounds and methods for synthesizing those compounds that are tRNA synthetase inhibitors and thus can be used to treat microbial infections. Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, drug precursors, metabolites, polymorphs with the same type activity, and N-oxides of these compounds Provided. Pharmaceutical compositions comprising the described compounds (Formula I) together with pharmaceutically acceptable carriers, excipients or diluents can be used for the treatment of microbial infections. Other aspects will be described in the accompanying description below, some of which will be apparent from the description or will be learned by actually carrying out the invention.

  In one aspect, the present invention provides a compound of formula I:

の構造を持つ化合物、および、その製薬学的に受容可能な塩、製薬学的に受容可能な溶媒化合物、立体異性体、薬剤前駆体、代謝産物、多型体、またはN-酸化物である。

And a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide thereof .

In the above formula,
Cy may be cycloalkyl or heterocyclyl;
X and Z may be alkylene;
Y may be NR ₁ (wherein R ₁ may be hydrogen, alkyl, or OCO alkyl);
X ₁ , X ₂ , X ₃ , and X ₄ may be CH or N; and
R may be OR ₂ , OCONHR ₂ , OCONHSO ₂ R ₂ , SR ₃ , or NR ₄ R _{5 (} wherein R ₂ may be aryl or heteroaryl, R ₃ is _{May be} hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl, and R ₄ and R ₅ are independently hydrogen, SO ₂ R ₆ , COR ₆ , CSR ₆ , or COOR _6. and in even better [equation, R ₆ is alkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl, _{heterocycloalkyl, oR 7, NHR 7, NHSO} 2 R 7, NHCOR 7, NHCSR 7 or NH, ₂ C = NHSO ₂ R ₇ (wherein R ₇ may be alkyl, aryl, heteroaryl, or heterocyclyl)], or R ₄ and R ₅ are their attachments Together with nitrogen to form a heterocycle It may also be}.

  The compound may include one or more of the following embodiments. For example, the compound has the formula:

の化合物、その製薬学的に受容可能な塩、製薬学的に受容可能な溶媒化合物、立体異性体、薬剤前駆体、代謝産物、多型体、またはN-酸化物である。

Or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide.

In the above formula,
Cy may be cyclopentyl or cyclohexyl;
X may be CH ₂ C (CH ₃ ), or CH (OH) C (CH ₃ );
Z may be CH ₂ ;
Y may be NH or NSO ₂ CH ₃ ;
X ₄ may be CH or N; and
R may be NR ₄ R ₅ [where R ₄ and R ₅ are independently hydrogen, SO ₂ R ₆ , COR ₆ , CONHR ₆ , CONHSO ₂ R ₆ , or COOH ₂ R ₆ (In the above formula, R ₆ is N (CH ₃ ) ₂ , NH ₂ , CH═CHCOOC ₂ H ₅ , (CH ₂ ) ₃ COOC ₂ H ₅ , phenyl, 1,2,3,4, -Tetrahydroisoquinolinyl, 2,2,2-trifluoroacetyl-1- (3,4-dihydro-1H-isoquinolin-2-yl), morpholinyl, or heteroaryl).

  In another embodiment, the compound has the formula:

Or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide.

In the above formula,
Cy may be cyclohexyl or cyclopentyl;
X is -CH ₂ CH (CH ₃ )-, -CH (F) CH (CH ₃ )-, -CH (OH) CH (CH ₃ )-, or -CH ₂ CH (F) CH _2-. May be;
Y may be NH;
Z may be —CH ₂ —;
X ₁ and X ₂ may be CH or N; and
R may be NHC (NH) NH ₂ , NHCOOCH ₂ R ₆ , or NHSO ₂ R ₆ (wherein R ₆ may be aryl, heteroaryl, or heterocyclyl).

  In another aspect, provided in the present invention is a method of treating or preventing a condition caused by or promoted by a Gram positive, Gram negative, anaerobic bacterium or fungal microorganism, wherein the treatment Or a method comprising administering to a subject in need of prevention a therapeutically effective amount of one or more compounds or pharmaceutical compositions described herein.

  Bacteria such as Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae can be the cause of bacterial infections.

  Microorganisms such as Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidiodes, Pneumocystis, Trichophyton, or Trichosporium Enterobactericeae can be the cause of fungal infections.

  Conditions include, for example, pneumonia transmitted from the community, upper and lower respiratory tract infections, skin and soft tissue infections, nosocomial lung or bone and joint infections, and other bacterial infections such as mastitis, catheter infections, foreign bodies, vulgaris It may be acne, prosthetic infection, or gastric ulcer disease.

  In another aspect, provided herein is a method for preparing the compounds described herein.

  In yet another aspect, provided herein is a method of treating or preventing a condition caused or promoted by gram positive, gram negative, anaerobic bacteria or fungal microorganisms. One or more of the aminoacyl-tRNA synthetase (ie, mupirocin) inhibitors, antibacterial agents, or mixtures thereof described herein in combination with one or more aminoacyl-tRNA synthetase (ie, mupirocin) inhibitors Administering a therapeutically effective amount of the compound or pharmaceutical composition.

  The following definitions apply to terms used in this specification.

The term “alkyl” refers to a single root, branched or unbranched, saturated hydrocarbon chain having from 1 to 20 carbon atoms, unless otherwise indicated. Examples of this term include chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, Examples include n-decyl and tetradecyl. The alkyl group further includes alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azide, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, carboxyalkyl, aryl, heterocyclyl, Heteroaryl, arylthio, thiol, arylthio, aryloxy, nitro, aminosulfonyl, aminocarbonylamino, -NHC (= O) Rf, -NRfRq, -C (= O) NRfRq-, NHC (= O) NRfRq, -C (═O) heteroaryl, C (═O) heterocyclyl, —OC (═O) NRfRq {wherein Rf and Rq are alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocyclyl, heteroaryl, Heterocyclylalkyl or heteroarylalkyl Independently selected from}, nitro, or —SO ₂ R _{6, where} R ₆ is alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl. One or more substituents may be substituted. Unless otherwise limited by definition, alkyl substituents are alkyl, carboxy, -NRfRq-, -C (= O) NRfRq, -OC (= O) NRfRq, NHC (= O) NRfRq (wherein Rf And Rq are as defined above), 1-3 substitutions selected from hydroxy, alkoxy, halogen, CF ₃ , cyano, and —SO ₂ R _{6, where} R ₆ is as defined above The alkyl group may also be oxygen, sulfur, or —NRa— {Ra is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, acyl, aralkyl, —C (= O) ORf (Rf is as defined above), SO ₂ R ₆ (R ₆ is as defined above), or C (= O) NRfRq (Rf and Rq are as defined above)} It may be interrupted by 1-5 atoms of the group selected. Unless otherwise limited by definition, all substituents are alkyl, carboxy, —NRfRq, —C (═O) NRfRq, —OC (═O) NRfRq (where Rf and Rq are as defined above), hydroxy May be further substituted with 1-3 substituents selected from, alkoxy, halogen, CF ₃ , cyano, and —SO ₂ R _{6, where} R ₆ is as defined above; or as defined above It may also be an alkyl group as defined above having the substituents as defined and interrupted by 1-5 atoms or groups as defined above.

  As used herein, the term “alkylene” is — (CH) n—, where n is an integer from 0 to 4 and one or more hydrogens are optionally substituted with alkyl, hydroxy, hydrogen, or oxime. Refers to the compound Alkylene may also be optionally interrupted by -CONH-, -C = O, or -C = NOH.

Unless otherwise indicated, the term “cycloalkyl” refers to a cyclic alkyl group of from 3 to 20 carbon atoms, and, unless otherwise defined by definition, optionally includes one or more olefinic bonds. A cyclic alkyl group having a single ring or a plurality of condensed rings which may be contained in Such cycloalkyl groups include, for example, single-ring structures including cyclopropyl, cyclobutyl, cyclooctyl, cyclopentenyl, and the like, and cyclic alkyls in which adamantanyl, bicyclo [2.2.1] heptane, or aryl groups are fused. Examples thereof include a multi-ring structure containing a group such as indane. Spiro and fused ring structures may also be included. Cycloalkyl groups are further alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azide, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, carboxyalkyl, arylthio, Thiol, alkylthio, aryl, aralkyl, aryloxy, aminosulfonyl, aminocarbonylamino, -NRfRq, NHC (= O) NRfRq, -NHC (= O) Rf, -C (= O) NRfRq, -OC (= O) NRfRq (wherein Rf and Rq are as defined above), nitro, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, or SO ₂ -R ₆ (where R ₆ is as defined above) It may be substituted with one or more substituents. Unless otherwise limited by definition, cycloalkyl substituents are alkyl, carboxy, hydroxy, alkoxy, halogen, CF ₃ , —NRfRq, —C (═O) NRfRq, —NHC (═O) NRfRq, —OC ( = O) NRfRq (Rf and Rq are as defined above), cyano, or -SO ₂ R ₆ (where R ₆ is as defined above) may be further substituted with 1-3 substituents Good. “Cycloalkyl” refers to an alkyl-cycloalkyl group linked through an alkyl moiety. The alkyl and cycloalkyl groups are as defined above.

Unless otherwise indicated, the term “aryl” refers to a carbocyclic aromatic group such as a phenyl, biphenyl, or naltyl ring, such as a halogen (eg, F, Cl, Br, I), hydroxy, thiol , Alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyl, aryloxy, CF ₃ , cyano, nitro, COORe (where Re is hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, heterocyclylalkyl, heteroarylalkyl ), NHC (= O) Rf, -NRfRq, -C (= O) NRfRq, -NHC (= O) NRfRq,
-OC (= O) NRfRq (Rf and Rq street defined above), - SO ₂ R ₆ (as R ₆ is as defined above), carboxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl or, It refers to a carbocyclic aromatic group optionally substituted by 1-3 substituents selected from aminocarbonylamino. The aryl group may optionally be fused with a cycloalkyl group, where the cycloalkyl group may optionally contain a heteroatom selected from O, N, or S. Aryl groups can also _{be, Cl, Br, NH 2,} OCH 3, CONH 2, NHCOCH 3, CH (OH) CH 3, C (CH 3) = NOH, C (CH 3) = NOCH 3, NH-N (= NH) NH _2, oxazolyl, pyrrolyl, pyrazolyl, pyridinyl, morpholinyl, pyrimidinyl, triazinyl, N- methyl - pyrazolyl, 2-oxo - oxazolidinyl, isoindolyl-1,3-dione, thiadiazolyl, pyrrolyl-3-carbaldehyde oxime, pyrrolyl -3-carbaldehyde, NHSO ₂ Rz, or NHCOR ₆ [(wherein R ₅ is C ₁ -C ₄ alkyl, thienyl, 3,5-dimethyl-isoxazolyl, N-methyl-imidazolyl, p-acetylphenyl 2,4-dimethyl-thiazolyl, 5-chloro-1,3-dimethyl-pyrazolyl, 2,5-dimethyl-furan-3-carboxylic acid methyl ester, 3-methyl-thiophene-2-carboxylic acid methyl ester, furan 2-Carboxylic acid methyl ester, 1- (3,4-dihy B -1H- isoquinolin-2-yl) -2,2,2-trifluoroethene Thanon, indol-2-yl - carbamic acid methyl ester or may be selected from phenyl carbaldehyde oxime,, R ₆ is methyl, (CH ₂ ) ₃ COOC ₂ H ₅ , NHC (CH ₃ ) ₂ , or isoxazolyl)], F, OH, NHSO ₂ CH ₃ , NHC (O) OCH ₃ , 5-oxo-1,5 -Dihydro-4H-1,2,4-triazol-4-yl; 5-methyl-1,3,4-oxadiazol-2-yl; 1-methyl-1H-pyrazol-4-yl; 3,5-dimethyl Isoxazol-4-yl; 1H-pyrrol-1-yl; thiopen-3-sulfonamido; 1H-tetrazol-1-yl; 1H-pyrrol-1-yl; 1,3-oxazol-5-yl; -1,2,4-triazol-1-yl; 1H-1,2,3-triazol-1-yl; 1-methyl-1H-imidazol-4-sulfonamide; 1,2,3-thiadiazol-4- 2-methyl-2H-tetrazol-5-yl; 5-methyl-1,3,4-oxazol-2-yl; Thio-1,3-thiazol-4-yl; thiopen-2-sulfonamide; 2-oxo-1,3-oxazolidin-3-yl; 1,2,4-oxadiazol-3-yl; 1H-pyrazol-1 It may be substituted by a substituent selected from -yl, or [(alkyl or dialkylamino) sulfonyl] amino.

Unless otherwise specified, the term “heteroaryl” refers to an aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group containing 8 to 10 ring atoms, One or more heteroatoms are independently selected from N, O, or S, and the heteroatoms are halogen (eg, F, Cl, Br, I), hydroxy, thiol, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, carboxy, aryl, alkoxy, aralkyl, cyano, nitro, heterocyclyl, heteroaryl, -NRfRq, CH = NOH, - in _{(CH 2) wC (= O} ) Rg { equation, w is, 0- Is an integer of 4, Rg is hydrogen, hydroxy, ORf, NRfRq, —NHORz, or —NHOH}, —C (═O) NRfRq and —NHC (═O) NRfRq, —SO ₂ R ₆ , —OC (= O) NRfRq, in -OC (= O) Rf, -OC (= O) ORf ( equation, R _6, Rf and Rq are as defined above, Rz is a Kill, cycloalkyl, aryl, heteroaryl, heterocyclyl, optionally substituted by heteroarylalkyl, or 1 to 4 substituents selected from the heterocyclylalkyl is heterocyclylalkyl). Heteroaryl _{also, Cl, CH 3, OCH 3} , NHCOCH 3, NHCOOCH 3, C 6 H 4 COOC 2 H 5, SO 2 thienyl, selected furanyl, phenyl, thienyl, trimethoxyphenyl, pyrazinyl, or isoxazolyl, substituted It may be substituted by a group. Unless otherwise limited by definition, the substituent is attached to a ring atom in the ring, ie, a carbon or heteroatom. Examples of heteroaryl groups include oxazolyl, imidazolyl, pyrazolyl, pyrrolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thiazolyl, oxadiazolyl, benzoimidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, Examples include thienyl, isoxazolyl, triazinyl, furanyl, benzofuranyl, indolyl, benzothiazolyl, or benzoxazolyl, isoquinolinyl, benzisoxazolyl, benzothienyl, pyrazolyl-3-one, and the like. The term “heteroaryl” also refers to 5-bromo-1,3-thiazol-2-yl; 2-amino-pyrimidin-5-yl; 1-benzofuran-2-yl; 1-benzothiophen-2-yl; 5-methyl-1H-benzimidazol-2-yl; 5-fluoro-3-methyl-1-benzothiophen-2-yl; 5-chloro-1,3-benzothiazol-2-yl; 2-amino-H -Benzimidazol-5-yl; 2-amino-1,3-benzothiazol-4-yl; 2-amino-1,3-benzothiazol-6-yl; 1,3-benzothiazol-2-acetamido-6-yl; 5-chloro-2,1,3-benzoxadiazol-4-yl; 2,1,3-benzothiadiazol-5-yl; 2- (dimethylamino) -1,3-benzothiazol-6-yl 1,3-benzothiazol-2-L-alaninamido-6-yl; optionally substituted thiophene (wherein the substituent is 3,5-dimethylisoxazol-4-yl or isoxazol-5- 1H-1,2,4-triazole Pyridine substituted by 1-yl; 1H-pyrrol-1-yl; 2-furyl; 3-furyl; 1H-tetrazol-1-yl; 2-thienyl; 1H-imidazolyl-1-yl; Morpholine-N-i; Br; NH ₂ ; NHC (NH) NH ₂ , or NHSO ₂ Rx (where Rx is methyl, 2-thiophenyl, or N-methyl-imidazolyl) .

Unless otherwise specified, the term “heterocyclyl” is a non-aromatic mono- or bicyclic cycloalkyl group having from 5 to 10 atoms, wherein 1 to 4 in the ring The carbon atom of is a benzene fused or fused heteroaryl substituted with O, S, or N and having 5-6 ring members and / or is optionally substituted. In this case, the substituents are halogen (eg, F, Cl, Br, I), hydroxy, thiol, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, aryl, alkoxy, alkaryl, cyano, nitro, oxo, carboxy, heterocyclyl, heteroaryl, -OC (= O) Rf, -OC (= O) ORf, -C (= O) NRfRq, SO 2 R 6, -OC (= O) NRfRq, -NHC (= O) NRfRq, -NRfRq (wherein R ₆ , Rf and Rq are as defined above) or guanidine. A heterocyclyl may optionally contain one or more double bonds. Unless otherwise limited by definition, the substituent is attached to a ring atom in the ring, ie, a carbon or heteroatom. Further, unless otherwise limited by definition, the heterocyclyl ring may optionally include one or more olefinic bond (s). Examples of heterocyclyl groups include oxazolidinyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl, dihydroisoxazolyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindolyl, pyridinyl, isoindole 1,3-dione, piperidinyl, Or piperazinyl is mentioned. The term “heterocyclyl” also refers to 2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinolin-7-yl; 1,2,3,4-tetrahydroisoquinolin-7-yl; Fluoroacetyl) indoline-5-yl; indoline-5-yl; 4-oxo-3,4-dihydroquinazolin-2-yl; 2-oxo-1,2-dihydroquinolin-6-yl; 1-methyl-2 -Oxo-1,2-dihydroquinolin-6-yl; 1-ethyl-2-oxo-1,2-dihydroquinolin-6-yl; or 2-oxo-2,3-dihydro-1,3-benzoxazol- 6-yl is mentioned.

“Aryl, heteroaryl, and heterocyclyl” groups include alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl, halogen, hydroxy, alkoxy, cyano, nitro, aryloxy, haloalkoxy , CORb, CSRb, COORb, S (O) aRb, OCOORb, NHSO ₂ Rb, NHCORb, NHCSRb, (CH) _0-2 C (= O) NRcRd, or NRcRd (where Rb, Rc, and Rd are , Hydrogen, alkyl, aryl, heteroaryl, heterocyclyl, and a is an integer of 0-2, and may be optionally substituted. Unless otherwise limited, all substituents may be further optionally substituted with the substituent (s) defined above.

  As used herein, the term “antibacterial agent” refers to an agent that destroys or inhibits the growth of bacteria, such as penicillin, cephalosporins, aminoglycosides, tetracyclines, macrolides, lincosamides, streptogramins, fluoroquinolones, polyquinones. Refers to peptide, rifampicin, cycloserine, aminocyclitol, glycopeptide, or oxazolidinone. Aminoacyl tRNA synthetase inhibitors and antibacterial agents may be widely selected from those known in the prior art, or those subsequently discovered, and / or those subsequently discovered and / or developed.

  The term “pharmaceutically acceptable solvate” refers to a solvate with water (eg, hydrate, hemihydrate, or sesquihydrate) or a pharmaceutically acceptable solvent. Solvent compounds of, for example, common organic solvents such as ethanol and the like. Such solvates are also included within the scope of this disclosure.

  The present invention also includes within its scope precursors of these agents. In general, such drug precursors are derivatives of these compounds, which are functional derivatives that can be readily converted to the required compounds in vivo. Conventional methods for the selection and preparation of suitable drug precursor derivatives are described, for example, in “Design of Prodrugs” ed. H Bundgaard, Elsevier, 1985. As used herein, the term “drug precursor” refers to a compound that is readily transformed in vivo to yield the parent compound of formula I, for example, by hydrolysis in blood.

  The described compounds may be metabolized in vivo and these metabolites are also included within the scope of the present invention.

  The term “polymorph” includes not only all crystalline forms of the compounds described herein, but also their amorphous forms, and is included in the present invention as such.

  The phrase “pharmaceutically acceptable carrier” includes non-toxic, inert, solid, semi-solid, or liquid fillers, diluents, encapsulating materials, or any type of auxiliary formulation. Intended.

  The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable monovalent, divalent, or trivalent, non-toxic metal or organic bases. Examples of such metal salts include, but are not limited to, lithium, sodium, potassium, calcium, magnesium, zinc, aluminum and the like. Examples of such organic bases include, but are not limited to, amino acids, ammonia, monoalkylammonium, dialkylammonium, trialkylammonium, N-methylglucamine, and the like. The free amino acid form of the compounds of the invention may be prepared from the salt form, if necessary, by contacting the salt with a dilute aqueous solution of an acid such as hydrochloric acid. Base addition salts may differ from the free acid forms of the compounds of the invention in physical properties, such as solubility and melting point.

  The term “pharmaceutically acceptable salts” may further refer to salts prepared from pharmaceutically acceptable non-toxic inorganic or organic acids. Examples of such inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitrous acid, nitric acid, nitric acid, carbonic acid, sulfuric acid, phosphoric acid and the like. Suitable organic acids include fatty acid, cyclo fatty acid, aromatic acid, heterocycle, carboxylic acid, and organic acid classes of sulfonic acid, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid , Malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, mesylic acid, salicylic acid, p-hydroxybenzoic acid, phenylacetic acid, mandel Examples include, but are not limited to, acid, embonic acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, panthenic acid, toluene sulfonic acid, 2-hydroxyethane sulfonic acid, and the like.

  The compounds of the present invention include stereoisomeric forms. The term “stereoisomer” refers to compounds that have the same chemical composition but differ in the arrangement of atoms and groups in space. Such include enantiomers, diastereomers, geometric isomers, conformers, and conformer isomers as defined in the IUPAC 1974 recommendation, Section E. All these stereoisomers are included within the scope of the present invention.

  As used herein, the term “subject” refers to a human or lower mammal.

  The term “treatment” as used herein includes treatment or prevention of bacterial or fungal infections as indicated in the methods of the invention, unless otherwise indicated.

  The term “pharmaceutically acceptable” is recognized by federal or state government regulators, or in the US pharmacopoeia or other recognized pharmacopoeia, more specifically animals. Means being posted for human use.

  The compounds described herein are prepared by familiar techniques well known to average organic synthesis professionals. In addition, the compounds of the invention are shown in Schemes I, Ia-Ie, Ia ′, II, IIa-IIe, III, IV, V, VI, VIa, VIb, VII, VIII, VIIIa, IX, X, and XI. May be prepared by the reaction sequence as described.

The sulfonamide of formula 5 can be prepared, for example, according to Scheme I. That is, a compound of formula 2 can be reacted with a compound of formula 3 to produce a compound of formula 4, which, when oxidized, produces a sulfonamide of formula 5 (in the above formula) , X ₁ -X ₄ and R ₆ are as defined above).

  The reaction of the compound of formula 2 with the compound of formula 3 can be carried out in the presence of one or more organic bases such as pyridine, triethylamine, trimethylamine, tributylamine, or 4-N-dimethylaminopyridine. It is. Oxidation of the compound of formula 4 may involve one or more oxidizing agents such as Dess-Martin periodinane, 2-iodoxybenzoic acid, N-chlorosuccinimide, pyridinium chlorochromate, Swern oxidizing reagent (oxalyl chloride and dimethyl sulfoxide). ), Pfitzner-Moffatt oxidation reagent (dicyclohexylcarbodiimide and dimethyl sulfoxide), Jones oxidation reagent (chromic acid, aqueous sulfuric acid, and acetone), pyridinium dichromate, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride , Or mixtures thereof, with one or more solvents such as chlorinated solvents (eg, chloroform, dichloromethane, carbon tetrachloride, or dichloroethane), polar aprotic solvents (eg, dimethylsulfoxide, dimethylformamide, acetone) , Tetrahydrofuran, or a Tonitoriru) or are performed in the presence of a solution in a mixture thereof. It is possible to use N-chlorosuccinamide in combination with dimethyl sulfide and 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride in combination with dimethyl sulfide.

Compounds of formula 8 can be prepared, for example, according to Scheme Ia. That is,
(a) A compound of formula 6 (when R ₆ is 4-fluorophenyl) is reacted with a compound of formula R ₈ H to produce a compound of formula 7. The latter is oxidized to produce a compound of formula 8, wherein R ₈ is an optionally substituted aryl, heteroaryl, or heterocyclyl.
(b) A compound of formula 6 (when R ₆ is 4-nitrophenyl) can be reacted with a reducing agent to produce the corresponding amine. The latter can react with 2,5-dimethoxytetrahydrofuran or 2,5-dimethoxy-3-furyltetrahydrofuran to produce a compound of formula 7, which can be oxidized to produce a compound of formula 8. It is possible (where R ₈ is a 5-membered, nitrogen-containing heteroaryl).

The reaction of a compound of formula 6 (wherein R ₆ is 4-fluorophenyl) with a compound of formula R ₈ H may be carried out by one or more inorganic bases such as potassium carbonate, sodium carbonate, sodium bicarbonate, sodium acetate Or dissolved in one or more polar, aprotic solvents such as N-methyl-2-pyrrolidinone, dimethylformamide, or dimethylsulfoxide in the presence of cesium carbonate. Reduction of the compound of formula 6 (R ₆ is 4-fluorophenyl) to give an amine compound may be performed by one or more reducing agents, eg, Raney nickel dissolved in hydrazine hydrate, zinc in the presence of hydrochloric acid, tin ions, Or it is carried out in the presence of lithium aluminum hydride. The amine compound thus formed is converted to a compound of formula 7 by reaction with 2,5-dimethoxytetrahydrofuran dissolved in one or more polar protic solvents such as water, methanol, ethanol, or acetic acid. . Oxidation of the compound of formula 7 to give the compound of formula 8 is performed using, for example, the procedure described in Scheme I.

A compound of formula 8c, wherein X ₁ and X ₂ are as defined above, R ₈ ′ is H or F, and R ₈ is 5-membered heteroaryl or 5-membered heterocyclyl. For example, according to the procedure described in Scheme Ia.

Compounds of formula 10 are prepared, for example, according to Scheme Ib. That is, reaction of a compound of formula 9 with a compound of formula R ₈ B (OH) ₂ gives a compound of formula 9a. When the latter is oxidized, a compound of formula 10 wherein R ₈ is H but is optionally substituted by aryl, heteroaryl, or heterocyclyl, and X ₁ -X ₄ is as defined above. Give).

The reaction of the compound of formula 9 with the compound of formula R ₈ B (OH) ₂ is carried out in one or more polar protic solvents such as methanol, ethanol, propanol, isopropanol, t-butanol, or water. The reaction of the compound of formula 9 may also include copper (I) iodide, palladium catalyst, eg, palladium (II) acetate, palladium (II) trifluoroacetate, palladium (II) propionate, tetrakis (triphenylphosphine) palladium. (0), tris (dibenzylidineacetone) palladium (0), or bis (triphenylphosphine) palladium (II) chloride in the presence of one or more inorganic bases such as potassium carbonate, sodium carbonate, carbonate It can be carried out in the presence of sodium hydrogen, sodium acetate, or cesium carbonate. Oxidation of the compound of formula 9a to give the compound of formula 10 can be performed using, for example, the procedure described in Scheme I.

Compounds of formula 14 can be prepared, for example, according to Scheme Ic. That is, reaction of a compound of formula 11 with a formula R ₆ COOH gives a compound of formula 12 (wherein R ₉ is a protecting group such as tert-butyldimethylsilyl, trimethylsilyl, 4-benzyloxybutyrate). Ryl, 1,4-diazabicyclo [2.2.1] octane, tertiary butoxycarbonyl, or tert-butyldiphenyl). Compounds of formula 12 can be oxidized to produce compounds of formula 14 (X ₁ -X ₄ and R ₆ are as defined above).

The reaction of the compound of formula 11 with the formula R ₆ COOH can be carried out using one or more binders such as 1-hydroxybenzotriazole, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, N, N ′ Of a solution of -dicyclohexylcarbodiimidazole or N, N'-carbonyldiimidazole in one or more aprotic solvents such as N-methyl-2-pyrrolidinone, dimethylformamide, or dimethylformamide It can be performed in the presence. The reaction of deprotecting the compound of formula 12 to produce the compound of formula 13 comprises reacting tetra-n-butylammonium fluoride with one or more solvents, such as ethers (eg, tetrahydrofuran, dioxane, or ether), Alternatively, it can be carried out in the presence of a solution dissolved in an aprotic solvent (for example, dimethyl sulfoxide, dimethyl formamide), ketones (acetone or ethyl methyl ketone), or a mixture thereof. Oxidation of the compound of formula 13 to produce the compound of formula 14 can be performed using, for example, the procedure described in Scheme I.

Compounds of formula 18 can be prepared, for example, according to Scheme Id. That is, the reaction of a compound of formula 11 and an imidazole produces a compound of formula 15, which when treated with a compound of formula R ₆ CH ₂ OH, wherein R ₉ is Protecting groups such as tert-butyldimethylsilyl, trimethylsilyl, 4-benzyloxybutyryl, 1,4-diazacyclo [2.2.1] octane, tertiary butoxycarbonyl, or tert-butyryldiphenylsilyl) This, when deprotected, produces a compound of formula 17, which is capable of producing a compound of formula 18 (X ₁ -X ₄ and R ₆ are as defined above) .

The reaction of the compound of formula 11 with imidazole may be carried out by using one or more binders such as N, N-carbonyldiimidazole, N, N-dicyclohexylcarbodiimide, or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide. Hydrochloric acid is added to one or more solvents such as chlorinated solvents (eg chloroform, dichloromethane, dichloroethane, or tetrachloromethane), polar aprotic solvents (eg dimethylformamide, dimethylformamide), ketones (acetone Or ethyl methyl ketone), or a mixture thereof in the presence of a solution. The reaction of a compound of formula 15 with a compound of formula R ₆ CH ₂ OH can be carried out using one or more solvents, such as chlorinated solvents (eg, dichloromethane, dichloroethane, chloroform, or tetrachloromethane), aprotic solvents (eg, Dimethylformamide, or dimethylformamide), or a mixture thereof. The reaction of deprotecting the compound of formula 16 to produce the compound of formula 17 involves reacting tetra-n-butylammonium fluoride with one or more solvents, such as ethers (eg, tetrahydrofuran, dioxane, or ether), Alternatively, it can be carried out in the presence of a solution dissolved in a polar aprotic solvent (eg, dimethyl sulfoxide, dimethylformamide), ketones (acetone or ethyl methyl ketone), or mixtures thereof. Oxidation of the compound of formula 17 to produce the compound of formula 18 can be performed using, for example, the procedure described in Scheme I.

  Compounds of formula 18 can be prepared, for example, according to Scheme Ie. That is, the reaction of a compound of formula 18a with chlorosulfonic acid yields a compound of formula 18b, which when treated with a compound of formula 2a yields a compound of formula 18c, which is oxidized. To produce a compound of formula 18d.

  The reaction of the compound of formula 18b with the compound of formula 2a can be carried out in one or more organic bases such as pyridine, triethylamine, trimethylamine, tributylamine, or 4-N-dimethylaminopyridine. The oxidation of formula 18c can be performed using, for example, the procedure described in Scheme I.

  Compounds of formula 24 can be prepared, for example, according to Scheme II. That is, reaction of a compound of formula 19 with a compound of formula 20 yields a compound of formula 21, which when treated with tosyl chloride yields a compound of formula 22, which is represented by the formula Cy-Ha To form a compound of formula 23 (where Ha is a halogen), which is finally deprotected to give a compound of formula 24 (in the S isomer, where Cy is As defined in). Similarly, the R isomeric form can be prepared.

  The reaction of the compound of formula 19 with the compound of formula 20 can be carried out using one or more solvents, such as chlorinated solvents (eg, chloroform, dichloromethane, dichloroethane, carbon tetrachloride, or dichloroethane), polar aprotic solvents (eg, dimethyl). Sulfoxide, dimethylformamide), or mixtures thereof. The reaction of the compound of formula 21 with tosyl chloride can be carried out by using one or more solvents such as ethers (eg ether, dioxane or tetrahydrofuran), chlorinated solvents (eg dichloromethane, dichloroethane or chloroform), or Can be carried out in a mixture of The reaction of the compound of formula 21 with tosyl chloride may also include one or more metal hydroxides, such as alkali metal hydroxides (eg, potassium hydroxide, sodium hydroxide, or lithium hydroxide), alkaline earth metal waters. It can be carried out in the presence of an oxide (calcium hydroxide or magnesium hydroxide) or a mixture thereof. The reaction of the compound of formula 22 with the compound of formula Cy-Ha can be carried out in the presence of magnesium (dry ether solution) in the presence of one or more solvents such as ethers (eg ether, dioxane or tetrahydrofuran), chlorine It can be carried out in a solvating solvent (eg dichloromethane or chloroform), or mixtures thereof. The reaction to deprotect the compound of formula 23 to form the compound of formula 24 comprises one or more solvents in the presence of one or more mineral acids, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, For example, it can be carried out in a polar protic solvent such as water, methanol, ethanol, propanol, isopropanol, or tert-butanol.

  Compounds of formula 26 (formula 24 where Cy is cyclohexyl) can also be prepared, for example, according to Scheme IIa. That is, the compound of formula 25 is reduced to produce the compound of formula 26.

  The reaction to reduce the compound of formula 25 to form the compound of formula 26 is carried out in the presence of one or more organic acids, for example acetic acid or trifluoroacetic acid, in one or more reducing agents, for example platinum oxide. Is possible.

  Compounds of formula 31 (formula 24 where Cy is piperazine) can also be prepared, for example, according to Scheme IIb. That is, the reaction of a compound of formula 27 with a nitroethanone produces a compound of formula 28, which is dehydrated to form a compound of formula 29, which is hydrogenated to produce a compound of formula 30, which is protected. Thus, it is possible to produce the compound of formula 31.

  The reaction of the compound of formula 27 with nitroethane can be carried out in the presence of one or more inorganic bases, such as sodium hydroxide, potassium hydroxide, cesium hydroxide, calcium hydroxide, or sodium bicarbonate. is there. The reaction in which the compound of formula 28 is dehydrated to form the compound of formula 29 can be carried out in the presence of acetic anhydride and sodium acetate. The reaction of hydrogenating a compound of formula 29 to form a compound of formula 30 comprises one or more protic polar solvents, such as, for example, in the presence of a hydrogenating agent such as sodium, platinum / hydrogen, or palladium on carbon / hydrogen. It can be carried out in methanol, ethanol, isopropanol, or water. The reaction to protect the compound of formula 30 to form the compound of formula 31 may be carried out in the presence of an N-protecting agent such as di-tert-butyl dicarbonate in the presence of one or more solvents, such as polar aprotic solvents ( For example, dimethylformamide or dimethyl sulfoxide), ketones (eg ethyl methyl ketone, methyl isobutyl ketone, or acetone), or mixtures thereof, one or more inorganic bases such as sodium carbonate, hydrogen carbonate It can be carried out in the presence of sodium, potassium carbonate, cesium carbonate, or calcium carbonate.

  Compounds of formula 31d can be prepared, for example, according to Scheme IIc. That is, the reaction of a compound of formula 31a with benzyl bromide yields a compound of formula 31b, which when treated by fluorine addition yields a compound of formula 31c, which is deprotected to yield formula 31d To produce the compound

  The reaction of the compound of formula 31a with benzyl bromide can be carried out by using one or more solvents, such as chlorinated solvents (eg, chloroform, dichloromethane, carbon tetrachloride, or dichloroethane), polar aprotic solvents (eg, dimethyl sulfoxide, Or dimethylformamide), ketones (eg, acetone or ethyl methyl ketone), or mixtures thereof. Fluorination of the compound of formula 31b with (diethylamino) sulfur trifluoride (DAST) can be accomplished using one or more solvents, such as chlorinated solvents (eg, dichloromethane, dichloroethane, or chloroform), ethers (eg, ethers, Dioxane or tetrahydrofuran), or mixtures thereof. Deprotection of the compound of formula 31c can be accomplished in the presence of a reducing agent (eg, palladium hydroxide, or raney nickel), or one or more mineral acids (eg, hydrochloric acid, hydrobromic acid, hydroiodic acid). It can be carried out in one or more polar protic solvents such as water, methanol, ethanol, propanol, isopropanol, or tert-butanol.

  Compounds of formula 31h can be prepared, for example, according to Scheme IId. That is, reaction of a compound of formula 31c with benzyl bromide yields a compound of formula 31f, which upon fluorination yields a compound of formula 31g, which is deprotected to yield a compound of formula 31h. Can be generated.

  The reaction of the compound of formula 31e with benzyl bromide can be carried out using one or more solvents, such as chlorinated solvents (eg, chloroform, dichloromethane, carbon tetrachloride, or dichloroethane), polar aprotic solvents (eg, dimethyl sulfoxide, Or dimethylformamide), ketones (eg, acetone, methyl ethyl ketone, or methyl isobutyl ketone), or mixtures thereof. Fluorination of the compound of formula 31f with (diethylamino) sulfur trifluoride (DAST) can be accomplished using one or more solvents such as chlorinated solvents (eg, dichloromethane, dichloroethane, carbon tetrachloride, or chloroform), ethers ( For example, it can be carried out in ether, dioxane or tetrahydrofuran), or mixtures thereof. Deprotection of the compound of formula 31g is carried out in the presence of a reducing agent (eg palladium hydroxide or raney nickel) or one or more mineral acids, eg hydrochloric acid, hydrobromic acid, hydroiodic acid. More than one type of solvent, such as nitriles (eg, acetonitrile or propionitrile), chlorinated solvents (eg, dichloromethane, dichloroethane, carbon tetrachloride, or chloroform), polar protic solvents (eg, water, methanol, ethanol, Propanol, isopropanol, or tert-butanol), or mixtures thereof.

  Compounds of formula 31j can be prepared, for example, according to Scheme IIe. That is, reduction of a compound of formula 31i produces a compound of formula 31j (RS isomer). Similarly, it is possible to prepare the SS isoform.

  Reduction of the compound of formula 31i is performed in one or more reducing agents (eg, platinum oxide, palladium hydroxide, or raney nickel) in the presence of one or more organic acids, eg, acetic acid or trifluoroacetic acid. It is possible.

Compounds of formula 32 can be prepared, for example, according to Scheme III. That is, a compound of formula 5 can be reacted with a compound of formula 24 to produce a compound of formula 33 (wherein Cy, X ₁ -X ₄ , and R ₆ are defined above). Street).

  The reaction of the compound of formula 5 with the compound of formula 24 may be performed in the presence of one or more reducing agents, for example, sodium cyanoborohydride, sodium borohydride, or sodium triacetoxyborohydride. Can be carried out in various polar protic solvents such as methanol, ethanol, propanol, isopropanol, or water.

  Compounds of formula 33 can be prepared, for example, according to Scheme IV using, for example, the procedure described in Scheme III.

  Compounds of formula 34 can be prepared, for example, according to Scheme V using, for example, the procedure described in Scheme III. In Scheme III-V, the compound of formula 24 can be substituted with a compound of formula 26, 31, 31d, 31h, or 31j to form sulfonamide, amide, and carbamate compounds, respectively.

Compounds of formula 39 can be prepared, for example, according to Scheme VI. That is, protection of a compound of formula 35 with a protective agent R ₉ Hal (wherein Hal is halogen) is a compound of formula 36 where R ₉ is tert-butyldimethylsilyl, trimethylsilyl, di-tert-butyldi Carbonate, 4-benzyloxybutyryl, 1,4-diazabicyclo [2.2.1] octane, tertiary butoxycarbonyl, or tert-butyldiphenylsilyl), which is reduced to form This produces a compound that reacts with a compound of formula R ₆ NCO to produce a compound of formula 38, which can be deprotected to produce a compound of formula 39.

The reaction to protect the compound of formula 35 to form the compound of formula 36 comprises one or more chlorinated solvents in the presence of one or more organic bases, for example, triethylamine, trimethylamine, pyridine, or tert-butylamine, For example, it can be carried out in dichloromethane, dichloroethane, chloroform, or tetrachloromethane. The reaction of reducing the compound of formula 36 to form the compound of formula 37 can include one or more reducing agents such as raney nickel dissolved in hydrazine hydrate, hydrochloric acid or zinc in the presence of lithium aluminum hydride, It can be carried out in the presence of tin or iron. The reaction of the compound of formula 37 with the compound of formula R ₆ NCO can be carried out in one or more chlorinated solvents such as dichloromethane, dichloroethane, chloroform, or tetrachloromethane. The reaction to deprotect the compound of formula 38 to form the compound of formula 39 comprises one or more polar protic solvents in the presence of one or more mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid. For example, in water, methanol, ethanol, propanol, or isopropanol.

Compounds of formula 39d can be prepared, for example, according to Scheme Via. That is, the reaction of a compound of formula 39a with a compound of formula 39b produces a compound of formula 39c, which when deprotected produces a compound of formula 39d (wherein X ₁ -X ₄ Is as defined above).

  The reaction of the compound of formula 39a with the compound of formula 39b can be carried out using one or more binders such as N, N-carbonyldiimidazole, N, N-dicyclohexylcarbodiimide, or 1- (3-dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloric acid is added to one or more solvents such as nitriles (acetonitrile or propionitrile), chlorinated solvents (eg chloroform, dichloromethane, dichloroethane or tetrachloromethane), polar aprotic solvents ( For example, it is carried out in the presence of a solution dissolved in dimethylformamide, dimethylformamide), ketones (acetone or ethylmethylketone), or a mixture thereof. Deprotection of the compound of formula 39c can be accomplished using one or more acids, such as mineral acids (eg, hydrochloric acid, hydrobromic acid, or hydroiodic acid), organic acids (eg, trifluoroacetic acid, or paratoluenesulfonic acid). ) Or mixtures thereof, in the presence of one or more polar protic solvents such as water, methanol, ethanol, propanol, or isopropanol.

式39gの化合物は、例えば、スキームVIbに従って調製することが可能である。すなわち、式39aの化合物と式39eの化合物との反応は、式39fの化合物を生成するが、これは、脱保護されると、式39gの化合物を生成する（式中、X₁-X₄は上に定義した通りであり、Rbは、メチル、メトキシ、またはアミノエチルである）。

Compounds of formula 39g can be prepared, for example, according to Scheme VIb. That is, reaction of a compound of formula 39a with a compound of formula 39e yields a compound of formula 39f, which when deprotected yields a compound of formula 39g (wherein X ₁ -X ₄ Is as defined above, and Rb is methyl, methoxy, or aminoethyl).

  The reaction of the compound of formula 39a with the compound of formula 39e can be carried out by using one or more binders such as N, N-carbonyldiimidazole, N, N-dicyclohexylcarbodiimide, or 1- (3-dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloride, one or more solvents such as nitriles (eg acetonitrile or propylonitrile), chlorinated solvents (eg chloroform, dichloromethane, dichloroethane or tetrachloromethane), polar aprotic It is carried out in the presence of a solution dissolved in a solvent (eg dimethyl sulfoxide, dimethylformamide), ketones (eg acetone, ethyl methyl ketone or methyl isobutyl ketone), or mixtures thereof. Deprotection of the compound of formula 39f can be accomplished using one or more acids, such as mineral acids (eg, hydrochloric acid, hydrobromic acid, or hydroiodic acid), organic acids (eg, trifluoroacetic acid, or paratoluenesulfonic acid). ) Or mixtures thereof, in the presence of one or more polar protic solvents such as water, methanol, ethanol, propanol, or isopropanol.

Compounds of formula 41 can be prepared, for example, according to Scheme VII. That is, the reaction of a compound of formula 37a with RxSO ₂ Cl yields a compound of formula 40, which when deprotected is a compound of formula 41 (wherein Cy and X ₁ -X ₄ are Rx is methyl, N (CH ₃ ) ₂ , NH ₂ , CH = CHCOOC ₂ H ₅ , (CH ₂ ) ₃ COOC ₂ H ₅ , phenyl, 1,2,3,4-tetrahydroquinolyl Nyl, 2,2,2-trifluoroacetyl-1- (3,4-dihydro-1H-isoquinolin-2-yl), morpholinyl, or heteroaryl).

The reaction of the compound of formula 37a with RxSO ₂ Cl can be carried out in the presence of one or more organic bases such as pyridine, triethylamine, or trimethylamine. Deprotection of the compound of formula 40 to produce the compound of formula 41 can be accomplished using one or more mineral acids such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, one or more polar protic solvents such as water Can be carried out in the presence of methanol, ethanol, propanol, or isopropanol.

Compounds of formula 44 and 46 can be prepared, for example, according to Scheme VIII. That is, deprotection of a compound of formula 35 with thiophenol or thioglycolic acid in the presence of a base such as potassium carbonate, sodium carbonate, or cesium carbonate produces a compound of formula 42, which
(1) reacts with a compound of formula 42a to produce a compound of formula 43, which is deprotected to produce a compound of formula 44, or
(2) Reacts with a compound of formula R ₆ NCO to produce a compound of formula 45, which can be deprotected to produce a compound of formula 46.

Deprotection of the compound of formula 35 to produce the compound of formula 42 may involve the use of one or more inorganic bases, such as cesium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, or calcium carbonate, in the presence of Solvents such as nitriles (eg acetonitrile or propylonitrile), acetates (eg ethyl acetate or methyl acetate), polar aprotic solvents (eg dimethyl sulfoxide or dimethylformamide), ketones In the presence of a solution dissolved in a class (for example, acetone or ethyl methyl ketone), or a mixture thereof. The reaction of the compound of formula 42 with the compound of formula 42a can be carried out in the presence of one or more organic bases such as pyridine, triethylamine, or trimethylamine. The reaction of the compound of formula 42 with the compound of formula R ₆ NCO can be carried out in a chlorinated solvent such as dichloromethane, dichloroethane, chloroform, dichloromethane, or tetrachloromethane. Deprotection of the compounds of formulas 43 and 45 yielding compounds of formulas 44 and 46, respectively, is one or more mineral acids, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, one or more polar It can be carried out in the presence of a protic solvent such as methanol, ethanol, propanol, isopropanol, or butanol.

Compounds of formula 46 can also be prepared, for example, according to Scheme VIIIa. That is, reaction of a compound of formula 42 with phenyl chloroformate yields a compound of formula 42b, which reacts with an amine of formula R ₆ NH ₂ to yield a compound of formula 45, which is deprotected. To produce the compound of formula 46.

  The reaction of the compound of formula 42 with phenyl chloroformate can be carried out by using one or more solvents such as chlorinated solvents (eg dichloromethane, dichloroethane, chloroform or tetrachloromethane), nitriles (acetonitrile or propionitrile), Or in the presence of a solution dissolved in a mixture thereof. The compound of formula 42b is in a solution dissolved in one or more chlorinated solvents such as dichloromethane, dichloroethane, chloroform, or carbon tetrachloride in the presence of one or more bases such as triethylamine, trimethylamine, or pyridine. It is possible to execute. The compound of formula 45 is one or more acids, such as organic acids (eg, trifluoroacetic acid, or acetic acid), mineral acids (eg, hydrochloric acid, hydrobromic acid, or hydroiodic acid), or mixtures thereof , Deprotection in the presence of one or more polar protic solvents such as methanol, ethanol, propanol, isopropanol, butanol, or water.

Compounds of formula 51 can be prepared, for example, according to Scheme IX. That is, reaction of a compound of formula 47 with a compound of formula 24 yields a compound of formula 48, which when protected yields a compound of formula 49, which reacts with a compound of formula R ₆ NCO. This produces a compound of formula 50, which is deprotected to produce a compound of formula 51.

The reaction of the compound of formula 47 with the compound of formula 24 may be carried out by using one or more reducing agents such as sodium cyanoborohydride or sodium borohydride, one or more organic acids such as acetic acid or trifluoroacetic acid. Can be carried out in one or more polar protic solvents such as methanol, ethanol, propanol, isopropanol, or butanol. Protection of the compound of formula 48 with a protecting agent such as di-tert-butyl dicarbonate can be carried out in one or more chlorinated solvents such as dichloromethane, dichloroethane, chloroform, or tetrachloromethane. The reaction of a compound of formula 49 with a compound of formula R ₆ NCO can be one or more organic bases such as triethylamine, trimethylamine, or pyridine, one or more chlorinated solvents such as dichloromethane, dichloroethane, or chloroform. It can be performed in the presence. Deprotection of the compound of formula 50 to produce the compound of formula 51 includes one or more mineral acids such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, one or more polar protic solvents such as water Can be carried out in the presence of methanol, ethanol, propanol, or isopropanol.

  Compounds of formula 54 can be prepared, for example, according to Scheme X. That is, reaction of a compound of formula 52 with a compound of formula 39b produces a compound of formula 53, which when deprotected produces a compound of formula 54.

  The reaction of the compound of formula 52 can be carried out using one or more solvents such as nitriles (eg, acetonitrile or propionitrile), chlorinated solvents (eg, chloroform, dichloromethane, dichloroethane, or tetrachloromethane), polar aprotic In the presence of a solution dissolved in an organic solvent (eg, dimethyl sulfoxide, or dimethylformamide), ketones (eg, acetone, ethyl methyl ketone, or methyl isobutyl ketone), or mixtures thereof. Deprotection of the compound of Formula 53 can be accomplished using one or more organic acids (eg, trifluoroacetic acid or paratoluenesulfonic acid), mineral acids (eg, hydrochloric acid, hydrobromic acid, or hydroiodic acid), Can be carried out in the presence of these solvents, for example nitriles (eg acetonitrile, or propionitrile), polar protic solvents (eg water, methanol, ethanol, propanol, or isopropanol), or mixtures thereof It is.

  Compounds of formula 59 can be prepared, for example, according to Scheme XI. That is, reaction of a compound of formula 55 with phenyl chloroformate produces a compound of formula 56, which reacts with hydrazine hydrate to produce a compound of formula 57, which is cyclized. This produces the compound of formula 58, which is deprotected to produce the compound of formula 59.

  The reaction of the compound of formula 55 with phenyl chloroformate can be carried out using one or more solvents, such as nitriles (eg, acetonitrile or propionitrile), chlorinated solvents (eg, chloroform, dichloromethane, dichloroethane, or tetrachloro). Methane), polar aprotic solvents (eg, dimethyl sulfoxide, or dimethylformamide), ketones (eg, acetone, ethyl methyl ketone, or methyl isobutyl ketone), or mixtures thereof in the presence of To be executed. The reaction of the compound of formula 56 may involve one or more binders such as N, N-carbonyldiimidazole, N, N-dicyclohexylcarbodiimide, or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride. One or more solvents such as nitriles (eg acetonitrile or propylonitrile), chlorinated solvents (eg chloroform, dichloromethane, dichloroethane or tetrachloromethane), polar aprotic solvents (eg dimethylsulfuric acid) Foxide, dimethylformamide), ketones (eg, acetone or ethyl methyl ketone), or a solution thereof in a mixture thereof. The reaction of a compound of formula 57 with formamidine acetate comprises reacting an acid such as acetic acid hydrochloric acid with one or more solvents such as nitriles (eg acetonitrile or propionitrile), chlorinated solvents (eg chloroform, Dichloromethane, dichloroethane, or tetrachloromethane), polar aprotic solvents (eg, dimethyl sulfoxide, or dimethylformamide), ketones (eg, acetone, or ethyl methyl ketone), or mixtures thereof Executed in the presence of. Deprotection of the compound of formula 58 can be accomplished using one or more organic acids (eg, trifluoroacetic acid, or paratoluenesulfonic acid), mineral acids (eg, hydrochloric acid, hydrobromic acid, or hydroiodic acid) or their Carried out in the presence of a mixture, one or more solvents such as nitriles (eg acetonitrile or propionitrile), polar protic solvents (eg water, methanol, ethanol, propanol or isopropanol), or mixtures thereof Is possible.

  In the above scheme where specific bases, oxidizing agents, reducing agents, binders, solvents, etc. are mentioned, other bases, oxidizing agents, reducing agents, binders, solvents, etc. known to those skilled in the art can also be used. I have to understand that. Similarly, the temperature and duration of the reaction may be adjusted according to the desired requirements.

  The compounds described herein have antibacterial activity against gram positive, gram negative, anaerobic and fungal infections. These compounds are useful as antibacterial agents for the treatment of infections in humans and animals.

Listed below are particularly exemplary compounds useful for such purposes.
N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3,4,5,6-pentafluorobenzenesulfonamide (Compound No. 1),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide (Compound No. 2),

5- (1-Benzothien-2-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 3) ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 4),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 5),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 6),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 7) ,

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 8),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (1-hydroxyethyl) phenyl] thiophene-2-sulfonamide (Compound No. 9),

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 10),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl] thiophene-2-sulfonamide (Compound No. 11),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 12),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 13),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl] thiophene-2-sulfonamide (Compound No. 14),

6-Chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] imidazo [2,1-b] [1,3] thiazol-5-sulfonamide (Compound No. 15)

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2-sulfonamide (Compound No. 16 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl ] Thiophene-2-sulfonamide (Compound No. 17),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl] isoxazol-3-yl) thiophene-2-sulfonamide (Compound No. 18),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-yl ] Thiophene-2-sulfonamide (Compound No. 19),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide (Compound No. 20 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene-2-sulfonamide (Compound No. 21),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene-2-sulfone An amide (Compound No. 22),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazole-5- Yl] thiophene-2-sulfonamide (Compound No. 23),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-yl ] Thiophene-2-sulfonamide (Compound No. 24),

N- [2-({[(1S) -2-cyclopeptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl ] Thiophene-2-sulfonamide (Compound No. 25),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide (Compound No. 26 ),

5-Chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 27) ,

Methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate (Compound No. 28),

Methyl 4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate (Compound No. 29),

5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide (Compound No. 30 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide (Compound No. 31),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide (Compound No. 32),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide (Compound No. 33),

N- [2-({[(1S) -2-cyclohexyl-1- (hydroxymethyl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 34),

Methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate (Compound No. 35) ,

5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 36 ),

5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide (Compound No. 37),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide (Compound No. 38),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide (Compound No. 39),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide (Compound No. 40),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide (Compound No. 41),

5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 42),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 43),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 44),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide (Compound No. 45),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] nicotinamide (Compound No. 46),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide (Compound No. 47),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide (Compound No. 48),

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] [(2-methylphenyl) sulfonyl] carbamate hydrochloride (Compound No. 49),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide (Compound No. 50),

5-bromo-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamidine (Compound No. 51),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamide (Compound No. 52),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-3-sulfonamide (Compound No. 53),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide (Compound No. 54),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide hydrochloride (Compound No. 55),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride (Compound No. 56),

5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride (Compound No. 57),

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 58),

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 59),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide (Compound No. 60),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide (Compound No. 61),

Methyl 3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4- (isopropylsulfonyl) thiophene-2-carboxylate (compound number 62),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide (Compound No. 63),

N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (hydroxymethyl) phenyl] thiophene-2-sulfonamide (Compound No. 64),

N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (hydroxymethyl) phenyl] thiophene-2-sulfonamide (Compound No. 65),

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate (Compound No. 66),

Methyl 4-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate (Compound No. 67) ,

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2-sulfonamide ( Compound No. 68),

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide (Compound No. 69),

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide (Compound No. 70) ,

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide (Compound No. 71),

N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide (Compound No. 72),

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide (Compound No. 73),

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] nicotinamide (Compound No. 74),

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] nicotinamide (Compound No. 75),

N- [3-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide (Compound No. 76),

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide (Compound No. 77),

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4-fluorobenzenesulfonamide (Compound No. 78),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-6-benzene Sulfonamide (Compound No. 79),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide (Compound No. 80),

Methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2-carboxylate (compound Number 81),

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2-carboxylate (compound number 82),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide (Compound No. 83),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide (Compound No. 84),

5-bromo-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide (Compound No. 85),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide (Compound No. 86),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide (Compound No. 87),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide (Compound No. 88),

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide (Compound No. 89 ),

(1-benzothien-2-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 90),

5- (1-Benzothien-2-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 91) ,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 92) ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (4-methoxyphenyl) thiophene-2-sulfonamide (Compound No. 93),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide (Compound No. 94),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide (Compound No. 95),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-6-benzene Sulfonamide (Compound No. 96),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide (Compound No. 97),

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 98),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- [4- (4-methoxyphenyl) piperazin-1-yl] acetamide (Compound No. 99 ),

5-Chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 100) ,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide (Compound No. 101),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) thiophene-2-sulfone An amide (Compound No. 102),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) thiophene-2- Sulfonamide (Compound No. 103),

Ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4-oxadiazole -5-carboxylate (Compound No. 104),

Ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4-oxadiazole -5-carboxylate (Compound No. 105),

Ethyl 3- [5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4- Oxadiazole-5-carboxylate (Compound No. 106),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide (Compound No. 107),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide (Compound No. 108),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide (Compound No. 109) ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide (Compound No. 110),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide (Compound No. 111),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide (Compound No. 112) ,

Methyl 3-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate (Compound No. 113),

Methyl 3-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate (Compound No. 114),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide (Compound No. 115),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (2-thienylsulfonyl) -1,2,3,4-tetrahydroisoquinoline-6- Benzenesulfonamide (Compound No. 116),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide (Compound No. 117),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide (Compound No. 118),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 119),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 120),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide (compound Number 121),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide (Compound No. 122),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide (Compound No. 123),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide (Compound No. 124) ,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide (Compound No. 125 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-hydroxyethaneimidoyl] phenyl} thiophene-2 -Sulfonamide (Compound No. 126),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-methoxyethaneimidoyl] phenyl} thiophene-2 -Sulfonamide (Compound No. 127),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide (Compound No. 128),

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-methoxyphenyl) carbamate (Compound No. 129),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide (Compound No. 130),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide (Compound No. 131),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide (Compound No. 132),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (2-thienylsulfonyl) -1 , 2,3,4-Tetrahydroisoquinoline-6-sulfonamide (Compound No. 133),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (trifluoroacetyl) -1, 2,3,4-tetrahydroisoquinoline-6-sulfonamide (Compound No. 134),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline -6-sulfonamide (Compound No. 135),

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (compound Number 136),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide (Compound No. 137),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide (Compound No. 138),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (1,3-oxazol-2-yl) thiophene-2-sulfonamide (compound Number 139),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide (Compound No. 140),

N- (4-acetylphenyl) -N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea (Compound No. 141),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 142),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-4-ylthiophene-2-sulfonamide (Compound No. 143),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-3-ylthiophene-2-sulfonamide (Compound No. 144),

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-acetylphenyl) carbamate (Compound No. 145),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide (compound Number 146),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide ( Compound No. 147),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide (Compound No. 148) ,

6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (4-methoxyphenyl) -3,4-dihydroisoquinoline- 2 (1H) -carboxamide (Compound No. 149),

6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (isopropyl) -3,4-dihydroisoquinoline-2 (1H ) -Carboxamide (Compound No. 150),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-ylcarbonyl) -1,2,3,4-tetrahydro Isoquinoline-6-sulfonamide (Compound No. 151),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-({[(4-methoxyphenyl) amino] carbonyl} amino) benzenesulfonamide (compound Number 152),

4-({[(4-acetylphenyl) amino] carbonyl} amino) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (compound Number 153)

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (Compound No. 154),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrimidin-2-yl-1H-imidazol-4-sulfonamide (Compound No. 155),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide (Compound No. 156),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide (Compound No. 157),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide (Compound No. 158),

N- {3- [5-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} acetamide (Compound No. 159),

N- {3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} acetamide (Compound No. 160),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 161),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 162),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide (Compound No. 163),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide (Compound No. 164),

4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzamide (Compound No. 165),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylurea (Compound No. 166),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylthiourea (Compound No. 167),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-methoxyphenyl) urea (Compound No. 168),

N- (4-acetylphenyl) -6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3,4-dihydroisoquinoline- 2 (1H) -carboxamide (Compound No. 169),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (Compound No. 170),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylthiourea (Compound No. 171),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isoxazole-5-carboxamide (Compound No. 172),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-carboxamide (Compound No. 173),

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide (Compound No. 174),

tert-butyl 4- (2-{[2- (2-furoylamino) benzyl] amino} propyl) piperidine-1-carboxylate (Compound No. 175),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-nitrobenzamide (Compound No. 176),

tert-butyl 4- [2-({2-[(4-fluorobenzoyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate (Compound No. 177),

tert-butyl 4- [2-({2-[(2-thionylcarbonyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate (Compound No. 178),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide (Compound No. 179),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 180),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide (Compound No. 181),

tert-butyl 4- {2-[(2-{[(5-isoxazol-5-yl-2-thienyl) carbonyl] amino} benzyl) amino] propyl} piperidine-1-carboxylate (Compound No. 182),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide (Compound No. 183),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-[4- (1,3-oxazol-5-yl) phenyl] urea (Compound No. 183a),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(methylsulfonyl) amino] benzenesulfonamide (Compound No. 183b),

N- (4-chlorophenyl) -N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) urea (Compound No. 184),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-phenylurea (Compound No. 185),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4-dichlorophenyl) urea (Compound No. 186),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4,5-trichlorophenyl) urea (Compound No. 187),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(2,4-dichlorophenyl) urea (Compound No. 188),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(4-fluorophenyl) urea (Compound No. 189),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-1-naphthylurea (Compound No. 190),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylurea (Compound No. 191),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylthiourea (Compound No. 192),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-naphthylthiourea (Compound No. 193),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(trichloromethyl) thiourea (Compound No. 194),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-phenylpiperazine-1-carboxamide (Compound No. 195),

4-benzyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide (Compound No. 196),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide (Compound No. 197),

4- (4-chlorophenyl) -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide (Compound No. 198),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-methylpiperazine-1-carboxamide (Compound No. 199),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) morpholine-4-carboxamide (Compound No. 200),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-pyrimidin-4-ylpiperazine-1-carboxamide (Compound No. 201),

4-chloro-N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenesulfonamide (Compound No. 202),

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} -4-methylbenzenesulfonamide (Compound No. 203),

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzamide (Compound No. 204),

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenecarbothioamide (Compound No. 205),

4-[(4-chlorophenyl) sulfonyl] -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide (Compound No. 206),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (phenylsulfonyl) piperazine-1-carboxamide (Compound No. 207),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(4-methylphenyl) sulfonyl] piperazine-1-carboxamide (Compound No. 208),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (2-thienylsulfonyl) piperazine-1-carboxamide (Compound No. 209),

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-chlorobenzenesulfonamide (Compound No. 210),

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-methylenesulfonamide (Compound No. 211),

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} methanesulfonamide (Compound No. 212),

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} thiophene-2-sulfonamide (Compound No. 213),

N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide (Compound No. 214),

4-methyl-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide (Compound No. 215),

4-chloro-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide (Compound No. 216),

N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide (Compound No. 217),

5-bromo-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide (Compound No. 218),

4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 219),

N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 220),

N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 221),

5-bromo-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 222),

4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 223),

4-chloro-N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 224),

N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 225),

N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea (Compound No. 226),

N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea (Compound No. 227),

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} methanesulfonamide (Compound No. 228),

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide (Compound No. 229),

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} -4-methylbenzenesulfonamide (Compound No. 230),

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide (Compound No. 231),

5-bromo-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide (Compound No. 232),

4-chloro-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide (Compound No. 233),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-methoxy-4-piperazin-1-ylbenzenesulfonamide (Compound No. 234),

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -5- (phenylsulfonyl) -2-sulfonamide (Compound No. 235),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-benzofuran-2-carboxamide (Compound No. 236),

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) acetamide (compound Number 237),

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl (4-methoxyphenyl) carbamate (Compound No. 238),

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -6- (1H-imidazol-1-yl) nicotinamide (Compound No. 239),

N- (4-{[(2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} thiophene-2-sulfonamide (Compound No. 240),

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide (Compound No. 241),

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide (Compound No. 242),

2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl (4-acetylphenyl) carbamate (Compound No. 243),

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide (Compound No. 244),

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -4-fluorobenzenesulfonamide (Compound No. 245),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -6- (3-furyl) nicotinamide (Compound No. 246),

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide (Compound No. 247),

N- (3-{[(2-cycloheptyl-1-methylethyl) amino] methyl} pyridin-2-yl) -2-furamide (Compound No. 248),

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide (Compound No. 249),

N- (2-{[(2-Cyclohex-1-en-1-yl-1-methylethyl) amino] methyl} phenyl) -5- (1,3-oxazol-5-yl) furan-2-sulfone An amide (Compound No. 250),

N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3-methylisoxazol-5-yl) urea (Compound No. 251),

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-imidazol-1-yl) phenyl) carbamate (Compound No. 252),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5- (3-furyl) nicotinamide (Compound No. 253),

1-benzofuran-2-ylmethyl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate (Compound No. 254),

N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 255),

N-1-benzothien-2-yl-N ′-[2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] urea (Compound 256),

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-pyrazol-1-yl) phenyl) carbamate (Compound No. 257),

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate (Compound No. 258),

3,3′-bipyridin-6-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate (Compound No. 259),

Pyridin-4-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate (Compound No. 260),

N-1-benzothien-2-yl-N ′-(4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea (Compound No. 261),

N-1-benzothien-2-yl-N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea (Compound No. 262),

3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate (Compound No. 263),

3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl 1-benzothien-2-ylcarbamate (Compound No. 264),

N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) urea (Compound No. 265),

N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) urea (Compound No. 266),

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate (Compound No. 267),

4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate (Compound No. 268),

1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) carbamate (Compound No. 269),

1-benzothien-2-yl (4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate (Compound No. 270),

1-benzothien-2-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate (Compound No. 271),

2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate (Compound No. 272),

2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl 1-benzothien-2-ylcarbamate (Compound No. 273),

1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] carbamate (Compound No. 274),

1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) carbamate (Compound No. 275),

1-benzothien-2-yl (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) carbamate (Compound No. 276),

N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) acetamide ( Compound No. 277),

1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) pyridin-3-yl] carbamate (Compound No. 278),

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide (Compound No. 279),

1-benzothien-2-yl (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl] pyridin-3-yl) carbamate (Compound No. 280),

3-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate (Compound No. 281),

N-1-benzothien-2-yl-N ′-(2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) urea (compound 282),

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide (Compound No. 283),

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) -2- (1H-pyrazol-1-yl) acetamide (Compound No. 284),

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) isonicotinamide (Compound No. 285),

4-chloro-N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) benzenesulfonamide (Compound No. 286),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-morpholin-4-ylphenyl) urea (Compound No. 287),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[3- (2-furyl) -1H-pyrazol-5-yl) urea ( Compound No. 288),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole- 3-yl) urea (compound number 289),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(4-methoxy-1,2-benzoxazol-3-yl) urea (Compound No. 290),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(3,4-dimethylisoxazol-5-yl) urea (Compound No. 291 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[1-methyl-3- (2-thienyl) -1H-pyrazole-5- Il] Urea (Compound No. 292),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide (Compound No. 293),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide (Compound No. 294),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide (Compound No. 295),

4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 296),

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (Compound No. 297),

2-thienylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 298),

2-thienylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 299),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide (Compound No. 300),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- {3-[(E)-(hydroxyimino) methyl] -1H-pyrrole-1 -Il} benzenesulfonamide (Compound No. 301)

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzamide (Compound No. 302)

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[4- (1,2,3-thiadiazol-4-yl) phenyl) urea (Compound No. 303),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-6-carboxamide (Compound No. 304),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-dimethylisoxazol-4-sulfonamide (Compound No. 305),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide (Compound No. 306),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxazole-4- Sulfonamide (Compound No. 307),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4-sulfone An amide (Compound No. 308),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-hydroxyethyl) benzenesulfonamide (Compound No. 309)

Pyridin-3-ylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 310),

Pyridin-3-ylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 311),

Pyridin-3-ylmethyl [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 312),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide (Compound No. 313),

5-chloro-N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzenethiophene-2-sulfone An amide (Compound No. 314),

Ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate (Compound No. 315),

4-acetyl-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] benzenesulfonamide (Compound No. 316) ,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide (Compound No. 317),

N-1,3-benzothiazol-2-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea (Compound No. 318),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[4 [(1,3-oxazol-5-yl) phenyl] urea (compound Number 319),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl ) Benzenesulfonamide (compound no. 320),

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide ( Compound No. 321),

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 322),

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide (Compound No. 323),

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4- Tetrahydroisoquinoline-6-sulfonamide (Compound No. 324),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 325 ),

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-5-ylthiophene-2-sulfonamide (Compound No. 326) ,

N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-3-ylthiophene-2-sulfonamide (Compound No. 327) ,

N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 328 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 329 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-oxo-1,3-oxazolidine-3-yl) benzenesulfonamide (compound Number 330),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide (Compound No. 331),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (1-methyl-1H-pyrazol-4-yl) thiophene-2-sulfonamide ( Compound No. 332),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (2-thienylsulfonyl) -1H-imidazol-4-sulfonamide (Compound No. 333) ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiazol-4-sulfonamide (Compound No. 334),

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4-sulfone An amide (Compound No. 335),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide (Compound No. 336),

4-[(butylsulfonyl) amino] -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 337),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(ethylsulfonyl) amino] benzenesulfonamide (Compound No. 338),

5-chloro-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl-1H -Pyrazol-4-sulfonamide (Compound No. 339),

Methyl 4-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2,5- Dimethyl-3-furoate (Compound No. 340),

Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -3-methylthiophene -2-carboxylate (Compound No. 341),

Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-furoate ( Compound No. 342),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(3-oxo-1,3-dihydro-2-benzofuran-5-yl) Urea (compound number 343),

2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) amino] benzamide (Compound No. 344),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isoquinolin-5-ylurea (Compound No. 345),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-morpholin-4-ylurea (Compound No. 346),

N-1,3-benzothiazol-6-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) urea (Compound No. 347),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-1,3-thiazol-2-ylurea (Compound No. 348),

Ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate (Compound No. 349),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide (Compound No. 350),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl ) Benzenesulfonamide (Compound No. 351),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (compound Number 352),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2- (trifluoroacetyl) -1,2 , 3,4-Tetrahydroisoquinoline-7-sulfonamide (Compound No. 353),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide (Compound No. 354),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide (Compound No. 355),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide (Compound No. 356),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide (Compound No. 357),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide (Compound No. 358 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide (Compound No. 359 ),

N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (Compound No. 360),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide (Compound No. 361),

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 362),

N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4- Sulfonamide (Compound No. 363),

N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4- Sulfonamide (Compound No. 364),

5-chloro-N- [4-[({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl- 1H-pyrazole-4-sulfonamide (Compound No. 365),

N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N, N-dimethylsulfamide (Compound No. 366),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide (Compound No. 367 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide (Compound No. 368),

N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (Compound No. 369) ,

N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (Compound No. 370) ,

3-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 371),

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 372),

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide (Compound No. 373),

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxazole-4- Sulfonamide (Compound No. 374),

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide (Compound No. 375),

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide (Compound No. 376),

Ethyl 5-{[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} -5-oxopentoate (compound Number 377),

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-5-sulfonamide (Compound No. 378),

5-chloro-N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl-1H -Pyrazol-4-sulfonamide (Compound No. 379),

N- [2-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide (Compound No. 380),

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide (Compound No. 381),

N- (2-{[[(1S) -2-cyclohexyl-1-methylethyl] (methylsulfonyl) amino] methyl} phenyl) -2-[(methylsulfonyl) amino] benzenesulfonamide (Compound No. 382 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide (Compound No. 383),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide (Compound No. 384),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide (Compound No. 385),

[5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 386),

N-[(1S) -2-cyclopentyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide (Compound No. 387),

N-[(1S) -2-cyclohexyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide (Compound No. 388),

Methyl [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1H-benzimidazol-2-yl] carbamate (Compound No. 389),

Methyl [6-({[4-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -1H-benzimidazol-2- Yl] carbamate (Compound No. 390),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-hydroxyethaneimidoyl] benzenesulfonamide (Compound No. 391) ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-methoxyethaneimidoyl] benzenesulfonamide (Compound No. 392) ,

4-{[amino (imino) methyl] amino} -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 393),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] sulfamide (Compound No. 394),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -4-[(1E) -N-hydroxyethane Imidoyl] benzenesulfonamide (Compound No. 395),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-{[(isopropylamino) carbonyl] amino} benzenesulfonamide (Compound No. 396),

Ethyl (2Z) -4-{[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} -4-oxobut-2-enoate (Compound No. 397),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide (Compound No. 398),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide (Compound No. 399),

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] thiophene-2-sulfonamide (Compound No. 400),

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-5-sulfonamide (Compound No. 401),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] guanidine (Compound No. 402),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl ) Benzenesulfonamide (Compound No. 403),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide (Compound No. 404 ),

N- [2-({[2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide (Compound No. 405),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3,5-dimethylisoxazol-4-yl) benzenesulfonamide (Compound No. 406),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide (Compound No. 407 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide (Compound No. 408),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-[(methylsulfonyl) amino) benzenesulfonamide (Compound No. 409),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-{[(dimethylamino) sulfonyl) amino] benzenesulfonamide (Compound No. 410),

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -1-benzothiophene-2-sulfonamide (Compound No. 411),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-{[(1-methyl-1H-imidazol-4-yl) sulfonyl] amino} pyridine-2-sulfone An amide (Compound No. 412),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(methylsulfonyl) amino] pyridine-2-sulfonamide (Compound No. 413),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(2-thienylsulfonyl) amino] pyridine-2-sulfonamide (Compound No. 414),

5-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-2-sulfonamide (Compound No. 415),

[5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate (Compound No. 416),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluoro-5- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 417),

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-4-sulfonamide (Compound No. 418),

N- [2-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide (Compound No. 419),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide (Compound No. 420),

N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 421 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide (Compound No. 422),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine-3-sulfone An amide (Compound No. 423),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] thiophene-2-sulfonamide (Compound No. 424),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide (Compound No. 425),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine-3-sulfonamide (Compound No. 426),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide (Compound No. 427),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide (Compound No. 428),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide (Compound No. 429),

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 430),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide (Compound No. 431) ,

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -5-isoxazol-5-ylthiophene-2-benzenesulfonamide hydrochloride (Compound No. 432),

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 433),

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-6-sulfonamide (Compound No. 434),

5-{[amino (imino) methyl] amino} -N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide (Compound No. 435),

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] -1-methyl-1H-imidazol-4-sulfone An amide (Compound No. 436),

N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] acetamide (Compound No. 437),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methyl-1H-benzimidazol-2-sulfonamide (Compound No. 438),

4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluorobenzenesulfonamide (Compound No. 439),

4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxybenzenesulfonamide (Compound No. 440),

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] acetamide (Compound No. 441),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxy-4-[(methylsulfonyl) amino] benzenesulfonamide (Compound No. 442),

Methyl [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] carbamate (Compound No. 443),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide (Compound No. 444 ),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide (Compound No. 445),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide (Compound No. 446 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide (Compound No. 447),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide (Compound No. 448),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide (Compound No. 449),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide (Compound No. 450),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide (Compound No. 451),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (Compound No. 452),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (Compound No. 453),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide (Compound No. 454),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide (Compound No. 455) ,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide (Compound No. 456),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide (Compound No. 457),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide (Compound No. 458),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide (Compound No. 459) ,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide (Compound No. 460),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide (compound Number 461),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 462),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 463) ,

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfone An amide (Compound No. 464),

N- [4-({[2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (Compound No. 465),

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 466),

N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide (Compound No. 467),

N- (4-{[(2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) thiophene-2-sulfonamide (Compound No. 468),

5-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide (Compound No. 469),

5-Chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzooxadiazol-4-sulfonamide (Compound No. 470),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-carboxamide (Compound No. 471),

N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) thiophene-2-sulfonamide (Compound No. 472),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiazol-5-sulfonamide (Compound No. 473),

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] thiophene-2-sulfonamide (Compound No. 474),

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] thiophene-2-sulfonamide (Compound No. 475),

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] acetamide (Compound No. 476),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzenesulfonamide (compound Number 477),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide (Compound No. 478),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide (compound Number 479),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazol-1-yl) benzene Sulfonamide (Compound No. 480),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (trifluoroacetyl) indoline-5-sulfonamide (Compound No. 481),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] indoline-5-sulfonamide (Compound No. 482),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide (Compound No. 483),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide (Compound No. 484 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,4-difluorobenzenesulfonamide (Compound No. 485),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide (Compound No. 486),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide (compound Number 487),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide (Compound No. 488),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide (Compound No. 489 ),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide (Compound No. 490),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide (Compound No. 491),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridin-3-sulfonamide (Compound No. 492),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridine-3-sulfonamide (Compound No. 493),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (Compound No. 494),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide (Compound No. 495),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6-sulfonamide (Compound No. 496),

6-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide (Compound No. 497),

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyrimidine-5-sulfonamide (Compound No. 498),

6-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide (Compound No. 499),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide (Compound No. 500),

5-chloro-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide (Compound No. 501),

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide (Compound No. 502),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (dimethylamino) -1,3-benzothiazol-6-sulfonamide (Compound No. 503),

N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] -L-alaninamide (compound Number 504),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxo-3,4-dihydroquinoline-2-sulfonamide (Compound No. 505),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide (Compound No. 506),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide (Compound No. 507),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroisoquinoline-6-sulfonamide (Compound No. 508),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-imidazol-1-yl) benzenesulfonamide (Compound No. 509),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide (Compound No. 510) ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroisoquinoline-6-sulfonamide (Compound No. 511),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroisoquinoline-6-sulfonamide (Compound No. 512),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide (Compound No. 513),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide (Compound No. 514),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide (Compound No. 515) ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide (Compound No. 516),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide (compound Number 517),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide (Compound No. 518),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide (Compound No. 519),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide (Compound No. 520 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide (Compound No. 521 ),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-[(1-methyl-1H-imidazol-4-yl) sulfonyl] indoline-5-sulfonamide (compound Number 522),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (methylsulfonyl) indoline-5-sulfonamide (Compound No. 523),

N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazole -4-sulfonamide (Compound No. 524),

1-acetyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) indoline-5-sulfonamide (Compound No. 525),

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide (Compound No. 526),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide (Compound No. 527),

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazole-6-sulfonamide (Compound No. 528),

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 529),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 530),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 531),

2-amino-N- [2-({[(1S) -2-cyclopropyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 532),

N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) nonanamide (Compound No. 533),

4-amino-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-hydroxybenzensulfonamide (Compound No. 534),

N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} -2-hydroxyphenyl) thiophene-2-sulfonamide (Compound No. 535),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzothiazol-6-sulfonamide (compound Number 536),

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 537),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxoindoline-6-sulfonamide (Compound No. 538),

5-chloro-N- [2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl] -1benzothiophene-2-sulfonamide (Compound No. 539),

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 540),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzothiophene-2-sulfonamide (Compound No. 541),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzothiophene-2-sulfonamide (Compound No. 542),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-fluoro-1-benzothiophene-2-sulfonamide (Compound No. 543),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide (Compound No. 544),

N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 545),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-oxoindoline-6-sulfonamide (Compound No. 546),

4-amino-N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 547),

5- (6-Aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 548 ),

5- (6-Aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide (Compound No. 549 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide (Compound No. 550),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide (Compound No. 551),

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 552),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 553),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide (compound Number 554),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide (Compound No. 555),

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazol-6-sulfonamide (Compound No. 556),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide (Compound No. 557),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide (Compound No. 558),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide (Compound No. 559),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide (Compound No. 560),

N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide (Compound No. 561),

N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide (compound Number 562),

2-Amino-N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide (Compound No. 563 ),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (1H-pyrrol-1-yl) -1,3-thiazol-5-sulfonamide (Compound No. 564),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide (Compound No. 565),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide (Compound No. 566),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzenesulfonamide (compound Number 567),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzenesulfonamide (compound Number 568),

N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -4- (1H-pyrrol-1-yl) benzenesulfonamide (Compound No. 569),

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-5-sulfonamide (Compound No. 570),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3-sulfonamide ( Compound No. 571),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3-sulfonamide ( Compound No. 572),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide (Compound No. 573 ),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide (Compound No. 574),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide (Compound No. 575),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzazothiazine-6-sulfonamide (Compound No. 576),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzazothiazine-6-sulfonamide (Compound No. 577),

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-mercapto-1,3-benzoxazole-6-sulfonamide (Compound No. 578),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide (Compound No. 579),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide (Compound No. 580),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -N′-pyrimidin-2-ylbenzene-1,4-disulfonamide (Compound No. 581) ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide (Compound No. 582),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide (Compound No. 583),

N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3,4-thiadiazol-2-yl] acetamide (Compound No. 584),

5-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiazol-2-sulfonamide (Compound No. 585),

5-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiazol-2-sulfonamide (Compound No. 586),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide (Compound No. 587),

5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide (Compound No. 588),

N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 589),

N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-thiazol-2-yl] acetamide (compound Number 590),

N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide (compound Number 591),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide ( Compound No. 592),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide ( Compound No. 593),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide (Compound No. 594),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide (Compound No. 595),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-sulfonamide (Compound No. 596),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-sulfonamide (Compound No. 597),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazol-6-sulfonamide (Compound No. 598),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazol-6-sulfonamide (Compound No. 599),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-5-sulfonamide (compound Number 600),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-5-sulfonamide (compound Number 601),

N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -1-benzothiophene-2-sulfonamide (Compound No. 602),

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide (Compound No. 603),

5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid (Compound No. 604),

5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid (Compound No. 605),

Methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate (Compound No. 606),

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate (Compound No. 607),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-ylsulfonyl) benzenesulfonamide (Compound No. 608),

Methyl 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl- 3-Furoate (Compound No. 609),

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl-3 -Furic acid (Compound No. 610),

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -N, N, 2 -Trimethyl-3-furamide (Compound No. 611),

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl-3 -Furamide (Compound No. 612),

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) aniline (Compound No. 613),

2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) aniline (Compound No. 614),

1- (cyanomethyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6-sulfonamide ( Compound No. 615),

4-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide (Compound No. 616),

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-2-sulfone An amide (Compound No. 617),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-2-sulfonamide (Compound No. 618),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide (Compound No. 619),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide (Compound No. 620),

N- [2-({[1-Methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide (Compound No. 621).

  Because of its antimicrobial activity, the compounds described herein may be administered to animals for oral, topical, rectal, nasal, or parenteral routes for treatment. The pharmaceutical compositions of the invention comprise a pharmaceutically effective amount of a compound described herein formulated with one or more pharmaceutically acceptable carriers.

  Solid preparations for oral administration include capsules, tablets, pills, powders, granules, cachets, and suppositories. In the case of solid phase preparations, the active compound is at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate, dicalcium phosphate, and / or a filler or bulking agent. For example, starch, lactose, sucrose, glucose, mannitol, and silicic acid; binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, or acacia; disintegrants such as agar, calcium carbonate, potato Starch, alginic acid, certain silicates and sodium carbonate; absorption enhancers such as quaternary ammonium compounds; wetting agents such as cetyl alcohol or glycerol monostearate; adsorbents such as kaolin; lubricants , Eg talc, calcium stearate , Magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, or pills, the dosage form may further comprise a buffer.

  Tablet, capsule, pill, and granule solid preparations may be prepared with coatings and shells, for example, enteric coatings, and other coatings well known in the pharmaceutical formulating art.

  Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In the case of liquid preparations, the active compounds are water or other solvents, solubilizers and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene Glycols, dimethylformamide, oils such as cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil, glycerol, and fatty acid esters of sorbitan and mixtures thereof may be mixed. In addition to the inert diluent, the oral composition may further include adjuvants such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and fragrances.

  Injectable preparations, for example, sterile injectable solutions, aqueous suspensions may be formulated according to the prior art using suitable dispersing agents, wetting agents, and suspending agents. Acceptable vehicles and solvents include Ringer's solution and isotonic sodium chloride.

  Dosage forms for topical application or transdermal administration of the compounds provided herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Eye drops, ear drops, eye ointments, powders, and solutions are also considered to be within the scope of the present invention.

  The pharmaceutical formulation may be provided as a unit dosage form. In this dosage form, the formulation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form may be a packaging formulation. That is, the packaging may include the powder in individual capsules or vials or ampoules, or may include ointment capsules, powders, tablets, gels, the cream itself, or any of these packaged dosage forms. Any suitable number may be used.

The examples described below illustrate synthetic procedures for the preparation of representative compounds. These examples are provided to illustrate certain aspects of the present disclosure and are not intended to limit the scope of the invention. The scope of the invention is defined by the claims.
Example General process

Preparation of a compound of formula 4 To a pyridine solution of a compound of formula 2 (1 eq), a compound of formula 3 (1.2 eq) was added in portions at about 0-5 ° C. The reaction mixture was allowed to stand at ambient temperature and stirred overnight. The solvent was removed under reduced pressure. Water was added to the residue and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by column chromatography to obtain the required product.

Preparation of compound of formula 5 To a solution of compound of formula 4 (1.0 eq) in dichloromethane (20-30 mL) was added Dess-Martin periodinane (1.5 eq). The reaction mixture was stirred overnight at ambient temperature, filtered and the mother liquor was washed with aqueous sodium bicarbonate. The organic layer was dried and evaporated under reduced pressure. The residue was purified by column chromatography to give the required product.

Preparation of the compound of formula 9a To a solution of the compound of formula 9 (10.0 eq, prepared according to Scheme I) in propanol (15 mL) was added the compound of formula R ₈ B (OH) ₂ (12.0 eq). The reaction mixture was degassed with argon for about 15 minutes. To the reaction mixture was added tetrakis (triphenylphosphine) palladium (0) (1.0 eq). To this reaction mixture was added aqueous sodium carbonate (10.0 equiv). The reaction mixture was heated to about 100 ° C. and stirred in the dark under argon atmosphere for about 5 hours. The reaction mixture was filtered, the residue was concentrated and the product was purified by column chromatography.

Preparation of the compound of formula 10 The compound of formula 10 was prepared using the procedure described for the compound of formula 5.

Preparation of the compound of formula 12 The compound of formula 11 (1.0 eq) and the compound of formula R ₆ COOH (1.2 eq) were poured into dry dimethylformamide (3-10 mL) and cooled to 0 ° C. 1-Hydroxybenzotriazole (1.2 equivalents) and N-methylpyrrolidone (3.0 equivalents) were added and stirred for about 15 minutes. 1-Ethyl-3- [3- (dimethylamino) propyl] carbodiimide (1.5 eq) was added and the resulting mixture was stirred at ambient temperature for about 12 hours, quenched with water and extracted with dichloromethane. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue was purified on a silica gel column.

Preparation of compound of formula 13 The compound of formula 12 (1.0 eq) was added to dry tetrahydrofuran and tetrabutylammonium fluoride (1.2 eq) was added. After stirring at ambient temperature for about 1 hour, the solvent was distilled off under reduced pressure and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column.

Preparation of the compound of formula 14 The compound of formula 14 was prepared using the procedure described for the compound of formula 5.

Preparation of compound of formula 16 Compound 11 (1.0 eq) was charged into dry dichloromethane (5-10 mL) and imidazole (1.5 eq) and N, N'-carbonyldiimidazole (1.5 eq) were added. The resulting mixture was stirred at room temperature for about 2 hours, quenched with water and extracted with dichloromethane. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was dissolved in dichloromethane (5-10 mL) and imidazole (1.5 eq) and compound of formula R ₂ CH ₂ OH (1.2 eq) were added. The resulting mixture was stirred at ambient temperature for about 5 hours, quenched with water and extracted with dichloromethane. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue was purified on a silica gel column.

Preparation of the compound of formula 17 The compound of formula 16 (1.0 eq) was poured into dry tetrahydrofuran and tetrahydroammonium fluoride (1.2 eq) was added. After stirring at ambient temperature for about 1 hour, the solvent was removed under reduced pressure and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column.

Preparation of the compound of formula 18 The compound of formula 18 was prepared using the procedure described for the compound of formula 5.

Preparation of the compound of formula 18b The compound of formula 18a (10.0 mmol) was added to raw chlorosulfonic acid (10 mL) in several portions at about 0 ° C. After the addition was complete, the resulting mixture was slowly warmed to about 50 ° C. over about 12 hours. The reaction mixture was poured into ice. The solid was filtered, washed thoroughly with cold water and dried over phosphorus pentachloride under reduced pressure to form the desired compound.

Preparation of the compound of formula 18c The compound of formula 18b (1.0 eq) was added to the compound of formula 2a (1.0 eq) dissolved in pyridine at ambient temperature. After stirring for about 12 hours, the mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and evaporated to form the crude compound of formula 18c. This was purified by silica gel column chromatography eluting with methanol / dichloromethane.

Preparation of compounds of formula 18d
Dess-Martin periodinane (1.5 eq) was added to a solution of compound of formula 18c (1.0 eq) in dichloromethane (20-30 mL). The reaction mixture was stirred at ambient temperature overnight, filtered and the mother liquor was washed with aqueous sodium bicarbonate. The organic layer was dried and evaporated under reduced pressure. The residue was purified by column chromatography and the desired product was formed.

Preparation of compounds of formula 21
Di-tert-butyl bicarbonate (1.1 eq) was slowly added to a solution of L-aramine (1.0 eq) in dichloromethane at 0-5 ° C. The reaction mixture was stirred at ambient temperature for about 3 hours. The reaction mixture was diluted with dichloromethane, washed with water and brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified by column chromatography to give the desired product.

Preparation of the compound of formula 22 To a solution of the compound of formula 21 (1.0 eq) in ether (20-30 mL) was added tosyl chloride (1.3 eq). The reaction mixture was stirred for about 15 hours and cooled to 0 ° C. Potassium hydroxide (about 1.25 equivalent powder) was added and stirring was continued for about 15 minutes. An additional 1.25 equivalents of potassium hydroxide was added and the reaction mixture was stirred for an additional 15 minutes. The reaction mixture was refluxed at about 40-50 ° C. for about 3 hours. The reaction mixture was diluted with water and the compound was extracted with ethyl acetate. The organic layer was dried and evaporated under reduced pressure. The product was purified by silica gel column chromatography to give the desired compound.

Preparation of compounds of formula 23
In a two-branched round bottom flask, Mg (50.3 eq) was suspended in ether (100-125 mL), cooled to 0 ° C., the compound of formula Cy-Ha (50.3 eq) was slowly added and tetrahydrofuran ( 100-110 mL). Iodine crystals were added to evaluate the end point of the reaction. The reaction mixture was stirred for about 2 hours. The reaction mixture was cooled to about −40 ° C., and CuBr—Me ₂ S complex (1.0 equivalent) was added thereto. To this reaction mixture was slowly added the compound of formula 22 (10.0 equiv) dissolved in tetrahydrofuran. The reaction mixture was stirred for about 2 hours and quenched with the addition of a saturated solution of ammonium chloride. The reaction mixture was stirred overnight and extracted with ethyl acetate. The organic layer was dried and evaporated under reduced pressure. The product was purified by column chromatography.

Preparation of compound of formula 24 The reaction of deprotecting the compound of formula 23 to give the compound of formula 24 was carried out according to methods well known in the art.

Preparation of compounds of formula 26
(S) -Amphetamine (3.5 equivalents) was dissolved in acetic acid (30-40 mL). To this was added platinum oxide (1.0 eq) and the suspension was stirred at about 50 psi (Hz). After about 24 hours, platinum oxide (2 g) was added and stirred at a pressure of about 50 psi (Hz). The reaction mixture was filtered through a celite pad. When the mother liquor was distilled off, the final component (10 grams) was obtained as the acetate salt. This was used directly in the next step without further purification.

Preparation of compound of formula 28 Pyridine-4-carboxaldehyde (1 eq) and nitroethane (6.0 eq) were charged into a round bottom flask containing a magnetic stirrer. To this vigorously stirred reaction mixture, sodium hydroxide (2.0 eq) was added at ambient temperature and maintained at ambient temperature for about 3 hours. During that time, a yellowish white solid product separated. This was collected by filtration and used in the next reaction without further purification.

Preparation of the compound of formula 29 The compound of formula 28 (1.0 equiv) was added to the stirring acetic anhydride solution (50-75 mL). The reaction mixture was stirred at ambient temperature for about 1 hour. Meanwhile, what was initially a white suspension turned into a dark yellow solution. Volatiles were removed under reduced pressure and the contents were dissolved in dichloromethane (500-600 mL). Washed with a saturated aqueous solution of sodium bicarbonate. After drying over anhydrous sodium sulfate and purification by column chromatography on silica gel (230-400 mesh) using dichloromethane as an eluent, the product was obtained as a yellow viscous liquid.

Preparation of the compound of formula 30 The compound of formula 29 (1.0 eq) and platinum oxide (0.32 eq) were suspended in glacial acetic acid (30-40 mL). The reaction mixture was placed under 55 psi pressure of hydrogen at ambient temperature for about 16 hours, filtered through a celite pad and the volatiles removed under reduced pressure to give the required product as a colorless oil.

Preparation of the compound of formula 31 Isobutyl methyl ketone (100-125 mL) was added to a flask containing the compound of formula 30 (1.0 eq) and sodium carbonate (2.5 eq). This mixture of different molecules was heated under reflux under nitrogen, and water was removed from the reaction mixture with a Dean-Stark trap. When the imine formation was complete, the flask was cooled to 0 ° C. Di-tert-butyl dicarbonate (1.0 equivalent) was added dropwise to the reaction mixture, and stirring was continued for about 1 hour. The reaction mixture was quenched with water. The separated isobutyl methyl ketone was separated, and the volatile component was distilled off under reduced pressure to obtain an imine intermediate. When this was heated with water and n-butanol at about 50 ° C., it was hydrolyzed to obtain the required product.

Preparation of compound of formula 31b Potassium carbonate (2.0 eq) and benzyl bromide (2.0 eq) were added to a solution of compound of formula 31a (1.0 eq) in dry acetonitrile (5 mL). The resulting mixture was heated at about 60 ° C. for about 8 hours. The reaction mixture was filtered and washed with dichloromethane. The filtrate was concentrated and the residue was purified on a silica gel column to form the desired compound.

Preparation of the compound of formula 31c The compound of formula 31b (1.0 eq) was poured into dry dichloromethane (5 mL) and cooled to about −20 ° C. Diethylaminosulfur trifluoride (DAST, 1.5 eq) was added and the resulting mixture was slowly warmed to about 0 ° C. and stirred for about 2 hours. The reaction mixture was quenched with a saturated aqueous solution of sodium bicarbonate and extracted with dichloromethane. The organic layer was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column to form the desired compound.

Preparation of compound of formula 31d Palladium hydroxide (0.2 gram, 20% over a carbon bed) was added to a solution of compound of formula 31c (1.0 gram, 2.95 mmol) in methanol (15 mL). The resulting mixture was stirred for about 12 hours under nitrogen. The reaction mixture was filtered and washed thoroughly with methanol. Concentration of the filtrate formed the desired compound.

Preparation of the compound of formula 31f The compound of formula 31f was prepared according to the procedure described in Example 23.

Preparation of the compound of formula 31g The compound of formula 31g was prepared according to the procedure described in Example 24.

Preparation of the compound of formula 31h The compound of formula 31h was prepared according to the procedure described in Example 25.

Preparation of the compound of formula 31j The compound of formula 31j was prepared according to the procedure described in Example 18.

Preparation of the compound of formula 32 To a solution of the compound of formula 5 (1.0 eq) in methanol (20-30 mL) was added the compound of formula 24 (2.45 eq). After stirring for about 1 hour, sodium cyanoborohydride (2.45 eq) was added to the reaction mixture. The reaction mixture was stirred overnight and then the solvent was removed in vacuo. The residue was dissolved in dichloromethane, washed with water, brine, and dried over anhydrous sodium sulfate. The product was purified by column chromatography.

Preparation of compounds of formula 33 and 34 To a solution of the compound of formula 14 (1.0 eq) or the compound of formula 18 (1.0 eq) in methanol (20-30 mL) was added the compound of formula 24 (2.45 eq). After stirring for about 1 hour, sodium cyanoborohydride (2.45 eq) was added to the reaction mixture. The reaction mixture was stirred overnight and then the solvent was removed in vacuo. The residue was dissolved in dichloromethane, washed with water, brine, and dried over anhydrous sodium sulfate. The product was purified by column chromatography.

Preparation of the compound of formula 36 The compound of formula 35 (1.0 eq) was charged into dichloromethane (75-100 mL), to which triethylamine (1.5 eq) was added at ambient temperature. This was cooled to 0 ° C., 25 mL of di-tert-butyl dicarbonate (1.2 eq) was added dropwise and the contents were stirred overnight at ambient temperature, quenched with water and extracted with dichloromethane. The solvent was distilled off and the crude product was purified on a silica gel column.

Preparation of the compound of formula 37 The compound of formula 36 (1.0 equivalent) was added to methanol (10-15 mL) and cooled to 0 ° C. To this was added Raney nickel (1.0 equivalent), and then hydrazine hydrate (10-15 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for about 1 hour, filtered through a celite pad. When the filtrate was distilled off, the desired compound was obtained.

Preparation of compound of formula 39 The compound of formula 37 (1.0 eq) was charged into dichloromethane (5-10 mL) and cooled to 0 ° C. To it was added R ₆ NCO (1.2 eq) and the reaction mixture was stirred at room temperature overnight. This was then filtered and the filtrate was distilled off to give the compound of formula 38. The compound of formula 38 (1.4 equivalents) was charged to a round bottom flask and cooled to 0 ° C. To this mixture was added ethanolic hydrochloric acid (5-10 mL) and the reaction mixture was stirred overnight at ambient temperature. When the solvent was distilled off, an amine salt was obtained. This was put into dichloromethane, cooled, and free amine was obtained as basic using triethylamine. This crude product was purified by controlled thin layer chromatography.

Preparation of the compound of formula 39c The compound of formula 39a (1.0 eq) was charged into a round bottom flask, to which acetonitrile (10 mL) was added, followed by the compound of formula 39b (1.5 eq). The reaction mixture was heated to about 70 ° C. for about 10 hours, cooled to ambient temperature, and water was added. Then extracted with ethyl acetate. The solvent was distilled off and the residue thus formed was purified by column chromatography.

Preparation of the compound of formula 39d The compound of formula 39c (1.54 equiv) was charged to a round bottom flask and cooled to about 0 ° C. To it was added ethanolic hydrochloric acid (5-10 mL) and the reaction mixture was stirred overnight at ambient temperature. When the solvent was distilled off, an amine salt was obtained. This was put into dichloromethane, cooled, and free amine was obtained as basic using triethylamine. The crude product of formula 39d was purified by controlled thin layer chromatography.

Preparation of the compound of formula 39f The compound of formula 39a (1.0 eq) was dissolved in dichloromethane (10 mL) and cooled to about 0 ° C. To it was added diisopropylethylamine (Hunig base) under an argon atmosphere. Next, the compound of formula 39e (1.3 eq) was added. The reaction mixture was stirred for about 2 hours, brought to about 0 ° C. to ambient temperature and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to form the desired compound.

Preparation of the compound of formula 39g The compound of formula 39g was prepared according to the procedure described in Example 36.

Preparation of compound of formula 41 The compound of formula 37a (1.0 eq) was charged into pyridine (5-10 mL) and cooled to 0 ° C. To this mixture was added R _X SO ₂ Cl (1.2 eq) in several portions and the contents were stirred at 0 ° C. for about 1 h, quenched with water and extracted with dichloromethane. The organic layer was washed with dilute hydrochloric acid, water, and brine to form a crude product of formula 40.

  The compound of formula 40 (1.54 equivalents) was charged to a round bottom flask and cooled to 0 ° C. To this was added ethanolic hydrochloric acid (5-10 mL) and the reaction mixture was stirred overnight at ambient temperature. When the solvent was distilled off, an amine salt was obtained. This was poured into dichloromethane, cooled, and free amine was obtained as basic using triethylamine. This crude product was purified by controlled thin layer chromatography.

Preparation of the compound of formula 42 The compound of formula 35 (1.0 eq) was charged into acetonitrile (10-20 mL) to which cesium carbonate (4.0 eq) and thiophenol (3.0 eq) were added at ambient temperature. The reaction mixture was heated at about 50 ° C. for about 4 hours, cooled to ambient temperature, quenched with water and extracted with ethyl acetate. When the solvent was distilled off, an unpurified product was obtained. This was purified by silica gel chromatography.

Preparation of compound of formula 44 The amine of formula 42 (1.0 equiv) was charged into pyridine (5-10 mL) and cooled to 0 ° C. To it was added the compound of formula 42a (1.2 eq) in several portions and the contents were stirred at about 0 ° C. for about 1 hour, quenched with water and extracted with dichloromethane. The organic layer was washed with dilute hydrochloric acid, water, and brine, and the solvent was distilled off to form the compound of formula 43.

  The compound of formula 43 (1.0 eq) was charged into a round bottom flask and cooled to 0 ° C. To this mixture was added ethanolic hydrochloric acid (5-10 mL) and the reaction mixture was stirred at room temperature overnight. When the solvent was distilled off, an amine salt was obtained. This was poured into dichloromethane, cooled, and free amine was obtained as basic using triethylamine. This crude product was purified by controlled thin layer chromatography.

Preparation of compound of formula 46 The amine of formula 42 (1.0 eq) was charged into dichloromethane (5-10 mL) and cooled to 0 ° C. To this mixture was added R ₆ NCO (1.2 eq) and the reaction mixture was stirred at room temperature overnight. Next, this was filtered and the filtrate was distilled off to obtain the compound of formula 45.

  The compound of formula 45 (1.0 equiv) was charged to a round bottom flask and cooled to 0 ° C. To this mixture was added ethanolic hydrochloric acid (10-15 mL) and the reaction mixture was stirred at room temperature for about 5 hours. When the solvent was distilled off, an amine salt was obtained. This was poured into dichloromethane, cooled, and free amine was obtained as basic using triethylamine. This crude product was purified by controlled thin layer chromatography.

Preparation of the compound of formula 42b The compound of formula 42 (1.0 eq) was charged into dichloromethane (5-10 mL) and cooled to about 0 ° C. To this was added triethylamine (1.5 eq) followed by phenyl chloroformate (1.2 eq) dropwise. The reaction mixture was stirred at about 0 ° C. for about 30 minutes. The reaction mixture was then quenched with water and extracted with dichloromethane. When the solvent was distilled off, the desired compound was formed.

Preparation of the compound of formula 48 The compound of formula 47 (3.0 eq) and the compound of formula 24 (1.0 eq) were poured into methanol containing about 1% acetic acid and stirred at ambient temperature for about 24 hours. Sodium cyanoborohydride (1.5 eq) was added and the resulting mixture was stirred at room temperature for about 2 hours. The solvent was removed and the residue was extracted with dichloromethane. The organic layer was washed with aqueous sodium hydrogen carbonate solution, water, and brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column to give the desired compound.

Preparation of compound of formula 49 The compound of formula 48 (1.0 eq) was charged into dry dichloromethane (5-10 mL) and di-tert-butyl dicarbonate (1.2 eq) was added. The resulting mixture was stirred at ambient temperature for about 12 hours. Removal of the solvent and purification on a silica gel column gave the desired compound.

Preparation of compound of formula 50 The compound of formula 49 (1.0 eq) was charged into dry dichloromethane (5-10 mL) and cooled to 0 ° C. To this was added triethylamine (2.0 eq) and formula R ₆ NCO (1.5 eq). The resulting mixture was slowly warmed to ambient temperature and stirred for about 3 hours. The reaction was quenched with water and extracted with dichloromethane.
Next, this was filtered and the filtrate was distilled off to obtain the compound of formula 45. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column.

Preparation of the compound of formula 51 The compound of formula 50 (1.0 eq) was dissolved in a solution of trifluoroacetic acid in dichloromethane (5-10 mL) (about 20%) and stirred for about 3 hours. The reaction was quenched with aqueous sodium bicarbonate and extracted with dichloromethane. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified on a silica gel column.

Preparation of the compound of formula 54 The compound of formula 52 (1.0 eq) was charged into a round bottom flask, to which acetonitrile (10 mL) was added, and then the compound of formula 39b (1.5 eq) was added dropwise. The reaction mixture was heated at about 70 ° C. for about 10 hours, cooled to ambient temperature, water added to it and extracted with ethyl acetate. The solvent was distilled off and the resulting residue was purified by column chromatography to form the compound of formula 53. This was deprotected according to the procedure described below.

Preparation of compound of formula 56 Triethylamine (1.5 eq) and phenyl chloroformate (1.2 eq) are added to a solution of compound of formula 55 (1.0 eq) in dichloromethane (30 mL), cooled to about 0 ° C. and about 2 h. Stir. The reaction mixture was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to form the desired compound.

Preparation of the compound of formula 57 A mixture of the compound of formula 56 (1.0 eq), hydrazine hydrate (2.5 eq), and dioxane was stirred at about 80 ° C. for about 2 hours. The reaction mixture was distilled off under reduced pressure. The residue was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to form the desired compound.

Preparation of the compound of formula 59 A mixture of the compound of formula 57 (1.0 eq), formamidine acetate (3 eq), acetic acid (3 eq), and dimethylformamide (20 mL) was stirred at about 80 ° C. for about 3 h. The reaction mixture was diluted with ethyl acetate, washed with water and dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The product was purified by column chromatography eluting with ethyl acetate and hexane to form the compound of formula 58. When deprotected, a compound of formula 59 was formed.

The following compounds were similarly prepared according to the general process described above.
Compound No. 1: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3,4,5,6-pentafluorobenzenesulfonamide, mass ( m / z): 477.3; Melting point: 63-64

Compound No. 2: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide, mass (m / z): 499.3; melting point: rubbery

Compound No. 3: 5- (1-benzothien-2-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, Mass (m / z): 525.2; Melting point: 59-61

Compound No. 4: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide, mass (m / z): 529.3; Melting point: 55-57

Compound No. 5: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 433.1 Melting point: 49-51


Compound No. 6: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide, mass (m / z): 515.2; Melting point: rubbery

Compound No. 7: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide, Mass (m / z): 543.2; Melting point: Rubbery

Compound No. 8: 5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 497.1; melting point: rubbery

Compound No. 9: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (1-hydroxyethyl) phenyl] thiophene-2-sulfone Amide, mass (m / z): 513.1; melting point: 52-55

Compound No. 10: 5- (3-acetylphenyl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass ( m / z): 525.1; melting point: rubbery

Compound No. 11: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl] thiophene-2-sulfonamide, mass (m / z): 529.1; Melting point: rubbery

Compound No. 12: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 429.2 Melting point: rubbery

Compound No. 13: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 457.2; melting point: rubbery

Compound No. 14: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl] thiophene-2-sulfonamide, mass (m / z): 515.3; Melting point: 47-48

Compound No. 15: 6-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] imidazo [2,1-b] [1,3] thiazole- 5-sulfonamide, mass (m / z): 467.1; melting point: rubbery

Compound No. 16: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2-sulfonamide , Mass (m / z): 537.3; melting point: rubbery

Compound No. 17: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazole -3-yl] thiophene-2-sulfonamide, mass (m / z): 541.3; melting point: 69

Compound No. 18: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl] isoxazol-3-yl) thiophene- 2-sulfonamide, mass (m / z): 528.2; melting point: 110

Compound No. 19: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazole -5-yl] thiophene-2-sulfonamide, mass (m / z): 541.2; melting point: rubbery

Compound No. 20: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide , Mass (m / z): 539.1; melting point: rubbery

Compound No. 21: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene- 2-sulfonamide, mass (m / z): 514.0; melting point: rubbery

Compound No. 22: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene -2-sulfonamide, mass (m / z): 542.1; melting point: rubbery

Compound No. 23: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H- Pyrazol-5-yl] thiophene-2-sulfonamide, mass (m / z): 555.1; melting point: rubbery

Compound No. 24: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazole -5-yl] thiophene-2-sulfonamide, mass (m / z): 527.0; melting point: rubbery

Compound No. 25: N- [2-({[(1S) -2-cyclopeptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazole -3-yl] thiophene-2-sulfonamide, mass (m / z): 555.1; melting point: rubbery

Compound No. 26: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide , Mass (m / z): 553.2; melting point: 59

Compound No. 27: 5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide, Mass (m / z): 491.2; Melting point: 82-84

Compound No. 28: methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate, mass (m / z): 465.2; Melting point: rubbery

Compound No. 29: methyl 4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate, mass (m / z): 463.2; Melting point: rubbery

Compound No. 30: 5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide , Mass (m / z): 439.4; melting point: rubbery

Compound No. 31: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,2'-bithiophene-5-sulfonamide, mass (m / z) : 475.2; melting point: rubbery

Compound No. 32: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide, mass (m / m z): 459.3; melting point: rubbery

Compound No. 33: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide, mass (m / z): 469.3 Melting point: 81-83

Compound No. 34: N- [2-({[(1S) -2-cyclohexyl-1- (hydroxymethyl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 409.3; Melting point: 79-80

Compound No. 35: methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate, Mass (m / z): 479.2; Melting point: rubbery

Compound No. 36: 5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide , Mass (m / z): 505.2; melting point: rubbery

Compound No. 37: 5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfone Amide, mass (m / z): 453.2; melting point: rubbery

Compound No. 38: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide, mass (m / z ): 489.2; melting point: rubbery


Compound No. 39: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide, mass (m / m z): 445.2; melting point: rubbery

Compound No. 40: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide, mass (m / z): 473.2; melting point: rubbery

Compound No. 41: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide, mass (m / z): 455.2 Melting point: 61-62.5

Compound No. 42: 5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 457.1 Melting point: 135-136.5

Compound No. 43: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 379.2; melting point: rubber Condition

Compound No. 44: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 407.2; melting point: Rubbery

Compound No. 45: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide, mass (m / z): 352.3; melting point: rubbery

Compound No. 46: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] nicotinamide, mass (m / z): 352.3; melting point: 113-114

Compound No. 47: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide, mass (m / z) : 461.2; melting point: rubbery

Compound No. 48: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide, mass (m / m z): 523.3; Melting point: 114-116

Compound No. 49: 2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] [(2-methylphenyl) sulfonyl] carbamate hydrochloride, mass (m / z): 445.2; Melting point: 151-152.5

Compound No. 50: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide, mass (m / z): 480.3 Melting point: 58-60

Compound No. 51: 5-bromo-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamidine, mass (m / z): 419.2; melting point : 60-62

Compound No. 52: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamide, mass (m / z): 341.2; melting point: 48-50

Compound No. 53: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-3-sulfonamide, mass (m / z): 443.2 Melting point: 50-52

Compound No. 54: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide, mass (m / z): 357.2; melting point: 48- 50

Compound No. 55: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide hydrochloride, mass (m / z): 371.3; Melting point: 143-145

Compound No. 56: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride, mass (m / z): 327.3; melting point: 174 -176

Compound No. 57: 5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride, mass (m / z): 405.1 Melting point: 84-86

Compound No. 58: 5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 511.2; Melting point: rubbery

Compound No. 59: 5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfone Amide, mass (m / z): 513.2; melting point: rubbery

Compound No. 60: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide, mass (m / z) : 475.2; melting point: rubbery

Compound No. 61: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide, mass ( m / z): 513.2; Melting point: 34-35

Compound No. 62: methyl 3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4- (isopropylsulfonyl) thiophene-2-carboxy Rate, mass (m / z): 557.2; Melting point: 111-112.5

Compound No. 63: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide, mass (m / z): 487.2; melting point: 56-58

Compound No. 64: N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (hydroxymethyl) phenyl] thiophene-2-sulfone Amide, mass (m / z): 499.0; melting point: 62-63

Compound No. 65: N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (hydroxymethyl) phenyl] thiophene-2-sulfone Amide, mass (m / z): 199.0; melting point: 144-146

Compound No. 66: methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate, mass (m / z): 451.3; Melting point: 58-60

Compound No. 67: methyl 4-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate, Mass (m / z): 477.1; Melting point: 135-136.5

Compound No. 68: N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2 -Sulfonamide, mass (m / z): 551.2; melting point: 40-41

Compound No. 69: N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide, mass (m / z): 473.2; Melting point: 55-56

Compound No. 70: N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide, Mass (m / z): 473.2; Melting point: 62-63

Compound No. 71: N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide, mass ( m / z): 446.0; Melting point: 81-82

Compound No. 72: N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide, mass (m / z ): 371.3; Melting point: 118-119

Compound No. 73: N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide, mass (m / m z): 385.3; melting point: rubbery

Compound No. 74: N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] nicotinamide, mass (m / z): 338.3; melting point: 80-82

Compound No. 75: N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] nicotinamide, mass (m / z): 366.2; melting point: 105- 107

Compound No. 76: N- [3-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide, mass (m / z): 408.3; melting point: rubbery

Compound No. 77: N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide, mass (m / z): 394.1 Melting point: 172-173

Compound No. 78: N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4-fluorobenzenesulfonamide, mass (m / z): 406.3; melting point: 148-149

Compound No. 79: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline -6-benzenesulfonamide, mass (m / z): 538.1; melting point: 68

Compound No. 80: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide, mass (m / z): 442.1; Melting point: rubbery

Compound No. 81: Methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2- Carboxylate, mass (m / z): 462.1; melting point: rubbery

Compound No. 82: methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2-carboxyl Rate, mass (m / z): 434.1; Melting point: rubbery

Compound No. 83: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide, mass (m / z ): 377.0; Melting point: 42-44

Compound No. 84: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide, mass (m / m z): 405.2; melting point: 43-45

Compound No. 85: 5-bromo-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide, mass (m / z): 433.0; Melting point: rubbery

Compound No. 86: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide, mass (m / m z): 509.1; melting point: 97-98

Compound No. 87: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide, mass (m / m z): 460.2; Melting point: 68-69.5

Compound No. 88: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide, mass (m / z): 366.2; melting point: rubbery

Compound No. 89: 5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide , Mass (m / z): 425.0; melting point: rubbery

Compound No. 90: (1-Benzothien-2-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 539.2; Melting point: 128-130

Compound No. 91: 5- (1-benzothien-2-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, Mass (m / z): 511.2; Melting point: 124-126

Compound No. 92: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide, Mass (m / z): 543.2; Melting point: 45-46

Compound No. 93: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (4-methoxyphenyl) thiophene-2-sulfonamide, mass (m / z): 485.2; melting point: 101-102

Compound No. 94: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide, mass (m / z) : 461.2; melting point: rubbery

Compound No. 95: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide, mass (m / z ): 489.2; melting point: rubbery

Compound No. 96: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline -6-benzenesulfonamide, mass (m / z): 524.0; melting point: 55

Compound No. 97: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide, mass (m / z): 428.1; melting point: rubbery

Compound No. 98: 5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfone Amide, mass (m / z): 499.0; melting point: rubbery

Compound No. 99: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- [4- (4-methoxyphenyl) piperazin-1-yl] acetamide , Mass (m / z): 479.2; melting point: rubbery

Compound No. 100: 5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide, Mass (m / z): 477.08; Melting point: 74-76

Compound No. 101: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide, mass (m / z): 574.1; Melting point: 148-150

Compound No. 102: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) thiophene -2-sulfonamide, mass (m / z): 476.00; melting point: 158-159

Compound No. 103: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) Thiophene-2-sulfonamide, mass (m / z): 504.10; melting point: 80-82

Compound No. 104: ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2 , 4-oxadiazol-5-carboxylate, mass (m / z): 533.10; melting point: 40-41

Compound No. 105: ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2 , 4-oxadiazol-5-carboxylate, mass (m / z): 519.00; melting point: 56-58

Compound No. 106: ethyl 3- [5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1, 2,4-oxadiazol-5-carboxylate, mass (m / z): 547.10; melting point: 54-56

Compound No. 107: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide, mass (m / z): 422.0779.2; Melting point: 56-58

Compound No. 108: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide, mass (m / z): 408.1; Melting point: 60-61

Compound No. 109: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide, Mass (m / z): 436.0; Melting point: 53-55

Compound No. 110: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide, mass (m / z): 357.1; Melting point: rubbery

Compound No. 111: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide, mass (m / z): 338.2; melting point: 70-72

Compound No. 112: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide, Mass (m / z): 451.2; Melting point: Rubbery

Compound No. 113: methyl 3-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate, mass (m / z ): 437.0; melting point: rubbery

Compound No. 114: methyl 3-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate, mass (m / m z): 465.1; melting point: 53-57

Compound No. 115: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide, mass ( m / z): 467.1; melting point: 62-64

Compound No. 116: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (2-thienylsulfonyl) -1,2,3,4-tetrahydro Isoquinoline-6-benzenesulfonamide, mass (m / z): 588.0; melting point: 80-81

Compound No. 117: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide, mass (m / z): 494.1; Melting point: rubbery

Compound No. 118: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide, mass (m / z): 466.1 Melting point: rubbery

Compound No. 119: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide, mass (m / z): 452.1; melting point: 207-209

Compound No. 120: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide, mass (m / z): 438.1; melting point: 135-137

Compound No. 121: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide, mass (m / z): 454.1; melting point: 110-112

Compound No. 122: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide, mass (m / z): 377.1; Melting point: 55-56

Compound No. 123: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide, mass (m / z): 391.1 Melting point: 51-52

Compound No. 124: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide, Mass (m / z): 437.2; Melting point: Rubbery

Compound No. 125: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide , Mass (m / z): 465.3; melting point: 115-117

Compound No. 126: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-hydroxyethaneimidoyl] phenyl } Thiophen-2-sulfonamide, mass (m / z): 526.1; melting point: 73-77

Compound No. 127: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-methoxyethaneimidoyl] phenyl } Thiophen-2-sulfonamide, mass (m / z): 540.1; melting point: 48-50

Compound No. 128: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide, mass (m / z): 355.2; melting point: rubbery

Compound No. 129: 2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-methoxyphenyl) carbamate, mass (m / z): 397.1; melting point: 56-57

Compound No. 130: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide, mass (m / m z): 547.0; melting point: 85-87

Compound No. 131: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide, mass (m / z ): 519; Melting point: 50-52

Compound No. 132: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide, mass (m / z ): 533.0; Melting point: 175-177

Compound No. 133: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (2-thienyl (Sulphonyl) -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 688.1; melting point: 80

Compound No. 134: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (trifluoroacetyl ) -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 638.1; melting point: 132

Compound No. 135: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -1,2,3, 4-tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 542.1; melting point: 93

Compound No. 136: 5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophen-2- Sulfonamide, mass (m / z): 527.1; melting point: 53

Compound No. 137: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide, mass (m / z): 453.1; melting point: 60-62

Compound No. 138: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide, mass (m / z): 439.1; melting point: 56-58

Compound No. 139: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (1,3-oxazol-2-yl) thiophene-2- Sulfonamide, mass (m / z): 474.0; melting point: 48-50

Compound No. 140: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide, mass (m / z): 343.2; melting point: rubbery

Compound No. 141: N- (4-acetylphenyl) -N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea, mass (m / z): 408.1; melting point: 150-151 ° C

Compound No. 142: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 429.2 Melting point: rubbery

Compound No. 143: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-4-ylthiophene-2-sulfonamide, mass (m / m z): 470.0; Melting point: 84-86 ° C

Compound No. 144: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-3-ylthiophene-2-sulfonamide, mass (m / m z): 456.0; Melting point: 78-80 ° C

Compound No. 145: 2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-acetylphenyl) carbamate, mass (m / z): 409.1; melting point: 63-65 ° C.

Compound No. 146: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide, mass (m / z): 440.0; melting point: 174-175 ° C

Compound No. 147: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) Benzenesulfonamide, mass (m / z): 468.1; melting point: 177-178 ° C

Compound No. 148: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide, Mass (m / z): 437.2; Melting point: Rubbery

Compound No. 149: 6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (4-methoxyphenyl) -3,4 -Dihydroisoquinoline-2 (1H) -carboxamide, mass (m / z): 578.1; melting point: 96-98 ° C

Compound No. 150: 6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (isopropyl) -3,4-dihydroisoquinoline -2 (1H) -carboxamide, mass (m / z): 513.1; melting point: 94-95 ° C

Compound No. 151: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-ylcarbonyl) -1,2,3 , 4-Tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 522.1; melting point: 79-81 ° C.

Compound No. 152: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-({[(4-methoxyphenyl) amino] carbonyl} amino) benzene Sulfonamide, mass (m / z): 551.1; melting point: 97-98 ° C

Compound No. 153: 4-({[(4-acetylphenyl) amino] carbonyl} amino) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzene Sulfonamide, mass (m / z): 563.1; melting point: 155-156 ° C

Compound No. 154: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 548.0; Melting point: 82-83 ° C

Compound No. 155: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrimidin-2-yl-1H-imidazol-4-sulfonamide, mass (m / z): 455.1; Melting point: 90-92 ° C

Compound No. 156: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide, mass (m / z): 391.0; melting point : 122-124 ℃

Compound No. 157: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide, mass (m / z): 377.1; melting point : 150-152 ℃

Compound No. 158: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide, mass (m / z): 405.2; Melting point: 133-134 ° C

Compound No. 159: N- {3- [5-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} acetamide, mass (m / z): 526.1; Melting point: 95-98 ° C

Compound No. 160: N- {3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} Acetamide, mass (m / z): 512.0; melting point: 84-87 ° C

Compound No. 161: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfone Amide, mass (m / z): 559.1; melting point: rubbery

Compound No. 162: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfone Amide, mass (m / z): 545.1; melting point: rubbery

Compound No. 163: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide, mass (m / z): 355.2; melting point: 103 -105 ℃

Compound No. 164: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide, mass (m / z): 369.1; melting point: 118 -120 ℃

Compound No. 165: 4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzamide, mass (m / z): 366.2; melting point: 116- 118 ℃

Compound No. 166: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N'-isopropylurea, mass (m / z): 332.2; melting point: 61 -62 ℃

Compound No. 167: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N'-isopropylthiourea, mass (m / z) :; Melting point: 167- 169 ° C

Compound No. 168: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-methoxyphenyl) urea, mass (m / z): 396.1; Melting point: 52-54 ° C

Compound No. 169: N- (4-acetylphenyl) -6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3,4 -Dihydroisoquinoline-2 (1H) -carboxamide, mass (m / z): 589.2; melting point: 92-97 ° C

Compound No. 170: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 456.1; Melting point: 88-90 ° C

Compound No. 171: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -N'-isopropylthiourea, mass (m / z): 346.2; melting point: Rubbery

Compound No. 172: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isoxazole-5-carboxamide, mass (m / z): 342.1; melting point: measured Z

Compound No. 173: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-carboxamide, mass (m / z ): 460.0; Melting point: 65-67 ° C

Compound No. 174: N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide, mass (m / z): 383.2; melting point: 73-74 ℃

Compound No. 175: tert-butyl 4- (2-{[2- (2-furoylamino) benzyl] amino} propyl) piperidine-1-carboxylate, mass (m / z): 442.2; melting point: 65-67 ° C.

Compound No. 176: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-nitrobenzamide, mass (m / z): 396.1; melting point: 76 -77 ℃

Compound No. 177: tert-butyl 4- [2-({2-[(4-fluorobenzoyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate, mass (m / z): 470.1; melting point: 40-42 ℃

Compound No. 178: tert-butyl 4- [2-({2-[(2-thionylcarbonyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate, mass (m / z): 458.1; melting point: 48 -49 ℃

Compound No. 179: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide, mass (m / z): 455.1; Melting point: 90-92 ° C

Compound No. 180: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z) : 409.0; Melting point: 74-76 ° C

Compound No. 181: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide, mass (m / m z): 407.1; Melting point: 146-147 ° C

Compound No. 182: tert-butyl 4- {2-[(2-{[(5-isoxazol-5-yl-2-thienyl) carbonyl] amino} benzyl) amino] propyl} piperidine-1-carboxylate, mass ( m / z): 561.1; Melting point: 75-80 ° C

Compound No. 183: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide, mass (m / m z): 446.1; Melting point: 51-55 ° C

Compound No. 183a: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-[4- (1,3-oxazol-5-yl) phenyl] urea, mass (m / z): 433.2; Melting point: 72-74 ° C

Compound No. 183b: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(methylsulfonyl) amino] benzenesulfonamide,

The following compounds can be prepared according to the general process described above.

Compound No. 184: N- (4-chlorophenyl) -N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) urea,

Compound No. 185: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-phenylurea,

Compound No. 186: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4-dichlorophenyl) urea,

Compound No. 187: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4,5-trichlorophenyl) urea,

Compound No. 188: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(2,4-dichlorophenyl) urea,

Compound No. 189: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(4-fluorophenyl) urea,

Compound No. 190: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-1-naphthylurea,

Compound No. 191: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylurea,

Compound No. 192: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylthiourea,

Compound No. 193: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-naphthylthiourea,

Compound No. 194: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N '-(trichloromethyl) thiourea,

Compound No. 195: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-phenylpiperazine-1-carboxamide,

Compound No. 196: 4-Benzyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

Compound No. 197: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

Compound No. 198: 4- (4-chlorophenyl) -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

Compound No. 199: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-methylpiperazine-1-carboxamide,

Compound No. 200: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) morpholine-4-carboxamide,

Compound No. 201: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-pyrimidin-4-ylpiperazine-1-carboxamide,

Compound No. 202: 4-chloro-N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenesulfonamide,

Compound No. 203: N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} -4-methylbenzenesulfonamide,

Compound No. 204: N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzamide,

Compound No. 205: N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenecarbothioamide,

Compound No. 206: 4-[(4-chlorophenyl) sulfonyl] -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

Compound No. 207: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (phenylsulfonyl) piperazine-1-carboxamide,

Compound No. 208: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(4-methylphenyl) sulfonyl] piperazine-1-carboxamide,

Compound No. 209: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (2-thienylsulfonyl) piperazine-1-carboxamide,

Compound No. 210: N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-chlorobenzenesulfonamide,

Compound No. 211: N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-methylenesulfonamide,

Compound No. 212: N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} methanesulfonamide,

Compound No. 213: N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} thiophene-2-sulfonamide,

Compound No. 214: N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

Compound No. 215: 4-Methyl-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

Compound No. 216: 4-chloro-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

Compound No. 217: N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

Compound No. 218: 5-bromo-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

Compound No. 219: 4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

Compound No. 220: N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

Compound No. 221: N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

Compound No. 222: 5-bromo-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

Compound No. 223: 4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

Compound No. 224: 4-chloro-N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

Compound No. 225: N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

Compound No. 226: N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea,

Compound No. 227: N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea,

Compound No. 228: N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} methanesulfonamide,

Compound No. 229: N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide,

Compound No. 230: N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} -4-methylbenzenesulfonamide,

Compound No. 231: N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide,

Compound No. 232: 5-bromo-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide,

Compound No. 233: 4-chloro-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide,

Compound No. 234: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-methoxy-4-piperazin-1-ylbenzenesulfonamide,

Compound No. 235: N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -5- (phenylsulfonyl) -2-sulfonamide,

Compound No. 236: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-benzofuran-2-carboxamide,

Compound No. 237: N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl Acetamide,

Compound No. 238: 2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl (4-methoxyphenyl) carbamate,

Compound No. 239: N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -6- (1H-imidazol-1-yl) nicotinamide,

Compound No. 240: N- (4-{[(2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} thiophene-2-sulfonamide,

Compound No. 241: N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide,

Compound No. 242: N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

Compound No. 243: 2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl (4-acetylphenyl) carbamate,

Compound No. 244: N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide,

Compound No. 245: N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -4-fluorobenzenesulfonamide,

Compound No. 246: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -6- (3-furyl) nicotinamide,

Compound No. 247: N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide,

Compound No. 248: N- (3-{[(2-cycloheptyl-1-methylethyl) amino] methyl} pyridin-2-yl) -2-furamide,

Compound No. 249: N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide,

Compound No. 250: N- (2-{[(2-cyclohexyl-1-en-1-yl-1-methylethyl) amino] methyl} phenyl) -5- (1,3-oxazol-5-yl) furan -2-sulfonamide,

Compound No. 251: N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -N '-(3-methylisoxazol-5-yl) urea

Compound No. 252: 2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-imidazol-1-yl) phenyl) carbamate,

Compound No. 253: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5- (3-furyl) nicotinamide,

Compound No. 254: 1-benzofuran-2-ylmethyl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

Compound No. 255: N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

Compound 256: N-1-benzothien-2-yl-N ′-[2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] urea,

Compound No. 257: 2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-pyrazol-1-yl) phenyl) carbamate,

Compound No. 258: 2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate,

Compound No. 259: 3,3′-bipyridin-6-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

Compound No. 260: Pyridin-4-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

Compound No. 261: N-1-benzothien-2-yl-N ′-(4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea,

Compound No. 262: N-1-benzothien-2-yl-N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea,

Compound No. 263: 3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate,

Compound No. 264: 3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl 1-benzothien-2-ylcarbamate,

Compound No. 265: N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) urea

Compound No. 266: N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) urea

Compound No. 267: 2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate,

Compound No. 268: 4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate,

Compound No. 269: 1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) carbamate,

Compound No. 270: 1-benzothien-2-yl (4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate,

Compound No. 271: 1-benzothien-2-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate,

Compound No. 272: 2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate,

Compound No. 273: 2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl 1-benzothien-2-ylcarbamate,

Compound No. 274: 1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] carbamate,

Compound No. 275: 1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) carbamate,

Compound No. 276: 1-benzothien-2-yl (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) carbamate,

Compound No. 277: N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindole-2- Yl) acetamide,

Compound No. 278: 1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) pyridin-3-yl] carbamate,

Compound No. 279: N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide,

Compound No. 280: 1-benzothien-2-yl (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl] pyridin-3-yl) carbamate,

Compound No. 281: 3-{[(1-Methyl-2-piperidin-4-ylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate,

Compound 282: N-1-benzothien-2-yl-N ′-(2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) urea,

Compound No. 283: N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

Compound No. 284: N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) -2- (1H-pyrazol-1-yl) acetamide,

Compound No. 285: N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) isonicotinamide,

Compound No. 286: 4-chloro-N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) benzenesulfonamide, mass (m / z ): 464.1; Melting point: 162-163

Compound No. 287: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(4-morpholin-4-ylphenyl) urea, mass ( m / z): 451.3; Melting point: 68-70

Compound No. 288: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[3- (2-furyl) -1H-pyrazol-5- Il) Urea, mass (m / z): 422.2; melting point: 103-105

Compound No. 289: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(5-oxo-1-phenyl-4,5-dihydro- 1H-pyrazol-3-yl) urea, mass (m / z): 448.2; melting point: 162-164

Compound No. 290: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(4-methoxy-1,2-benzoxazol-3-yl) Urea, mass (m / z): 437.2; melting point: 70-71

Compound No. 291: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(3,4-dimethylisoxazol-5-yl) urea , Mass (m / z): 385.2; melting point: 53-55

Compound No. 292: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[1-methyl-3- (2-thienyl) -1H- Pyrazol-5-yl] urea, mass (m / z): 452.2; melting point: 105-107

Compound No. 293: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide, mass (m / z): 376.50; Melting point: 55-56

Compound No. 294: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide, mass (m / z): 363.1; Melting point: 120-122

Compound No. 295: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide, mass (m / z) : 444.3; Melting point: 69-72

Compound No. 296: 4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide, mass (m / z): 402.3; melting point: 74-76

Compound No. 297: N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 534.1; Melting point: 93.8-95

Compound No. 298: 2-thienylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / z): 387.2

Compound No. 299: 2-thienylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / z): 373.2

Compound No. 300: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfone Amide, mass (m / z): 545.1

Compound No. 301: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- {3-[(E)-(hydroxyimino) methyl] -1H -Pyrrol-1-yl} benzenesulfonamide, mass (m / z): 495.1; melting point: 150-152

Compound No. 302: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzamide, mass (m / z): 444.2; Melting point: 84-86

Compound No. 303: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[4- (1,2,3-thiadiazol-4-yl ) Phenyl) urea, mass (m / z): 450.2; melting point: 158-159

Compound No. 304: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-6-carboxamide, mass (m / z) 391.2

Compound No. 305: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-dimethylisoxazol-4-sulfonamide, mass (m / m z): 406.2; melting point: 104-106

Compound No. 306: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide, mass ( m / z): 497.1

Compound No. 307: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxa Sol-4-sulfonamide, mass (m / z): 561.0; melting point: 82-84

Compound No. 308: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazole -4-sulfonamide, mass (m / z): 546.1; melting point: 175-177

Compound No. 309: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-hydroxyethyl) benzenesulfonamide, mass (m / z): 431.1 Melting point: 42-44

Compound No. 310: pyridin-3-ylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / z): 382.3

Compound No. 311: Pyridin-3-ylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / z): 368.2

Compound No. 312: Pyridin-3-ylmethyl [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / z): 398.1

Compound No. 313: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide, mass (m / z): 441.2; Melting point: 85-87

Compound No. 314: 5-chloro-N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzenethiophene -2-sulfonamide, mass (m / z): 507.1; melting point: 110-112

Compound No. 315: ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate, mass ( m / z): 527.1

Compound No. 316: 4-acetyl-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] benzenesulfonamide, Mass (m / z): 584.2; Melting point: 117-119

Compound No. 317: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1 , 3-thiazol-5-sulfonamide, mass (m / z): 577.1; melting point: 72-73

Compound No. 318: N-1,3-benzothiazol-2-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea, mass (m / m z): 423.1; melting point: 74-75

Compound No. 319: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[4 [(1,3-oxazol-5-yl) phenyl ] Urea, mass (m / z): 433.2; melting point: 133-135

Compound No. 320: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-dioxo-1,3-dihydro-2H-isoindole -2-yl) benzenesulfonamide, mass (m / z): 532.1; melting point: 142-144

Compound No. 321: N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6 -Sulfonamide, mass (m / z): 458.2; melting point: 127.1-129.1

Compound No. 322: N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass ( m / z): 459.0; Melting point: 78.8-82.1

Compound No. 323: N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfone Amide, mass (m / z): 476.0; melting point: 89.3-93.8

Compound No. 324: N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2, 3,4-tetrahydroisoquinoline-6-sulfonamide, mass (m / z): 554.1; melting point: 73.6-75.8

Compound No. 325: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide , Mass (m / z): 480.1; melting point: 53-54

Compound No. 326: N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-5-ylthiophene-2-sulfonamide, Mass (m / z): 461.0; Melting point: 107-108

Compound No. 327: N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-3-ylthiophene-2-sulfonamide, Mass (m / z): 447.0; Melting point: 97-99

Compound No. 328: N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4- (1H-pyrrol-1-yl) benzenesulfonamide , Mass (m / z): 453.2; melting point: 179-180

Compound No. 329: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide , Mass (m / z): 466.0; melting point: 76-78

Compound No. 330: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide, mass (m / z): 472.2; melting point: 75-77

Compound No. 331: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide, mass (m / z): 548.2; Melting point: 162-165

Compound No. 332: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (1-methyl-1H-pyrazol-4-yl) thiophene-2 -Sulfonamide, mass (m / z): 473.1; melting point: 85-87

Compound No. 333: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (2-thienylsulfonyl) -1H-imidazol-4-sulfonamide, Mass (m / z): 523.0; Melting point: 67-69

Compound No. 334: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiazol-4-sulfonamide, mass ( m / z): 431.0; Melting point: 72-74

Compound No. 335: N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazole -4-sulfonamide, mass (m / z): 532.1; melting point: 114.6-116.2

Compound No. 336: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide, mass (m / z ): 466.1; Melting point: 78.6-80.9

Compound No. 337: 4-[(butylsulfonyl) amino] -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide, mass (m / z ): 522.2; Melting point: 53-56

Compound No. 338: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(ethylsulfonyl) amino] benzenesulfonamide, mass (m / z ): 494.1; Melting point: 65-67

Compound No. 339: 5-Chloro-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3 -Dimethyl-1H-pyrazole-4-sulfonamide, mass (m / z): 594.2; melting point: 75-78

Compound No. 340: Methyl 4-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl)- 2,5-dimethyl-3-furoate, mass (m / z): 618.2; melting point: 65-67

Compound No. 341: Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl)- 3-methylthiophene-2-carboxylate, mass (m / z): 620.2; melting point: 93-95

Compound No. 342: Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl)- 2-Furoate, mass (m / z): 590.2; melting point: 109-111

Compound No. 343: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(3-oxo-1,3-dihydro-2-benzofuran- 5-yl) urea, mass (m / z): 422.2; melting point: 169-172

Compound No. 344: 2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) amino] benzamide, mass (m / z): 392.2 Melting point: 51-54

Compound No. 345: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N'-isoquinolin-5-ylurea, mass (m / z): 417.2; Melting point: 156-158

Compound No. 346: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N'-morpholin-4-ylurea, mass (m / z): 375.2 Melting point: 132-134

Compound No. 347: N-1,3-benzothiazol-6-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) urea, mass (m / z) : 423.1; melting point: 150-153

Compound No. 348: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-1,3-thiazol-2-ylurea, mass (m / z ): 373.2; Melting point: 51-54

Compound No. 349: Ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate, mass ( m / z): 541.1

Compound No. 350: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide, mass (m / z): 444; melting point: 80-82

Compound No. 351: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazole -1-yl) benzenesulfonamide, mass (m / z): 470.1; melting point: 92-94

Compound No. 352: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzene Sulfonamide, mass (m / z): 468.2; melting point: 88-90

Compound No. 353: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, mass (m / z): 693.2; melting point: 114-116

Compound No. 354: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide, mass (m / z): 464.2; melting point: 60-62

Compound No. 355: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide, mass (m / z): 450.2; melting point: 135-137

Compound No. 356: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide, mass (m / z): 465.2; melting point: 63-64

Compound No. 357: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide, mass (m / z): 451.2; melting point: 120-122

Compound No. 358: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide , Mass (m / z): 467.2; melting point: 75-77

Compound No. 359: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide , Mass (m / z): 453.2; melting point: 65-67

Compound No. 360: N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfone Amide, mass (m / z): 458.2; melting point: 142.5-145

Compound No. 361: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfone Amide, mass (m / z): 476.2; melting point: 117.6-121.8

Compound No. 362: N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass ( m / z): 459.2; Melting point: 79.4-80.5

Compound No. 363: N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H- Imidazol-4-sulfonamide, mass (m / z): 546.2; melting point: 115-118

Compound No. 364: N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H- Imidazol-4-sulfonamide, mass (m / z): 546.2; melting point: 92-95

Compound No. 365: 5-chloro-N- [4-[({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1, 3-Dimethyl-1H-pyrazole-4-sulfonamide, mass (m / z): 580.1; melting point: 78.7-84.3

Compound No. 366: N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N, N-dimethylsulfamide, mass (m / z): 354.2

Compound No. 367: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide , Mass (m / z): 471.2; melting point: 122-123

Compound No. 368: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide, mass (m / z): 454.1; Melting point: 50-52

Compound No. 369: N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide, Mass (m / z): 548.1; Melting point: 75-77

Compound No. 370: N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide, Mass (m / z): 548.1; Melting point: 75-77

Compound No. 371: 3-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide), mass (m / z): 402.2

Compound No. 372: 2-Amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide, mass (m / z): 402.1

Compound No. 373: N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1 , 3-thiazol-5-sulfonamide, mass (m / z): 577.1; melting point: 77-78

Compound No. 374: N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxa Sol-4-sulfonamide, mass (m / z): 561.1; melting point: 63-66

Compound No. 375: N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide, mass ( m / z): 497.1; Melting point: 97-99

Compound No. 376: N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide, mass (m / z): 548.1; Melting point: 68-70

Compound No. 377: Ethyl 5-{[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} -5-oxo Pentoate, mass (m / z): 544.2

Compound No. 378: 2-Amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-5-sulfonamide, mass (m / z): 459.1; melting point: 64-66

Compound No. 379: 5-Chloro-N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3 -Dimethyl-1H-pyrazole-4-sulfonamide, mass (m / z): 594.1; melting point: 65-67

Compound No. 380: N- [2-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1 , 3-thiazol-5-sulfonamide, mass (m / z): 577.2; melting point: 71-74

Compound No. 381: N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide, mass (m / z): 534.1; Melting point: 137.8-141.2

Compound No. 382: N- (2-{[[(1S) -2-cyclohexyl-1-methylethyl] (methylsulfonyl) amino] methyl} phenyl) -2-[(methylsulfonyl) amino] benzenesulfonamide , Mass (m / z): 558.1; melting point: 78-80 ° C

Compound No. 383: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide, mass (m / z): 439.1; melting point: 147-148

Compound No. 384: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide, mass (m / z): 453.1

Compound No. 385: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazole-1 -Yl) benzenesulfonamide, mass (m / z): 472.2; melting point: 136-137

Compound No. 386: [5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / m z): 454.2

Compound No. 387: N-[(1S) -2-cyclopentyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide, mass (m / z): 393.1

Compound No. 388: N-[(1S) -2-cyclohexyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide, mass (m / z): 407.1

Compound No. 389: Methyl [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1H-benzimidazol-2-yl] Carbamate, mass (m / z): 500.1; melting point: 122-124

Compound No. 390: Methyl [6-({[4-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -1H-benzimidazo Ru-2-yl] carbamate, mass (m / z): 655.2; melting point: 160-163

Compound No. 391: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-hydroxyethaneimidoyl] benzenesulfonamide, Mass (m / z): 444.1; Melting point: 144-147

Compound No. 392: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-methoxyethaneimidoyl] benzenesulfonamide, Mass (m / z): 458.1

Compound No. 393: 4-{[amino (imino) methyl] amino} -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide, mass ( m / z): 445.1; Melting point: 94-96

Compound No. 394: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] sulfamide, mass (m / z): 326.2

Compound No. 395: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -4-[(1E)- N-hydroxyethaneimidoyl] benzenesulfonamide, mass (m / z): 599.2; melting point: 120-122

Compound No. 396: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-{[(isopropylamino) carbonyl] amino} benzenesulfonamide, mass ( m / z): 487.2

Compound No. 397: ethyl (2Z) -4-{[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} -4-oxobut-2-enoate, mass ( m / z): 373.2; Melting point: 65-68

Compound No. 398: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide, mass (m / z): 427.5; Melting point: rubbery

Compound No. 399: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide, mass (m / z): 413.00; Melting point: 58-61 ℃

Compound No. 400: N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] thiophene-2-sulfonamide, mass (m / z): 394.5; melting point: rubber Condition

Compound No. 401: 2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-5-sulfonamide, mass (m / z): 442.04; melting point: 83-85 ° C

Compound No. 402: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] guanidine, mass (m / z): 290.40; melting point: rubbery

Compound No. 403: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-oxo-1,5-dihydro-4H-1,2,4-triazole -4-yl) benzenesulfonamide, mass (m / z): 470.4; melting point: rubbery

Compound No. 404: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide , Mass (m / z): 469.04; melting point: 62-64 ° C

Compound No. 405: N- [2-({[2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide, mass (m / z): 453.2; Melting point: 65-67 ° C

Compound No. 406: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3,5-dimethylisoxazol-4-yl) benzenesulfonamide, mass ( m / z): 482.1; Melting point: rubbery

Compound No. 407: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide , Mass (m / z): 488.0; melting point: rubbery

Compound No. 408: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene- 2-sulfonamide, mass (m / z): 473.9; melting point: 61-62 ° C

Compound No. 409: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-[(methylsulfonyl) amino) benzenesulfonamide, mass (m / z): 480.3; Melting point: 55-57 ℃

Compound No. 410: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-{[(dimethylamino) sulfonyl) amino] benzenesulfonamide, mass (m / z) : 509.20; Melting point: 53-56 ° C

Compound No. 411: N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -1-benzothiophene-2-sulfonamide, mass (m / z): 444.6 Melting point: 89.9-94.3 ℃

Compound No. 412: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-{[(1-methyl-1H-imidazol-4-yl) sulfonyl] amino} pyridine -2-sulfonamide, mass (m / z): 546.97; melting point: rubbery

Compound No. 413: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(methylsulfonyl) amino] pyridine-2-sulfonamide, mass (m / z) : 546.97; Melting point: Rubbery

Compound No. 414: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(2-thienylsulfonyl) amino] pyridine-2-sulfonamide, mass (m / m z): 548.93; melting point: 123-126 ° C

Compound No. 415: 5-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-2-sulfonamide, mass (m / z): 472.1; Melting point: 74-75 ° C

Compound No. 416: [5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate, mass (m / m z): 440.2; melting point: rubbery

Compound No. 417: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluoro-5- (1H-pyrrol-1-yl) benzenesulfonamide, mass (m / z): 470.3; Melting point: 65-66 ° C

Compound No. 418: 2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-4-sulfonamide, mass (m / z): 459.30; melting point: 58-60 ° C

Compound No. 419: N- [2-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide, mass (m / z ): 548.30; Melting point: 85-87 ° C

Compound No. 420: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide, mass (m / z): 394.2; Melting point: 146-148 ° C

Compound No. 421: N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide , Mass (m / z): 468.3; melting point: 106-108 ° C

Compound No. 422: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide, mass (m / z): 440.4; Melting point: 58-60 ° C

Compound No. 423: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine -3-sulfonamide, mass (m / z): 441.2; melting point: 153-155 ° C

Compound No. 424: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] thiophene-2-sulfonamide, mass (m / z): 394.2; melting point: 56 -58 ℃

Compound No. 425: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazole-1 -Yl) benzenesulfonamide, mass (m / z): 458.4; melting point: 122-124 ° C

Compound No. 426: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine-3-sulfone Amide, mass (m / z): 455.3; melting point: 108-109 ° C

Compound No. 427: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide, mass (m / z ): 455.3; Melting point: 175-176 ° C

Compound No. 428: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide, mass (m / m z): 453.3; Melting point: 98-100 ° C

Compound No. 429: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -3-fluoro-4- (1H-1,2,4-triazole-1 -Yl) benzenesulfonamide, mass (m / z): 473.6; melting point: 62-64 ° C

Compound No. 430: N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 411.0; melting point: rubber Condition

Compound No. 431: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide, Mass (m / z): 439.0; Melting point: 149-151 ° C

Compound No. 432: N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -5-isoxazol-5-ylthiophene-2-benzenesulfonamide hydrochloride, mass ( m / z): 497.62; melting point: 146-150 ° C

Compound No. 433: 2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass (m / z): 444.94; melting point: 61-63 ° C

Compound No. 434: 2-Amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-6-sulfonamide, mass (m / z): 427.96; melting point: 109-110 ° C

Compound No. 435: 5-{[amino (imino) methyl] amino} -N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide, mass (m / z): 446.00; melting point: rubbery

Compound No. 436: N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] -1-methyl-1H-imidazole -4-sulfonamide, mass (m / z): 576.5; melting point: rubbery

Compound No. 437: N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] acetamide, mass (m / z): 501.2; Melting point: 78-80 ° C

Compound No. 438: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methyl-1H-benzimidazol-2-sulfonamide, mass (m / z): 441.03; Melting point: 129-131 ° C

Compound No. 439: 4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluorobenzenesulfonamide, mass (m / z): 420; melting point: 58.4-60.2 ℃

Compound No. 440: 4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxybenzenesulfonamide, mass (m / z): 432.5; melting point: Rubbery

Compound No. 441: N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] acetamide, mass (m / z) : 474.02; Melting point: 82-85 ° C

Compound No. 442: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxy-4-[(methylsulfonyl) amino] benzenesulfonamide, mass (m / z ): 510; Melting point: rubbery

Compound No. 443: methyl [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] carbamate, mass (m / z): 460.00; melting point: 44-46 ℃

Compound No. 444: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide , Mass (m / z): 456.90; melting point: 142-144 ° C

Compound No. 445: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide, mass (m / z): 468.99; melting point: 58-60 ° C

Compound No. 446: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide , Mass (m / z): 454.94; melting point: 55-57 ° C

Compound No. 447: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl ) Benzenesulfonamide, mass (m / z): 455.01; melting point: 83-85 ° C

Compound No. 448: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide, mass (m / z): 453.9 Melting point: 94-95 ° C

Compound No. 449: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide, mass (m / m z): 439.9; Melting point: 64-65 ° C

Compound No. 450: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide, mass (m / z): 454.0 Melting point: 70-72 ° C

Compound No. 451: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide, mass (m / m z): 439.9; melting point: 68-70 ° C

Compound No. 452: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide, mass ( m / z): 468.0; Melting point: 55-57 ° C

Compound No. 453: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfone Amide, mass (m / z): 454.0; melting point: 68-69 ° C

Compound No. 454: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide, mass (m / m z): 455.9; melting point: 119-121 ° C

Compound No. 455: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide, Mass (m / z): 442.0; Melting point: 142-144 ° C

Compound No. 456: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide, mass (m / z): 469.9 Melting point: 91-92 ° C

Compound No. 457: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide, mass (m / m z): 455.9; melting point: 62-64 ° C

Compound No. 458: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide, mass (m / m z): 454.0; Melting point: 119-120 ° C

Compound No. 459: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide, Mass (m / z): 440.0; Melting point: 68-69 ° C

Compound No. 460: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide, mass (m / z): 484.0; Melting point: 88-89 ° C

Compound No. 461: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzene Sulfonamide, mass (m / z): 470.0; Melting point: rubbery

Compound No. 462: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide, mass (m / m z): 474.9; Melting point: 131-132 ° C

Compound No. 463: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide, Mass (m / z): 461.0; Melting point: 64-65 ° C

Compound No. 464: N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline -7-sulfonamide, mass (m / z): 556.0; melting point: rubbery

Compound No. 465: N- [4-({[2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide, mass (m / z): 565.9; Melting point: 85-86 ° C

Compound No. 466: N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide, mass (m / z): 470.1; Melting point: 80-81 ° C

Compound No. 467: N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfone Amide, mass (m / z): 556.0; melting point: 65-66 ° C

Compound No. 468: N- (4-{[(2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) thiophene-2-sulfonamide, mass (m / z ): 565.9; Melting point: 69-70 ° C

Compound No. 469: 5-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide, mass (m / z): 403.01; melting point: rubber Condition

Compound No. 470: 5-Chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzoxadiazole-4-sulfone Amide, mass (m / z): 462.89; melting point: rubbery

Compound No. 471: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-carboxamide, mass (m / z): 407.08; Melting point: rubbery

Compound No. 472: N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) thiophene-2-sulfonamide, mass (m / z): 435.1; melting point: rubbery

Compound No. 473: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiazol-5-sulfonamide, mass ( m / z): 430.95; melting point: rubbery

Compound No. 474: N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] thiophene-2-sulfonamide, mass (m / z): 577.93; Melting point: 101-103 ° C

Compound No. 475: N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] thiophene-2-sulfonamide, mass (m / z): 563.94; Melting point: 147-150 ° C

Compound No. 476: N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] acetamide, mass (m / z) : 459.97; Melting point: 118-120 ° C

Compound No. 477: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide, mass (m / z): 489.98; melting point: 141.142 ° C

Compound No. 478: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3 -Yl) benzenesulfonamide, mass (m / z): 475.94; melting point: 130-131 ° C.

Compound No. 479: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazol-1-yl) benzene Sulfonamide, mass (m / z): 471.99; melting point: 124-125 ° C

Compound No. 480: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazole-1 -Yl) benzenesulfonamide, mass (m / z): 457.96; melting point: 110-111 ° C.

Compound No. 481: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (trifluoroacetyl) indoline-5-sulfonamide, mass (m / z): 524.6 Melting point: 94.2-103 ° C

Compound No. 482: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] indoline-5-sulfonamide, mass (m / z): 428.2; melting point: 92.8-94.5 ° C.

Compound No. 483: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide, mass (m / z): 455.01; melting point: 52-54 ° C

Compound No. 484: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide , Mass (m / z): 441.02; Melting point: 128-130 ° C

Compound No. 485: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,4-difluorobenzenesulfonamide, mass (m / z): 409.01; Melting point: 78-80 ° C

Compound No. 486: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -4- (5-methyl-1,3,4-oxadiazol-2-yl ) Benzenesulfonamide, mass (m / z): 470.03; melting point: 64-66 ° C

Compound No. 487: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,3-triazol-1-yl) benzene Sulfonamide, mass (m / z): 440.04; melting point: 149-150 ° C

Compound No. 488: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide, mass (m / z): 471.01; melting point: 62-63 ° C

Compound No. 489: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide , Mass (m / z): 456.97; melting point: 123-124 ° C

Compound No. 490: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide, mass (m / z): 457.1; Melting point: 110-111 ℃

Compound No. 491: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide, mass (m / z ): 443.0; Melting point: 104-106 ° C

Compound No. 492: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridin-3-sulfonamide, mass (m / z): 473.0 Melting point: rubbery

Compound No. 493: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridin-3-sulfonamide, mass (m / m z): 459.0; melting point: rubbery

Compound No. 494: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide, mass ( m / z): 482.0; Melting point: 81-82 ° C

Compound No. 495: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfone Amide, mass (m / z): 468.0; melting point: 70-71 ° C

Compound No. 496: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6-sulfonamide, mass ( m / z): 440.0; Melting point: 83-84 ° C

Compound No. 497: 6-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide, mass (m / z): 465.9; melting point: 120 -121 ℃

Compound No. 498: 2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyrimidine-5-sulfonamide, mass (m / z): 404.00; melting point: 142 -144 ℃

Compound No. 499: 6-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide, mass (m / z): 403.00; melting point: 54 -56 ℃

Compound No. 500: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide, mass (m / z): 443.9; Melting point: 167-169 ° C

Compound No. 501: 5-chloro-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide, mass (m / z): 477.83; Melting point: 79-82 ° C

Compound No. 502: 5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide, mass (m / z): 463.82; melting point: 69-72 ° C

Compound No. 503: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (dimethylamino) -1,3-benzothiazol-6-sulfonamide, mass (m / m z): 486.88; melting point: rubbery

Compound No. 504: N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] -L- Alaninamide, mass (m / z): 456.00; melting point: 93-95 ° C

Compound No. 505: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxo-3,4-dihydroquinoline-2-sulfonamide, mass (m / z) : 529.93; melting point: rubbery

Compound No. 506: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfone Amide, mass (m / z): 537.9; melting point: 55-56 ° C

Compound No. 507: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, mass (m / z) : 441.9; Melting point: 116-117 ° C

Compound No. 508: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroisoquinoline-6-sulfonamide, mass (m / z) : 454.0; Melting point: 107-108 ° C

Compound No. 509: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-imidazol-1-yl) benzenesulfonamide, mass (m / z): 471.06; melting point: 70-72 ° C

Compound No. 510: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide, Mass (m / z): 475.0; Melting point: 81-82 ° C

Compound No. 511: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroisoquinoline-6-sulfone Amide, mass (m / z): 467.9; melting point: 84-86 ° C

Compound No. 512: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroisoquinoline-6-sulfone Amide, mass (m / z): 481.9; melting point: 87-88 ° C

Compound No. 513: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide, mass (m / m z): 469.8; Melting point: 85-87 ° C

Compound No. 514: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide, mass (m / m z): 453.9; Melting point: 66-67 ° C

Compound No. 515: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide, Mass (m / z): 455.8; Melting point: 158-159 ° C

Compound No. 516: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide, mass (m / z ): 456.9; Melting point: 108-109 ° C

Compound No. 517: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzene Sulfonamide, mass (m / z): 483.9; melting point: rubbery

Compound No. 518: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene- 2-sulfonamide, mass (m / z): 487.8; melting point: 84-86 ° C

Compound No. 519: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl ) Benzenesulfonamide, mass (m / z): 468.89; melting point: 94-96 ° C

Compound No. 520: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide , Mass (m / z): 454.93; melting point: 106-108 ° C

Compound No. 521: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide , Mass (m / z): 470.91; Melting point: 60-62 ° C

Compound No. 522: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-[(1-methyl-1H-imidazol-4-yl) sulfonyl] indoline-5- Sulfonamide, mass (m / z): 571.90; melting point: 78-83 ° C

Compound No. 523: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (methylsulfonyl) indoline-5-sulfonamide, mass (m / z): 506.07; Melting point: 74-76 ℃

Compound No. 524: N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl -1H-imidazol-4-sulfonamide, mass (m / z): 599.91; melting point: 67-68 ° C

Compound No. 525: 1-acetyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) indoline-5-sulfonamide, mass (m / z): 469.91; melting point: 76 -78 ℃

Compound No. 526: N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide, mass (m / z) : 444; melting point: rubbery

Compound No. 527: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3 -Yl) benzenesulfonamide, mass (m / z): 490; melting point: 111 ° C.

Compound No. 528: 2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazol-6-sulfonamide, mass (m / z): 442.91; melting point: rubbery

Compound No. 529: N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass (m / z): 443.85; melting point: Rubbery

Compound No. 530: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 400.83 Melting point: rubbery

Compound No. 531: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass (m / z): 429.89; melting point: rubbery

Compound No. 532: 2-amino-N- [2-({[(1S) -2-cyclopropyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass ( m / z): 416.56; melting point: rubbery

Compound No. 533: N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) nonanamide, mass (m / z): 541.95; melting point : 72 ℃

Compound No. 534: 4-amino-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-hydroxybenzensulfonamide, mass (m / z): 417.94; melting point : 65-67 ℃

Compound No. 535: N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} -2-hydroxyphenyl) thiophene-2-sulfonamide, mass (m / z): 563.71; melting point: 103-106 ° C

Compound No. 536: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzothiazol-6- Sulfonamide, mass (m / z): 430.33; melting point: 168-170 ° C

Compound No. 537: 2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass (m / z): 428.88; melting point: 146-149 ° C

Compound No. 538: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxoindoline-6-sulfonamide, mass (m / z): 427.88 Melting point: 75-78 ° C

Compound No. 539: 5-chloro-N- [2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl] -1 benzothiophene-2-sulfonamide, mass (m / z): 477.23; Melting point: 65-67 ℃

Compound No. 540: 5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / m z): 463.2; melting point: 54-55 ° C

Compound No. 541: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzothiophene-2-sulfonamide, mass (m / m z): 459.24; melting point: rubbery

Compound No. 542: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzothiophene-2-sulfonamide, mass (m / m z): 445.29; melting point: 92-95 ° C

Compound No. 543: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-fluoro-1-benzothiophene-2-sulfonamide, mass (m / z): 460.84 Melting point: 67-69 ° C

Compound No. 544: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide, mass (m / m z): 446.81; melting point: 55-56 ° C

Compound No. 545: N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z ): 496.76; Melting point: rubbery

Compound No. 546: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-oxoindoline-6-sulfonamide, mass (m / z): 441.91; melting point: rubber Condition

Compound No. 547: 4-amino-N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] benzenesulfonamide, mass (m / z): 455.87 Melting point: rubbery

Compound No. 548: 5- (6-Aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide , Mass (m / z): 484.91; melting point: 68-70 ° C

Compound No. 549: 5- (6-Aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide , Mass (m / z): 470.92; Melting point: 72-73 ° C

Compound No. 550: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide, mass (m / z): 456.06; Melting point: 147 ° C

Compound No. 551: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide, mass (m / z): 470; Melting point: 82 ° C

Compound No. 552: 2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide, mass (m / z): 459.15; melting point: rubbery

Compound No. 553: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 443.05 Melting point: 55-59 ° C

Compound No. 554: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazole-6- Sulfonamide, mass (m / z): 444.1; melting point: 167-169 ° C

Compound No. 555: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide, mass (m / z): 427.11; Melting point: 50-52 ℃

Compound No. 556: 2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazole-6-sulfonamide, mass (m / z): 443.14; melting point: 169-171 ° C

Compound No. 557: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide, mass (m / z ): 443.11; melting point: 58-60 ° C

Compound No. 558: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide, mass (m / z ): 457.14; melting point: 48-50 ° C

Compound No. 559: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide, mass (m / z ): 443.16; Melting point: 180-182 ° C

Compound No. 560: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide, mass (m / z ): 429.12; melting point: 158-160 ° C

Compound No. 561: N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide, mass (m / z): 534.06; Melting point: 120-124 ° C

Compound No. 562: N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2- Sulfonamide, mass (m / z): 602.12, melting point: 109-111 ° C

Compound No. 563: 2-Amino-N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide , Mass (m / z): 513.10; melting point: 149-153 ° C

Compound No. 564: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (1H-pyrrol-1-yl) -1,3-thiazol- 5-sulfonamide, mass (m / z): 445.04; melting point: 124-125 ° C

Compound No. 565: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfone Amide, mass (m / z): 456.11; melting point: 85-87 ° C

Compound No. 566: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfone Amide, mass (m / z): 442.09; melting point: 78-80 ° C

Compound No. 567: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzene Sulfonamide, mass (m / z): 491.06; melting point: 186-187 ° C

Compound No. 568: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzene Sulfonamide, mass (m / z): 477.09; melting point: 83-85 ° C

Compound No. 569: N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -4- (1H-pyrrol-1-yl) benzenesulfonamide, mass (m / z ): 466.14; melting point: rubbery

Compound No. 570: 2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-5-sulfonamide, mass (m / z): 409.11; melting point: 121-122 ° C

Compound No. 571: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3 -Sulfonamide, mass (m / z): 472.20; melting point: 112-114 ° C

Compound No. 572: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3 -Sulfonamide, mass (m / z): 458.18; melting point: 95-97 ° C

Compound No. 573: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide , Mass (m / z): 458.25; Melting point: 86-89 ° C

Compound No. 574: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide, mass (m / z): 460.19; melting point: 118-121 ° C

Compound No. 575: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide, mass (m / z): 446.17; melting point: 135-137 ° C

Compound No. 576: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzazothiazine- 6-sulfonamide, mass (m / z): 474.13; melting point: 171-174 ° C

Compound No. 577: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzethothiazine- 6-sulfonamide, mass (m / z): 460.19; melting point: 163-165 ° C

Compound No. 578: N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-mercapto-1,3-benzoxazol-6-sulfonamide, mass (m / z): 460.19; melting point: 250-252 ° C

Compound No. 579: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide, mass (m / z): 466; Melting point: 134.4 ° C

Compound No. 580: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide, mass (m / z): 552; Melting point: 152.9 ° C

Compound No. 581: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -N′-pyrimidin-2-ylbenzene-1,4-disulfonamide, Mass (m / z): 530; Melting point: 204.9 ° C

Compound No. 582: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide, mass (m / z): 404 Melting point: 126.6 ° C

Compound No. 583: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide, mass (m / z): 418 Melting point: rubbery

Compound No. 584: N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3,4-thiadiazole-2 -Il] acetamide, mass (m / z): 452.21; melting point: rubbery

Compound No. 585: 5-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiazol-2-sulfonamide, mass (m / z): 410.22; Melting point: rubbery

Compound No. 586: 5-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiazol-2-sulfonamide, mass (m / z): 396.17; Melting point: rubbery

Compound No. 587: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide, mass (m / m z): 461.08; melting point: 70-72 ° C

Compound No. 588: 5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide, mass (m / z ): 461.20; melting point: rubbery

Compound No. 589: N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass (m / z): 443.22 Melting point: 65-67 ° C

Compound No. 590: N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-thiazol-2-yl Acetamide, mass (m / z): 451.20; melting point: 70-72 ° C

Compound No. 591: N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazole-6- Sulfonamide, mass (m / z): 444; melting point: 80-82 ° C

Compound No. 592: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6 -Sulfonamide, mass (m / z): 457; melting point: 239-241 ° C

Compound No. 593: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6 -Sulfonamide, mass (m / z): 471; melting point: 208-210 ° C

Compound No. 594: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide, mass (m / z) : 457; Melting point: 244-246 ° C

Compound No. 595: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide, mass (m / z) : 471; Melting point: 243-245 ° C

Compound No. 596: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine- 6-sulfonamide, mass (m / z): 444; melting point: 158-160 ° C

Compound No. 597: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine- 6-sulfonamide, mass (m / z): 458; melting point: 93-95 ° C

Compound No. 598: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazole-6-sulfonamide, mass (m / z): 446; melting point: 244-246 ° C

Compound No. 599: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazole-6-sulfonamide, mass (m / z): 460; melting point: 244-246 ° C

Compound No. 600: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazole-5- Sulfonamide, mass (m / z): 430; melting point: 194-195 ° C

Compound No. 601: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazole-5- Sulfonamide, mass (m / z): 444; melting point: 107-109 ° C

Compound No. 602: N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -1-benzothiophene-2-sulfonamide, mass (m / z): 457.24; melting point : 81-83 ℃

Compound No. 603: 5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide, mass (m / z ): 447; melting point: rubbery

Compound No. 604: 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid, mass (m / z): 421; melting point: 195.9 ° C

Compound No. 605: 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid, mass (m / z): 435; melting point: 219.4 ° C

Compound No. 606: Methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate, mass (m / z): 449; melting point: rubbery

Compound No. 607: Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate, mass (m / z): 435; melting point: rubbery

Compound No. 608: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-ylsulfonyl) benzenesulfonamide, mass ( m / z): 502; Melting point: 139 ° C

Compound No. 609: Methyl 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl)- 2-methyl-3-furoate, mass (m / z): 590; melting point: 144-146 ° C

Compound No. 610: 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2 -Methyl-3-furoic acid, mass (m / z): 576; melting point: 226-228 ° C

Compound No. 611: 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -N , N, 2-Trimethyl-3-furamide, mass (m / z): 603; melting point: 143-145 ° C

Compound No. 612: 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2 -Methyl-3-furamide, mass (m / z): 575; melting point: 203-205 ° C

Compound No. 613: 2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) aniline, mass (m / z): 247; melting point: rubbery

Compound No. 614: 2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) aniline, mass (m / z): 233; melting point: rubbery

Compound No. 615: 1- (cyanomethyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6 -Sulfonamide, mass (m / z): 479; Melting point: 98-100 ° C

Compound No. 616: 4-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide, mass (m / z): 399; melting point: 114.8-117 ℃

Compound No. 617: N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazole -2-sulfonamide, mass (m / z): 532.0; melting point: 148.2-150 ° C

Compound No. 618: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-2-sulfonamide, mass (m / z ): 377; Melting point: 158-160 ° C

Compound No. 619: N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide, mass (m / z): 443; Melting point: 124.7-126 ° C

Compound No. 620: N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide, mass (m / z): 457; Melting point: rubbery

Compound No. 621: N- [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide, mass ( m / z): 445; melting point: 178-150 ° C.

  While the invention has been described with reference to specific embodiments thereof, several modifications and equivalents will become apparent to those skilled in the art which are within the scope of the invention. Included in

Microbiological activity
Minimal inhibitory concentration (MIC) experiments using the NCCLS method were performed for cation-regulated Mueller Hinton cultures for facultative anaerobic cultures (S. aureus, Enterococcus) and cation-regulated Mueller Hinton cultures for S. pneumoniae +2. Performed with 5% degraded horse blood. The MIC for H. influenzae strain was performed by the NCCLS broth dilution method with HTM broth. The culture grown overnight was adjusted to 0.5 Mcfarland with normal saline and diluted 100-fold. A drug stock solution 1 mg / ml dissolved in a solvent shown in DMSO / distilled water / NCCLS manual was prepared. NCCLS double dilution was performed, and the required concentration range of the drug by each medium was prepared in a 96-well microtiter plate. 100 μl of culture broth was added to wells already containing 100 μl broth containing antibiotics to approximately 3-7 × 10 ⁵ CFU / ml. The concentration of drug at which complete loss of growth occurred was judged as MIC.

  The compounds described herein showed excellent activity against microbial strains. Some of the compounds specifically mentioned herein (numbers 1-183b) are microbial strains such as Streptococcus pneumoniae (49619 and 6303), Haemophilius influenzae (49247), Streptococcus pyogenes (19615), or Staphylococcus aureus ( 25923). The compounds tested are for Streptococcus pneumoniae (49619) from about 2 Eg / mL to 64 Eg / mL or more, in the range of about 2 Eg / mL to about 64 Eg / mL, and in some cases from about 2 Eg / mL to about 32 Eg / mL. MIC values in the range of Eg / mL were shown. The tested compounds are against Haemophilus influenzae (49247) from about 1 Eg / mL to more than 64 Eg / mL, from about 1 Eg / mL to about 64 Eg / mL, and in some cases from about 1 Eg / mL to about 32 Eg / mL. MIC values in the range of Eg / mL were shown. The compounds tested are for Streptococcus pyogenes (19615) from about 2 Eg / mL to 64 Eg / mL or more, in the range of about 2 Eg / mL to about 64 Eg / mL, and in some cases from about 2 Eg / mL to about 32 Eg / mL. MIC values in the range of Eg / mL were shown. The compounds tested are for Staphylococcus aureus 25923 from about 1 Eg / mL to 64 Eg / mL or more, in the range of about 1 Eg / mL to about 64 Eg / mL, and in some cases from about 1 Eg / mL to about 32 Eg / mL. MIC values in the range of mL were shown.

  The compounds described herein showed excellent activity against microbial strains. Some of the compounds specifically mentioned herein (number 286-397) are microbial strains such as Streptococcus pneumoniae (3579, AB34, 49619 and 6303), Haemophilius influenzae (49247 and Elac), Streptococcus pyogenes (19615 ) Or Staphylococcus aureus (25923). The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 32 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae 3579. The tested compounds exhibited MIC values in the range of about 2 Eg / mL to 32 Eg / mL or more and about 2 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae AB34. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 32 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae ATCC 49619. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 32 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae 6303. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 32 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae ATCC 49247. The tested compounds showed MIC values in the range of about 1 Eg / mL to 32 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Haemophilus influenzae Dlac. The tested compounds exhibited MIC values in the range of about 4 Eg / mL to 32 Eg / mL or more and about 4 Eg / mL to about 16 Eg / mL against Streptococcus pyogenes 19615. The tested compounds exhibited MIC values in the range of about 8 Eg / mL to 32 Eg / mL or more and about 8 Eg / mL to about 16 Eg / mL against Streptococcus aureus ATCC 25923.

  The compounds described herein showed excellent activity against microbial strains. Some of the compounds specifically mentioned herein (number 398-521) are microbial strains such as Streptococcus pneumoniae (49619 and 6303), Haemophilius influenzae (49247), Streptococcus pyogenes (19615), Staphylococcus aureus (25923 ), Or MRSA 562. The tested compounds exhibited MIC values for Streptococcus pneumoniae 3579 ranging from about 1 Eg / mL to 16 Eg / mL or more, and from less than about 1 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 16 Eg / mL or more and less than about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae AB34. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 16 Eg / mL or more and less than about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae ATCC 49619. The tested compounds showed MIC values for Streptococcus pneumoniae 6303 ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values for Haemophilus influenzae 49247 ranging from about 2 Eg / mL to 16 Eg / mL or more and from about 2 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 16 Eg / mL or more and about 1 Eg / mL to about 16 Eg / mL against Haemophilus influenzae Dlac. The tested compounds exhibited MIC values for Streptococcus pyogenes 19615 ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values in the range of less than about 1 Eg / mL to 16 Eg / mL or more and less than about 1 Eg / mL to about 16 Eg / mL against Streptococcus aureus ATCC 25923. The tested compounds exhibited MIC values for MRSA 562 ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL.

Some of the compounds specifically mentioned herein (number 398-521) were also tested for their IC ₅₀ values in rat FRS, Streptococcus aureus FRS, Streptococcus pneumoniae FRS, and Haemophilus influenzae FRS.

The IC ₅₀ values for the compounds described herein are as follows:

IC ₅₀ values for rat FRS ranged from about 5000 nM to over 10,000 nM. IC ₅₀ values for Streptococcus aureus FRS ranged from about 5 nM to over 1000 nM, such as from about 5 nM to about 700 nM, and, for example, from about 5 nM to about 50 nM. IC ₅₀ values for Streptococcus pneumoniae FRS ranged from about 5 nM to 1000 nM or more, such as from about 5 nM to about 200 nM, and, for example, from about 5 nM to about 50 nM. IC ₅₀ values for Haemophilus influenzae FRS ranged from about 4 nM to over 1000 nM, such as from about 4 nM to about 100 nM, and, for example, from about 4 nM to about 50 nM.

  The compounds described herein showed excellent activity against microbial strains. Some of the compounds specifically mentioned herein (number 522-621) are microbial strains such as Streptococcus pneumoniae (3579, AB34, 49f19 and 6303), Haemophilius influenzae (49247 and Qlac), Streptococcus pyogenes (19615 ) Or Staphylococcus aureus (25923).

  The tested compounds exhibited MIC values in the range of about 0.5 Eg / mL to 16 Eg / mL or more and about 0.5 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae 3579. The tested compounds exhibited MIC values in the range of about 0.25 Eg / mL to 16 Eg / mL or more, and less than about 0.25 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae AB34. The compounds tested exhibited MIC values in the range of about 0.25 Eg / mL to 16 Eg / mL or more and about 0.25 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae ATCC 49619. The tested compounds exhibited MIC values in the range of about 1 Eg / mL to 16 Eg / mL and less than about 1 Eg / mL to about 16 Eg / mL against Streptococcus pneumoniae 6303. The tested compounds exhibited MIC values for Haemophilus influenzae 49247 ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values for Haemophilus influenzae Dlac ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL. The tested compounds exhibited MIC values for Streptococcus pyogenes 19615 ranging from less than about 1 Eg / mL to more than 16 Eg / mL and from less than about 1 Eg / mL to about 16 Eg / mL. The compounds tested exhibited MIC values ranging from less than about 0.5 Eg / mL to 16 Eg / mL or more, from about 0.5 Eg / mL to about 16 Eg / mL against Streptococcus aureus ATCC 25923.

Claims (20)

Formula I:

And a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide. In the above equation,
Cy is cycloalkyl or heterocyclyl;
X and Z are alkylene;
Y is NR ₁ (wherein R ₁ is hydrogen, alkyl, or OCO alkyl);
X ₁ , X ₂ , X ₃ , and X ₄ are CH or N; and
R is OR ₂ , OCONHR ₂ , OCONHSO ₂ R ₂ , SR ₃ , or NR ₄ R ₅ {wherein R ₂ is aryl or heteroaryl, R ₃ is hydrogen, alkyl, cycloalkyl , Heterocyclyl, heteroaryl, or aryl, and R ₄ and R ₅ are independently hydrogen, SO ₂ R ₆ , COR ₆ , CSR ₆ , or COOR ₆ [wherein R ₆ is alkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl, _{heterocycloalkyl, oR 7, NHR 7, NHSO} 2 R 7, NHCOR 7, NHCSR 7, or a _{NH 2 C = NHSO 2 R 7} ( equation Wherein R ₇ is alkyl, aryl, heteroaryl, or heterocyclyl)],
Alternatively, R ₄ and R ₅ together with their attached nitrogen form a heterocycle}. Formula Ia:

A pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide having the structure: In the above formula,
Cy is cyclopentyl or cyclohexyl;
X is CH ₂ C (CH ₃ ) or CH (OH) C (CH ₃ );
Z is CH ₂ ;
Y is NH or NSO ₂ CH ₃ ;
X ₄ is CH or N; and
R is NR ₄ R ₅ ;
In the preceding formula, R ₄ and R ₅ are independently hydrogen, SO ₂ R ₆ , COR ₆ , CONHR ₆ , CONHSO ₂ R ₆ , or COOH ₂ R ₆ ,
In the above formula, R ₆ is N (CH ₃ ) ₂ , NH ₂ , CH═CHCOOC ₂ H ₅ , (CH ₂ ) ₃ COOC ₂ H ₅ , phenyl, 1,2,3,4-tetrahydroisoquinolinyl. 2,2,2-trifluoroacetyl-1- (3,4-dihydro-1H-isoquinolin-2-yl), morpholinyl, or heteroaryl. Formula Ib:

A pharmaceutically acceptable salt, pharmaceutically acceptable solvate, stereoisomer, drug precursor, metabolite, polymorph, or N-oxide having the structure: In the above formula,
Cy is cyclohexyl or cyclopentyl;
X is -CH ₂ CH (CH ₃ )-, -CH (F) CH (CH ₃ )-, -CH (OH) CH (CH ₃ )-, or -CH ₂ CH (F) CH _2- ;
Y is NH;
Z is —CH ₂ —;
X ₁ and X ₂ are CH or N; and
R is NHC (NH) NH ₂ , NHCOOCH ₂ R ₆ , or NHSO ₂ R ₆ ;
In the previous formula, R ₆ is aryl, heteroaryl, or heterocyclyl. N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3,4,5,6-pentafluorobenzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide,

5- (1-benzothien-2-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl) thiophene-2-sulfonamide,

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (1-hydroxyethyl) phenyl] thiophene-2-sulfonamide,

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,5-dimethoxyphenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl] thiophene-2-sulfonamide,

6-Chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] imidazo [2,1-b] [1,3] thiazol-5-sulfonamide

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl Thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl] isoxazol-3-yl) thiophene-2-sulfonamide ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-yl Thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene-2-sulfonamide ,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [5- (trifluoromethyl) isoxazol-3-yl] thiophene-2-sulfone Amide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazole-5- Yl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-yl Thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopeptyl-1-methylethyl] amino} methyl) phenyl] -5- [1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl Thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (trifluoromethoxy) phenyl] thiophene-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide,

Methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate,

Methyl 4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate,

5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1- (hydroxymethyl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

Methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate,

5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-furyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-phenylthiophene-2-sulfonamide,

5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] nicotinamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,2′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide,

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] [(2-methylphenyl) sulfonyl] carbamate hydrochloride,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide,

5-bromo-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-furamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide hydrochloride,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride,

5-bromo-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-furamide hydrochloride,

5- (3-acetylphenyl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-methoxyphenyl) thiophene-2-sulfonamide,

Methyl 3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4- (isopropylsulfonyl) thiophene-2-carboxylate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (hydroxymethyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- [4- (hydroxymethyl) phenyl] thiophene-2-sulfonamide,

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -4-methylthiophene-2-carboxylate,

Methyl 4-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2,5-dimethyl-3-furoate,

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- [3- (trifluoromethyl) phenyl] thiophene-2-sulfonamide,

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide,

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3-fluorophenyl) thiophene-2-sulfonamide,

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide,

N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide,

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide,

N-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] nicotinamide,

N-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] nicotinamide,

N- [3-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide,

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] thiophene-2-sulfonamide,

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4-fluorobenzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-6-benzene Sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide,

Methyl 5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2-carboxylate,

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1-methyl-1H-pyrrole-2-carboxylate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-4-sulfonamide,

5-bromo-N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-bis (trifluoromethyl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-dimethyl-1H-pyrazol-4-sulfonamide,

(1-benzothien-2-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

5- (1-benzothien-2-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (3,4-dimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (4-methoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -3,3′-bithiophene-5-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-6-benzene Sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-benzenesulfonamide,

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- [4- (4-methoxyphenyl) piperazin-1-yl] acetamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-3-ylthiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) thiophene-2-sulfone Amide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (2-methyl-1,3-thiazol-4-yl) thiophene-2- Sulfonamide,

Ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4-oxadiazole -5-carboxylate,

Ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4-oxadiazole -5-carboxylate,

Ethyl 3- [5-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] -1,2,4- Oxadiazole-5-carboxylate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2,4-dimethyl-1,3-thiazol-5-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methylthiophene-2-carboxamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] isonicotinamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

Methyl 3-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate,

Methyl 3-({[2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) thiophene-2-carboxylate,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (2-thienylsulfonyl) -1,2,3,4-tetrahydroisoquinoline-6- Benzenesulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-phenoxypyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-hydroxyethaneimidoyl] phenyl} thiophene-2 -Sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- {3-[(1E) -N-methoxyethaneimidoyl] phenyl} thiophene-2 -Sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -2-furamide,

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-methoxyphenyl) carbamate,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (phenylsulfonyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (2-thienylsulfonyl) -1 , 2,3,4-tetrahydroisoquinoline-6-sulfonamide),

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -2- (trifluoroacetyl) -1, 2,3,4-tetrahydroisoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] [(2,2-dimethylpropanoyl) oxy] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline -6-sulfonamide,

5- (1,3-benzodioxol-5-yl) -N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -5- (1,3-oxazol-2-yl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-carboxamide,

N- (4-acetylphenyl) -N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-4-ylthiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-pyridin-3-ylthiophene-2-sulfonamide,

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl (4-acetylphenyl) carbamate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (4-methoxyphenyl) -3,4-dihydroisoquinoline- 2 (1H) -carboxamide,

6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -N- (isopropyl) -3,4-dihydroisoquinoline-2 (1H ) -Carboxamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-imidazol-1-ylcarbonyl) -1,2,3,4-tetrahydro Isoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-({[(4-methoxyphenyl) amino] carbonyl} amino) benzenesulfonamide,

4-({[(4-acetylphenyl) amino] carbonyl} amino) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrimidin-2-yl-1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide,

N- {3- [5-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} acetamide,

N- {3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] phenyl} acetamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide,

4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylurea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylthiourea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-methoxyphenyl) urea,

N- (4-acetylphenyl) -6-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3,4-dihydroisoquinoline- 2 (1H) -carboxamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -N′-isopropylthiourea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] isoxazole-5-carboxamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-carboxamide,

N- [2-({[(1S) -2-cycloheptyl-1-methylethyl] amino} methyl) phenyl] -4-fluorobenzamide,

tert-butyl 4- (2-{[2- (2-furoylamino) benzyl] amino} propyl) piperidine-1-carboxylate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-nitrobenzamide,

tert-butyl 4- [2-({2-[(4-fluorobenzoyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate,

tert-butyl 4- [2-({2-[(2-thionylcarbonyl) amino] benzyl} amino) propyl] piperidine-1-carboxylate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-carboxamide;

tert-butyl 4- {2-[(2-{[(5-isoxazol-5-yl-2-thienyl) carbonyl] amino} benzyl) amino] propyl} piperidine-1-carboxylate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-[4- (1,3-oxazol-5-yl) phenyl] urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(methylsulfonyl) amino] benzenesulfonamide,

N- (4-chlorophenyl) -N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-phenylurea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4-dichlorophenyl) urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3,4,5-trichlorophenyl) urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(2,4-dichlorophenyl) urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(4-fluorophenyl) urea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-1-naphthylurea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylurea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-isopropylthiourea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N′-naphthylthiourea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -N ′-(trichloromethyl) thiourea,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-phenylpiperazine-1-carboxamide,

4-benzyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

4- (4-chlorophenyl) -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-methylpiperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) morpholine-4-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-pyrimidin-4-ylpiperazine-1-carboxamide,

4-chloro-N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenesulfonamide,

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} -4-methylbenzenesulfonamide,

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzamide,

N-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] carbonyl} benzenecarbothioamide,

4-[(4-chlorophenyl) sulfonyl] -N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) piperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (phenylsulfonyl) piperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4-[(4-methylphenyl) sulfonyl] piperazine-1-carboxamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -4- (2-thienylsulfonyl) piperazine-1-carboxamide,

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-chlorobenzenesulfonamide,

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} -4-methylenesulfonamide,

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} methanesulfonamide,

N-{(1E) -amino [(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] methylene} thiophene-2-sulfonamide,

N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

4-methyl-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

4-chloro-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) benzenesulfonamide,

N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

5-bromo-N- (2-{[(1-methyl-2-piperazin-1-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

5-bromo-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

4-methyl-N- [2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

4-chloro-N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea,

N- (4-chlorophenyl) -N ′-[2-({[1-methyl-2- (4-phenylpiperazin-1-yl) ethyl] amino} methyl) phenyl] urea,

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} methanesulfonamide,

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide,

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} -4-methylbenzenesulfonamide,

N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide,

5-bromo-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} thiophene-2-sulfonamide,

4-chloro-N- {2-[({[(2-cyclohexyl-1-methylethyl) amino] carbonyl} amino) methyl] phenyl} benzenesulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-methoxy-4-piperazin-1-ylbenzenesulfonamide,

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -5- (phenylsulfonyl) -2-sulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-benzofuran-2-carboxamide,

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) acetamide,

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl (4-methoxyphenyl) carbamate,

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -6- (1H-imidazol-1-yl) nicotinamide,

N- (4-{[(2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} thiophene-2-sulfonamide,

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide,

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -2- (4-pyrimidin-2-ylpiperazin-1-yl) acetamide,

2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl (4-acetylphenyl) carbamate,

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide,

N- (2-{[(2-cycloheptyl-1-methylethyl) amino] methyl} phenyl) -4-fluorobenzenesulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -6- (3-furyl) nicotinamide,

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide,

N- (3-{[(2-cycloheptyl-1-methylethyl) amino] methyl} pyridin-2-yl) -2-furamide,

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) isonicotinamide,

N- (2-{[(2-Cyclohex-1-en-1-yl-1-methylethyl) amino] methyl} phenyl) -5- (1,3-oxazol-5-yl) furan-2-sulfone Amide,

N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -N ′-(3-methylisoxazol-5-yl) urea,

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-imidazol-1-yl) phenyl) carbamate,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5- (3-furyl) nicotinamide,

1-benzofuran-2-ylmethyl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

N- [2-({[1-methyl-2- (4-methylpiperazin-1-yl) ethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N-1-benzothien-2-yl-N ′-[2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] urea,

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (1H-pyrazol-1-yl) phenyl) carbamate,

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate,

3,3′-bipyridin-6-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

Pyridin-4-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) carbamate,

N-1-benzothien-2-yl-N ′-(4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea,

N-1-benzothien-2-yl-N ′-(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) urea,

3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate,

3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl 1-benzothien-2-ylcarbamate,

N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) urea,

N-1-benzothien-2-yl-N ′-(3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) urea,

2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate,

4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl 1-benzothien-2-ylcarbamate,

1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-2-yl) carbamate,

1-benzothien-2-yl (4-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate,

1-benzothien-2-yl (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-3-yl) carbamate,

2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl [4- (2-furyl) phenyl] carbamate,

2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl 1-benzothien-2-ylcarbamate,

1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] carbamate,

1-benzothien-2-yl (3-{[(2-cyclohexyl-1-methylethyl) amino] methyl} pyridin-4-yl) carbamate,

1-benzothien-2-yl (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) carbamate,

N- (2-{[(2-cyclopropyl-1-methylethyl) amino] methyl} phenyl) -2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) acetamide,

1-benzothien-2-yl [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) pyridin-3-yl] carbamate,

N- (2-{[(2-cyclopentyl-1-methylethyl) amino] methyl} phenyl) -2- (1H-1,2,4-triazol-1-yl) acetamide,

1-benzothien-2-yl (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl] pyridin-3-yl) carbamate,

3-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} pyridin-4-yl 1-benzothien-2-ylcarbamate,

N-1-benzothien-2-yl-N ′-(2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) urea,

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) -2- (1H-pyrazol-1-yl) acetamide,

N- (2-{[(1-methyl-2-piperidin-4-ylethyl) amino] methyl} phenyl) isonicotinamide,

4-chloro-N-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-morpholin-4-ylphenyl) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-[3- (2-furyl) -1H-pyrazol-5-yl) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole- 3-Ile) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(4-methoxy-1,2-benzoxazol-3-yl) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-(3,4-dimethylisoxazol-5-yl) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[1-methyl-3- (2-thienyl) -1H-pyrazole-5- Il] Urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-imidazol-4-sulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide,

4-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

2-thienylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate,

2-thienylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (2,3,4-trimethoxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- {3-[(E)-(hydroxyimino) methyl] -1H-pyrrole-1 -Il} benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-[4- (1,2,3-thiadiazol-4-yl) phenyl) urea ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-6-carboxamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-dimethylisoxazol-4-sulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxazole-4- Sulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4-sulfone Amide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-hydroxyethyl) benzenesulfonamide,

Pyridin-3-ylmethyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate,

Pyridin-3-ylmethyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate,

Pyridin-3-ylmethyl [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] carbamate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-pyrazin-2-yl-1H-imidazol-4-sulfonamide,

5-chloro-N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -3-methyl-1-benzenethiophene-2-sulfone Amide,

Ethyl 3- [5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate,

4-acetyl-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] benzenesulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide,

N-1,3-benzothiazol-2-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N ′-[4 [(1,3-oxazol-5-yl) phenyl] urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl ) Benzenesulfonamide,

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide,

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide,

N- [2-({[(1S, 2S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4- Tetrahydroisoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide,

N- [3-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-5-ylthiophene-2-sulfonamide,

N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -5-isoxazol-3-ylthiophene-2-sulfonamide,

N- [3-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) pyridin-2-yl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (3-formyl-1H-pyrrol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-oxo-1,3-oxazolidine-3-yl) benzenesulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (1-methyl-1H-pyrazol-4-yl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (2-thienylsulfonyl) -1H-imidazol-4-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiazol-4-sulfonamide,

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4-sulfone Amide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide,

4-[(butylsulfonyl) amino] -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(ethylsulfonyl) amino] benzenesulfonamide,

5-chloro-N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl-1H -Pyrazole-4-sulfonamide,

Methyl 4-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2,5- Dimethyl-3-furoate,

Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -3-methylthiophene -2-carboxylate,

Methyl 5-({[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-furoate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N '-(3-oxo-1,3-dihydro-2-benzofuran-5-yl) Urea,

2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} carbonyl) amino] benzamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-isoquinolin-5-ylurea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-morpholin-4-ylurea,

N-1,3-benzothiazol-6-yl-N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) urea,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N′-1,3-thiazol-2-ylurea,

Ethyl 3- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-thienyl] benzoate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,4-triazol-1-yl ) Benzenesulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2- (trifluoroacetyl) -1,2 , 3,4-tetrahydroisoquinoline-7-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyridin-3-ylbenzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-pyrimidin-5-ylbenzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-6-sulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -5-isoxazol-5-ylthiophene-2-sulfonamide,

N- [2-({[(1S, 2R) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4- Sulfonamide,

N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-4- Sulfonamide,

5-chloro-N- [4-[({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl- 1H-pyrazole-4-sulfonamide,

N ′-[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -N, N-dimethylsulfamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide,

N- [3-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

N- [2-[({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

3-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide,

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -3,5-dimethylisoxazole-4- Sulfonamide,

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] isoxazole-5-carboxamide,

N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide,

Ethyl 5-{[4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} -5-oxopentoate,

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-5-sulfonamide,

5-chloro-N- [3-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1,3-dimethyl-1H -Pyrazole-4-sulfonamide,

N- [2-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -2,4-dimethyl-1,3-thiazole -5-sulfonamide,

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide,

N- (2-{[[(1S) -2-cyclohexyl-1-methylethyl] (methylsulfonyl) amino] methyl} phenyl) -2-[(methylsulfonyl) amino] benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide,

[5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] carbamate,

N-[(1S) -2-cyclopentyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide,

N-[(1S) -2-cyclohexyl-1-methylethyl] -2-[(2-thienylsulfonyl) amino] benzamide,

Methyl [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1H-benzimidazol-2-yl] carbamate,

Methyl [6-({[4-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -1H-benzimidazol-2- Il] carbamate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-hydroxyethaneimidoyl] benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-[(1E) -N-methoxyethaneimidoyl] benzenesulfonamide,

4-{[amino (imino) methyl] amino} -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] sulfamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -4-[(1E) -N-hydroxyethane Imidoyl] benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-{[(isopropylamino) carbonyl] amino} benzenesulfonamide,

Ethyl (2Z) -4-{[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} -4-oxobut-2-enoate,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide,

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] thiophene-2-sulfonamide,

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-5-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] guanidine,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl ) Benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide,

N- [2-({[2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1-methyl-1H-pyrazol-4-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (3,5-dimethylisoxazol-4-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide ,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-[(methylsulfonyl) amino) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-{[(dimethylamino) sulfonyl) amino] benzenesulfonamide,

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -1-benzothiophene-2-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-{[(1-methyl-1H-imidazol-4-yl) sulfonyl] amino} pyridine-2-sulfone Amide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(methylsulfonyl) amino] pyridine-2-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-[(2-thienylsulfonyl) amino] pyridine-2-sulfonamide,

5-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-2-sulfonamide,

[5- (2-thienyl) isoxazol-3-yl] methyl [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] carbamate,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluoro-5- (1H-pyrrol-1-yl) benzenesulfonamide,

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-4-sulfonamide,

N- [2-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-2-hydroxy-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-oxazol-5-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine-3-sulfone Amide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-1,2,4-triazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro- (1H-tetrazol-1-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -3-fluoro-4- (1H-1,2,4-triazol-1-yl) benzene Sulfonamide,

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-pyrrol-1-yl) pyridine-3-sulfonamide,

N- [3-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-4-yl] -5-isoxazol-5-ylthiophene-2-benzenesulfonamide hydrochloride,

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1H-benzimidazol-6-sulfonamide,

5-{[amino (imino) methyl] amino} -N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide,

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] -1-methyl-1H-imidazol-4-sulfone Amide,

N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] acetamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methyl-1H-benzimidazol-2-sulfonamide,

4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-fluorobenzenesulfonamide,

4-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxybenzenesulfonamide,

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] acetamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-methoxy-4-[(methylsulfonyl) amino] benzenesulfonamide,

Methyl [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] carbamate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,3-thiadiazol-4-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (2-methyl-2H-tetrazol-5-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide ,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (3-furyl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-imidazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide),

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide,

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfone Amide,

N- [4-({[2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[2-cyclohexyl-2-fluoro-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-yl) benzenesulfonamide,

N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide,

N- (4-{[(2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) thiophene-2-sulfonamide,

5-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzoxadiazole-4-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-carboxamide,

N- (2-{[(3-cyclohexyl-2-fluoropropyl) amino] methyl} phenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,1,3-benzothiadiasol-5-sulfonamide,

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-methoxyphenyl] thiophene-2-sulfonamide,

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] thiophene-2-sulfonamide,

N- [4-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -3-hydroxyphenyl] acetamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-1,2,3-triazol-1-yl) benzene Sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (trifluoroacetyl) indoline-5-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] indoline-5-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,4-difluorobenzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) pyridin-3-yl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-1,2,3-triazol-1-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridin-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-morpholin-4-ylpyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6-sulfonamide,

6-bromo-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide,

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyrimidine-5-sulfonamide,

6-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] pyridine-3-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide,

5-chloro-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-2-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (dimethylamino) -1,3-benzothiazol-6-sulfonamide,

N- [6-({[2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-benzothiazol-2-yl] -L-alaninamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxo-3,4-dihydroquinoline-2-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2- (trifluoroacetyl) -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroisoquinoline-6-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-imidazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-3-methyl-1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-2-oxo-1,2-dihydroisoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-ethyl-2-oxo-1,2-dihydroisoquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-thienyl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (2-furyl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1H-tetrazol-1-yl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-pyrrolidin-1-ylpyridin-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3- (2-methyl-1,3-thiazol-4-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5- (3,5-dimethylisoxazol-4-yl) thiophene-2-sulfonamide ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonamide ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,2,4-oxadiazol-3-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (1H-pyrazol-1-yl) benzenesulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-[(1-methyl-1H-imidazol-4-yl) sulfonyl] indoline-5-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1- (methylsulfonyl) indoline-5-sulfonamide,

N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazole -4-sulfonamide,

1-acetyl-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) indoline-5-sulfonamide,

N- [4-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] acetamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-fluoro-4- (2-oxo-1,3-oxazolidine-3-yl) benzene Sulfonamide,

2-amino-N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazole-6-sulfonamide,

N- [2-({[2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

2-amino-N- [2-({[(1S) -2-cyclopropyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} phenyl) nonanamide,

4-amino-N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-hydroxybenzensulfonamide,

N- (4-{[(2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) amino] sulfonyl} -2-hydroxyphenyl) thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzothiazol-6-sulfonamide,

2-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxoindoline-6-sulfonamide,

5-chloro-N- [2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl] -1benzothiophene-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzothiophene-2-sulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -5-fluoro-1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide,

N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-oxoindoline-6-sulfonamide,

4-amino-N- [2-({[1- (cyclohexyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] benzenesulfonamide,

5- (6-aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

5- (6-aminopyridin-3-yl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] thiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4- (1,3-thiazol-2-yl) benzenesulfonamide,

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide,

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-benzoxazole-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-methoxy-1-benzofuran-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -5-hydroxy-1-benzofuran-2-sulfonamide,

N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -4-[(methylsulfonyl) amino] benzenesulfonamide,

N- [4-({[2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] thiophene-2-sulfonamide,

2-amino-N- [2-({[1- (cyclohexylmethyl) -2,2,2-trifluoroethyl] amino} methyl) phenyl] -1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2- (1H-pyrrol-1-yl) -1,3-thiazol-5-sulfonamide ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzenesulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3,5-difluoro-4- (1H-tetrazol-1-yl) benzenesulfonamide,

N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -4- (1H-pyrrol-1-yl) benzenesulfonamide,

2-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3-thiazol-5-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6- (1,2,3-thiadiazol-4-yl) pyridine-3-sulfonamide,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-hydroxy-1,3-benzothiazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzazothiazine-6-sulfonamide ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -3-oxo-3,4-dihydro-2H-1,4-benzazothiazine-6-sulfonamide ,

N- (2-{[(2-cyclohexyl-1-methylethyl) amino] methyl} phenyl) -2-mercapto-1,3-benzoxazole-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzene-1,4-disulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -N′-pyrimidin-2-ylbenzene-1,4-disulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -6-methoxypyridine-3-sulfonamide,

N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3,4-thiadiazol-2-yl] acetamide ,

5-amino-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiasol-2-sulfonamide,

5-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1,3,4-thiadiasol-2-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -5-fluoro-1-benzothiophene-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide,

N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,

N- [5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -1,3-thiazol-2-yl] acetamide,

N- [2-({[(1R) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2,3-dihydroxyquinoxaline-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-sulfonamide ,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,4-dihydro-2H-3,1-benzoxazine-6-sulfonamide ,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazol-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-mercapto-1,3-benzoxazole-6-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-5-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-2,3-dihydro-1,3-benzoxazol-5-sulfonamide,

N- (2-{[(2-cyclohexyl-1,1-dimethylethyl) amino] methyl} phenyl) -1-benzothiophene-2-sulfonamide,

5-chloro-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-benzofuran-2-sulfonamide,

5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid,

5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoic acid,

Methyl 5-({[2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate,

Methyl 5-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) -2-methyl-3-furoate,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4- (1H-pyrrol-1-ylsulfonyl) benzenesulfonamide,

Methyl 5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl- 3-Floate,

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl-3 -Furoic acid,

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -N, N, 2 -Trimethyl-3-furamide,

5-({[4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] amino} sulfonyl) -2-methyl-3 -Flamid,

2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) aniline,

2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) aniline,

1- (cyanomethyl) -N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -2-oxo-1,2-dihydroquinoline-6-sulfonamide,

4-amino-N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] benzenesulfonamide,

N- [4-({[2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] amino} sulfonyl) phenyl] -1-methyl-1H-imidazol-2-sulfone Amide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -1-methyl-1H-imidazol-2-sulfonamide,

N- [2-({[(1S) -2-cyclopentyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide,

N- [2-({[(1S) -2-cyclohexyl-1-methylethyl] amino} methyl) phenyl] -4-oxochroman-6-sulfonamide,

N- [2-({[1-methyl-2- (tetrahydro-2H-pyran-4-yl) ethyl] amino} methyl) phenyl] -1-benzothiophene-2-sulfonamide,
A pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, a polymorph, an N-oxide, or a mixture thereof.   A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 together with a pharmaceutically acceptable carrier, excipient, diluent, or mixture thereof.   A method of treating or preventing a subject suffering from a pathological condition caused by or promoted by a bacterial or fungal infection, wherein said subject in need of treatment or prevention 12. A method comprising administering a therapeutically effective amount of one or more compounds as claimed in claim 1.   The bacterial infection is selected from Staphylococci, Enterococci, Streptococci, Haemophilus, Propinibacterium, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae Claiming that the fungal infection arises from contact with a microorganism selected from Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidiodes, Pneumocystis, Trichophyton, or Trichosporium, 6. The method described in 6.   Community-acquired pneumonia, upper and lower respiratory tract infection, skin and soft tissue infection, nosocomial lung or bone and joint infection, mastitis, catheter infection, foreign body, acne vulgaris, prosthetic infection, and gastric ulcer disease The method according to claim 6, wherein the method is selected from: A process for preparing a compound of formula 32, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy, X ₁ -X ₄ , and R ₆ are as defined in claim 1;
Reaction of a compound of formula 5 with a compound of formula 24,

Said process comprising forming a compound of formula 32. A process for preparing a compound of formula 33, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy, X ₁ -X ₄ , and R ₆ are as defined in claim 1;
Reaction of a compound of formula 14 with a compound of formula 24

Said method comprising forming a compound of formula 33. A process for preparing a compound of formula 34, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy, X ₁ -X ₄ , and R ₆ are as defined in claim 1;
Reaction of a compound of formula 18 with a compound of formula 24,

Said method comprising forming a compound of formula 34. A process for preparing a compound of formula 46, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) deprotecting the compound of formula 35 with thiophenol;

Forming a compound of formula 42;

(b) reacting a compound of formula 42 with a compound of formula R ₆ NCO to form a compound of formula 45; and
(c) The method comprising deprotecting the compound of formula 45 to form a compound of formula 46. A process for preparing a compound of formula 51, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy, X ₁ -X ₄ , and R ₆ are as defined in claim 1;
(a) reacting a compound of formula 47 with a compound of formula 24;

Forming a compound of formula 48;

(b) deprotecting the compound of formula 48 to form the compound of formula 49;

(c) reacting a compound of formula 49 with a compound of formula R ₆ NCO to form a compound of formula 50; and

(d) The method comprising deprotecting the compound of formula 50 to form a compound of formula 51. A method for preparing a compound of formula 39, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy, X ₁ -X ₄ , and R ₆ are as defined in claim 1;
(a) protecting the compound of formula 35;

Forming a compound of formula 36;

(b) reducing the compound of formula 36 to form the compound of formula 37;

(b) reacting a compound of formula 37 with a compound of formula R ₆ NCO to form a compound of formula 38; and

(c) The method comprising deprotecting the compound of formula 38 to form a compound of formula 39. A method of preparing a compound of formula 39d, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 39a with a compound of formula 39b;

Forming a compound of formula 39c; and

(b) deprotecting the compound of formula 39c to form a compound of formula 39d. A method of preparing a compound of formula 39g, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 39a with a compound of formula 39e;

Forming a compound of formula 39f; and

(b) The method comprising deprotecting a compound of formula 39f to form a compound of formula 39g, wherein Rb is methyl, methoxy, or aminomethyl. A process for preparing a compound of formula 41, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 37a with RxSO ₂ Cl;

Forming a compound of formula 40; and

(b) Deprotecting the compound of formula 40 to formula 41 (wherein Rx is methyl, N (CH ₃ ) ₂ , NH ₂ , CH = CHCOOC ₂ H ₅ , (CH ₂ ) ₃ COOC ₂ H ₅ , phenyl 1,2,3,4-tetrahydroquinolinyl, 2,2,2-trifluoroacetyl-1- (3,4-dihydro-1H-isoquinolin-2-yl), morpholinyl, or heteroaryl) Forming said compound. A process for preparing a compound of formula 44, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 42 with a compound of formula 42a;

Forming a compound of formula 43; and

(b) deprotecting the compound of formula 43 to form a compound of formula 44. A process for preparing a compound of formula 54, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 52 with a compound of formula 39b;

Forming a compound of formula 53; and

(b) deprotecting the compound of formula 53 to form a compound of formula 54. A process for preparing a compound of formula 59, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate, a stereoisomer, a drug precursor, a metabolite, and an N-oxide, comprising:

Wherein Cy and X ₁ -X ₄ are as defined in claim 1;
(a) reacting a compound of formula 55 with phenyl chloroformate;

Forming a compound of formula 56;

(b) reacting the compound of formula 56 with hydrazine hydrate,

Forming a compound of formula 57;

(c) cyclizing the compound of formula 57 to form a compound of formula 58; and

(d) The method comprising deprotecting the compound of formula 58 to form a compound of formula 59.